US20150376700A1 - Analysis of nucleic acid sequences - Google Patents

Analysis of nucleic acid sequences Download PDF

Info

Publication number
US20150376700A1
US20150376700A1 US14/752,589 US201514752589A US2015376700A1 US 20150376700 A1 US20150376700 A1 US 20150376700A1 US 201514752589 A US201514752589 A US 201514752589A US 2015376700 A1 US2015376700 A1 US 2015376700A1
Authority
US
United States
Prior art keywords
nucleic acid
sequence
fragment
fragments
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/752,589
Other languages
English (en)
Inventor
Michael Schnall-Levin
Mirna Jarosz
Christopher Hindson
Kevin Ness
Serge Saxonov
Benjamin Hindson
Grace X. Y. Zheng
Patrick Marks
John Stuelpnagel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
10X Genomics Inc
Original Assignee
10X Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 10X Genomics Inc filed Critical 10X Genomics Inc
Priority to US14/752,589 priority Critical patent/US20150376700A1/en
Assigned to 10X GENOMICS, INC. reassignment 10X GENOMICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: STUELPNAGEL, JOHN, MARKS, PATRICK, SAXONOV, SERGE, HINDSON, BENJAMIN, HINDSON, Christopher, NESS, KEVIN, SCHNALL0LEVIN, MICHAEL, ZHENG, GRACE, JAROSZ, MIRNA
Assigned to 10X GENOMICS, INC. reassignment 10X GENOMICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: STUELPNAGEL, JOHN, MARKS, PATRICK, SAXONOV, SERGE, HINDSON, BENJAMIN, HINDSON, Christopher, NESS, KEVIN, SCHNALL-LEVIN, MICHAEL, ZHENG, GRACE, JAROSZ, MIRNA
Publication of US20150376700A1 publication Critical patent/US20150376700A1/en
Priority to US15/985,388 priority patent/US20180265928A1/en
Assigned to 10X GENOMICS, INC. reassignment 10X GENOMICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ZHENG, Xinying
Priority to US16/898,984 priority patent/US12163191B2/en
Priority to US18/934,042 priority patent/US20250059606A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G06F19/22—
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/20—Sequence assembly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/122—Massive parallel sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/16—Assays for determining copy number or wherein the copy number is of special importance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/159—Microreactors, e.g. emulsion PCR or sequencing, droplet PCR, microcapsules, i.e. non-liquid containers with a range of different permeability's for different reaction components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/60—Detection means characterised by use of a special device
    • C12Q2565/629—Detection means characterised by use of a special device being a microfluidic device
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • a fundamental understanding of a particular human genome may require more than simply identifying the presence or absence of certain genetic variations such as mutations. It is also important to determine whether certain genetic variations appear on the same or different chromosomes (also known as phasing). Information about patterns of genetic variations, such as haplotypes is also important, as is information about the number of copies of genes.
  • haplotype refers to sets of DNA sequence variants (alleles) that are inherited together in contiguous blocks.
  • the human genome contains two copies of each gene—a maternal copy and a paternal copy.
  • gene alleles “A” and “a” and “a” the genome of a given individual will include one of two haplotypes, “AB/ab”, where the A and B alleles reside on the same chromosome (the “cis” configuration), or “Ab/aB”, where the A and B alleles reside on different chromosomes (the “trans” configuration).
  • Phasing methods or assays can be used to determine whether a specified set of alleles reside on the same or different chromosomes.
  • several linked alleles that define a haplotype may correlate with, or be associated with, a particular disease phenotype; in such cases, a haplotype, rather than any one particular genetic variant, may be the most determinative factor as to whether a patient will display the disease.
  • Gene copy number also plays a role in some disease phenotypes. Most genes are normally present in two copies, however, amplified genes are genes that are present in more than two functional copies. In some instances, genes may also undergo a loss of functional copies. A loss or gain in gene copy number can lead to the production of abnormal levels of mRNA and protein expression, potentially leading to a cancerous state or other disorder. Cancer and other genetic disorders are often correlated with abnormal (increased or decreased) chromosome numbers (“aneuploidy”). Cytogenetic techniques such as fluorescence in situ hybridization or comparative genomic hybridization can be used to detect the presence of abnormal gene or chromosome copy numbers. Improved methods of detecting genetic phasing information, haplotypes or copy number variations are needed in the art.
  • the present disclosure provides methods and systems that may be useful in providing significant advances in the characterization of genetic material. These methods and systems can be useful in providing genetic characterizations that may be substantially difficult using generally available technologies, including, for example, haplotype phasing, identifying structural variations, e.g., deletions, duplications, copy-number variants, insertions, inversions, translocations, long tandem repeats (LTRs), short tandem repeats (STRs), and a variety of other useful characterizations.
  • haplotype phasing identifying structural variations, e.g., deletions, duplications, copy-number variants, insertions, inversions, translocations, long tandem repeats (LTRs), short tandem repeats (STRs), and a variety of other useful characterizations.
  • An aspect of the disclosure provides a method for identifying one or more variations in a nucleic acid, comprising: a) providing a first fragment of the nucleic acid, wherein the first fragment has a length greater than 10 kilobases (kb); (b) sequencing a plurality of second fragments of the first fragment to provide a plurality of fragment sequences, which plurality of fragment sequences share a common barcode sequence; (c) attributing the plurality of fragment sequences to the first fragment by a presence of the common barcode sequence; (d) determining a nucleic acid sequence of the first fragment using the plurality of fragment sequences, wherein the nucleic acid sequence is determined at an error rate of less than 1%; and; (e) identifying the one or more variations in the nucleic acid sequence of the first fragment determined in (d), thereby identifying the one or more variations within the nucleic acid.
  • the first fragment is in a discrete partition in among a plurality of discrete partitions. In some cases, the discrete partition is a droplet in an emulsion. In some cases the identifying comprises identifying phased variants in the nucleic acid sequence of the first fragment. In some cases, the identifying comprises identifying one or more structural variations in the nucleic acid from the nucleic acid sequence of the first fragment. In some cases, the first fragment has a length greater than 15 kb. In some cases, the first fragment has a length greater than 20 kb. In some cases, the determining comprises mapping the plurality of fragment sequences to a reference. In some cases, the determining comprises assembling the plurality of fragment sequences with the common barcode sequence.
  • the method for identifying one or more variations further comprises providing a plurality of first fragments of the nucleic acid that are at least 10 kb in length, and the identifying comprises determining a nucleic acid sequence from each of the plurality of first fragments and identifying the one or more variations in the nucleic acid from the nucleic acid sequence from each of the plurality of first fragments.
  • the method for identifying one or more variations further comprises linking two or more nucleic acid sequences of the plurality of first fragments in an inferred contig based upon overlapping nucleic acid sequences of the two or more nucleic acid sequences, wherein the maximum inferred contig length is at least 10 kb. In some cases, the maximum inferred contig length is at least 20 kb. In some cases, the maximum inferred contig length is at least 40 kb. In some cases, the maximum inferred contig length is at least 50 kb. In some cases, the maximum inferred contig length is at least 100 kb. In some cases, the maximum inferred contig length is at least 200 kb.
  • the maximum inferred contig length is at least 500 kb. In some cases, the maximum inferred contig length is at least 750 kb. In some cases, the maximum inferred contig length is at least 1 megabase (Mb). In some cases, the maximum inferred contig length is at least 1.75 Mb. In some cases, the maximum inferred contig length is at least 2.5 Mb.
  • the method for identifying one or more variations further comprises linking two or more nucleic acid sequences of the plurality of first fragments in a phase block based upon overlapping phased variants within the two or more nucleic acid sequences of the plurality of first fragments, wherein the maximum phase block length is at least 10 kb. In some cases, the maximum phase block length is at least 20 kb. In some cases, the maximum phase block length is at least 40 kb. In some cases, the maximum phase block length is at least 50 kb. In some cases, the maximum phase block length is at least 100 kb. In some cases, the maximum phase block length is at least 200 kb. In some cases, the maximum phase block length is at least 500 kb.
  • the maximum phase block length is at least 750 kb. In some cases, the maximum phase block length is at least 1 Mb. In some cases, the maximum phase block length is at least 1.75 Mb. In some cases, maximum phase block length is at least 2.5 Mb.
  • the method for identifying one or more variations further comprises linking two or more nucleic acid sequences of the plurality of first fragments in an inferred contig based upon overlapping nucleic acid sequences of the two or more nucleic acid sequences, thereby creating a population of inferred contigs, wherein the N50 of the population of inferred contigs is at least 10 kb. In some cases, the N50 of the population of inferred contigs is at least 20 kb. In some cases, the N50 of the population of inferred contigs is at least 40 kb. In some cases, the N50 of the population of inferred contigs is at least 50 kb.
  • the N50 of the population of inferred contigs is at least 100 kb. In some cases, the N50 of the population of inferred contigs is at least 200 kb. In some cases, the N50 of the population of inferred contigs is at least 500 kb. In some cases, the N50 of the population of inferred contigs is at least 750 kb. In some cases, the N50 of the population of inferred contigs is at least 1 Mb. In some cases, the N50 of the population of inferred contigs is at least 1.75 Mb. In some cases, the N50 of the population of inferred contigs is at least 2.5 Mb.
  • the method for identifying one or more variations further comprises linking two or more nucleic acid sequences of the plurality of first fragments in a phase block based upon overlapping phased variants within the two or more nucleic acid sequences of the plurality of first fragments, thereby creating a population of phase blocks, wherein the N50 of the population of phase blocks is at least 10 kb. In some cases, the N50 of the population of phase blocks is at least 20 kb. In some cases, the N50 of the population of phase blocks is at least 40 kb. In some cases, the N50 of the population of phase blocks is at least 50 kb. In some cases, the N50 of the population of phase blocks is at least 100 kb.
  • the N50 of the population of phase blocks is at least 200 kb. In some cases, the N50 of the population of phase blocks is at least 500 kb. In some cases, the N50 of the population of phase blocks is at least 750 kb. In some cases, the N50 of the population of phase blocks is at least 1 Mb. In some cases, the N50 of the population of phase blocks is at least 1.75 Mb. In some cases, the N50 of the population of phase blocks is at least 2.5 Mb.
  • An additional aspect of the disclosure provides a method of determining a presence of a structural variation of a nucleic acid.
  • the method can comprise: (a) providing a plurality of first fragment molecules of the nucleic acid, wherein a given first fragment molecule of the plurality of first fragment molecules comprises the structural variation; (b) sequencing a plurality of second fragment molecules of each of the plurality of first fragment molecules to provide a plurality of fragment sequences, wherein each of the plurality of fragment sequences corresponding to a given first fragment molecule shares a common barcode sequence; and (c) determining the presence of the structural variation by (i) mapping the plurality of fragment sequences to a reference sequence, (ii) identifying the plurality of fragment sequences that share the common barcode sequence, and (iii) identifying the structural variation based on a presence of an elevated amount of the plurality of fragment sequences sharing the common barcode sequence that map to the reference sequence at locations that are further apart than a length of the given first fragment molecule, which elevated amount is relative
  • the elevated amount is 1% or more with respect to a total number of the first fragment molecules that are derived from a region of the nucleic acid having the structural variation. In some cases, the elevated amount is 2% or more with respect to the total number of the first fragment molecules that are derived from a region of the nucleic acid having the structural variation. In some cases, the locations are at least about 100 bases apart. In some cases, the locations are at least about 500 bases apart. In some cases, the locations are at least about 1 kilobase (kb) apart. In some cases, the locations are at least about 10 kb apart.
  • the method of determining a presence of a structural variation of a nucleic acid further comprises identifying the structural variation by creating an assembly of the given first fragment molecule from the plurality of fragment sequences, wherein the plurality of fragment sequences are selected as inputs for the assembly based upon a presence of the common barcode sequence.
  • the assembly is created by generating a consensus sequence from the plurality of fragment sequences.
  • the structural variation comprises a translocation.
  • An additional aspect of the disclosure provides a method of characterizing a variant nucleic acid sequence.
  • the method can comprise: (a) fragmenting a variant nucleic acid to provide a plurality of first fragments having a length greater than 10 kilobases (kb); (b) separating the plurality of first fragments into discrete partitions; (c) creating a plurality of second fragments from each first fragment within its respective partition, the plurality of second fragments having a barcode sequence attached thereto, which barcode sequence within a given partition is a common barcode sequence; (d) sequencing the plurality of second fragments and the barcode sequences attached thereto, to provide a plurality of second fragment sequences; (e) attributing the second fragment sequences to an original first fragment based at least in part on the presence of the common barcode sequence to provide a first fragment sequence context for the second fragment sequences; and (f) identifying a variant portion of the variant nucleic acid from the first fragment sequence context, thereby characterizing the variant nucleic acid
  • the attributing comprises assembling at least a portion of a sequence for an individual fragment from the plurality of first fragments from the plurality of second fragment sequences based, at least in part, on the presence of the common barcode sequence. In some cases, the attributing comprises mapping the plurality of second fragment sequences to an individual first fragment from the plurality of first fragments based at least in part upon the common barcode sequence.
  • the method of characterizing a variant nucleic acid sequence further comprises linking two or more of the plurality of first fragments into an inferred contig, based upon overlapping sequence between the two or more of the plurality of first fragments.
  • the identifying comprises identifying one or more phased variants from the first fragment sequence context.
  • the method of characterizing a variant nucleic acid sequence further comprises linking two or more of the plurality of first fragments into a phase block, based upon overlapping phased variants between the two or more of the plurality of first fragments.
  • the identifying comprises identifying one or more structural variations from the first fragment sequence context.
  • the one or more structural variations are independently selected from insertions, deletions, translocations, retrotransposons, inversions, and duplications.
  • the structural variation comprises an insertion or a translocation
  • the first fragment sequence context indicates a presence of the insertion or translocation.
  • An additional aspect of the disclosure provides a method of identifying variants in a sequence of a nucleic acid.
  • the method comprises: obtaining nucleic acid sequences of a plurality of individual fragment molecules of the nucleic acid, the nucleic acid sequences of the plurality of individual fragment molecules each having a length of at least 1 kilobase (kb); linking sequences of one or more of the plurality of individual fragment molecules in one or more inferred contigs; and identifying one or more variants from the one or more inferred contigs.
  • the obtaining comprises obtaining the nucleic acid sequences of a plurality of fragment molecules that are greater than 10 kb in length.
  • the obtaining comprises: providing a plurality of barcoded fragments of each individual fragment molecule of the plurality of individual fragment molecules, the barcoded fragments of a given individual fragment molecule having a common barcode; sequencing the plurality of barcoded fragments of the plurality of individual fragment molecules, the sequencing providing a sequencing error rate of less than 1%; and determining a sequence of the plurality of individual fragment molecules from sequences of the plurality of barcoded fragments and their associated barcodes.
  • the linking comprises identifying one or more overlapping sequences between two or more individual fragment molecules to link the two or more individual fragment molecules into the one or more inferred contigs. In some cases, the linking comprises identifying one or more common variants between two or more individual fragment molecules to link the two or more individual fragment molecules into the one or more inferred contigs. In some cases, the one or more common variants are phased variants, and the one or more inferred contigs comprise a maximum phase block length of at least 100 kb. In some cases, the one or more variants identified in the identifying comprise structural variations. In some cases, the structural variations are selected from insertions, deletions, translocations, retrotransposons, inversions, and duplications.
  • An additional aspect of the disclosure provides a method of characterizing nucleic acids.
  • the method comprises: obtaining nucleic acid sequences of a plurality of fragment molecules having a length of at least 10 kilobases (kb); identifying one or more phased variant positions in the nucleic acid sequences of the plurality of fragment molecules; linking the nucleic acid sequences of at least a first fragment molecule to at least a second fragment molecule based upon a presence of one or more common phased variant positions within the first and second fragment molecules, to provide a phase block with a maximum phase block length of at least 10 kb; and identifying one or more phased variants from the phase block with the maximum phase block length of at least 10 kb.
  • the method of characterizing nucleic acids further comprises identifying one or more additional phased variants from the phase block.
  • the plurality of fragment molecules are in discrete partitions. In some cases, the discrete partitions are droplets in an emulsion.
  • the length of the plurality of fragment molecules is at least 50 kb. In some cases, the length of the plurality of fragment molecules is at least 100 kb.
  • the maximum phase block length is at least 50 kb. In some cases, the maximum phase block length is at least 100 kb. In some cases, the maximum phase block length is at least 1 Mb. In some cases, the maximum phase block length is at least 2 Mb. In some cases, the maximum phase block length is at least 2.5 Mb.
  • An additional aspect of the disclosure provides a method comprising: (a) partitioning a first nucleic acid into a first partition, where the first nucleic acid comprises the target sequence derived from a first chromosome of an organism; (b) partitioning a second nucleic acid into a second partition, where the second nucleic acid comprises the target sequence derived from a second chromosome of the organism; (c) in the first partition, attaching a first barcode sequence to fragments of the first nucleic acid or to copies of portions of the first nucleic acid to provide first barcoded fragments; (d) in the second partition, attaching a second barcode sequence to fragments of the second nucleic acid or to copies of portions of the second nucleic acid to provide second barcoded fragments, the second barcode sequence being different from the first barcode sequence; (e) determining the nucleic acid sequence of the first and second barcoded fragments, and assembling a nucleic acid sequence of the first and second nucleic acids; and (f)
  • oligonucleotides comprising the first barcode sequence are co-partitioned with the first nucleic acid
  • oligonucleotides comprising the second barcode sequence are co-partitioned with the second nucleic acid.
  • the oligonucleotides comprising the first barcode sequence are releasably attached to a first bead
  • the oligonucleotides comprising the second barcode sequence are releasably attached to a second bead
  • the co-partitioning comprises co-partitioning the first and second beads into the first and second partitions, respectively.
  • the first and second partitions comprise droplets in an emulsion.
  • the first chromosome is a paternal chromosome and the second chromosome is a maternal chromosome. In some cases, the first chromosome and the second chromosome are homologous chromosomes. In some cases, the first nucleic acid and the second nucleic acid comprise one or more variations.
  • the first and second chromosomes are derived from a fetus. In some cases, the first and second nucleic acids are obtained from a sample taken from a pregnant woman. In some cases, the first chromosome is chromosome 21, 18, or 13. In some cases, the second chromosome is chromosome 21, 18, or 13. In some cases, the method further comprises determining the relative quantity of the first or second chromosome. In some cases, the method further comprises determining the quantity of the first or second chromosome relative to a reference chromosome. In some cases, the first chromosome or second chromosome, or both, has an increase in copy number. In some cases, the increase in copy number is a result of cancer or aneuploidy. In some cases, the first chromosome or second chromosome, or both, has a decrease in copy number. In some cases, the decrease in copy number is a result of cancer or aneuploidy.
  • An additional aspect of the disclosure provides a method comprising: (a) partitioning a first nucleic acid into a first partition, where the first nucleic acid comprises the target sequence derived from a first chromosome of an organism; (b) partitioning a second nucleic acid into a second partition, where the second nucleic acid comprises the target sequence derived from a second chromosome of the organism; (c) in the first partition, attaching a first barcode sequence to fragments of the first nucleic acid or to copies of portions of the first nucleic acid to provide first barcoded fragments; (d) in the second partition, attaching a second barcode sequence to fragments of the second nucleic acid or to copies of portions of the second nucleic acid to provide second barcoded fragments, the second barcode sequence being different from the first barcode sequence; (e) determining the nucleic acid sequence of the first and second barcoded fragments, and assembling a nucleic acid sequence of the first and second nucleic acids; and (f)
  • oligonucleotides comprising the first barcode sequence are co-partitioned with the first nucleic acid
  • oligonucleotides comprising the second barcode sequence are co-partitioned with the second nucleic acid.
  • the oligonucleotides comprising the first barcode sequence are releasably attached to a first bead
  • the oligonucleotides comprising the second barcode sequence are releasably attached to a second bead
  • the co-partitioning comprises co-partitioning the first and second beads into the first and second partitions, respectively.
  • the first and second partitions comprise droplets in an emulsion.
  • the first chromosome is a paternal chromosome and the second chromosome is a maternal chromosome.
  • first chromosome and the second chromosome are homologous chromosomes.
  • the first nucleic acid and the second nucleic acid comprise one or more variations.
  • the first and second chromosomes are derived from a fetus.
  • the first and second nucleic acids are obtained from a sample taken from a pregnant woman.
  • the first chromosome is chromosome 21, 18, or 13.
  • the second chromosome is chromosome 21, 18, or 13.
  • the method further comprises determining the relative quantity of the first or second chromosome. In some cases, the method further comprises determining the quantity of the first or second chromosome relative to a reference chromosome. In some cases, the first chromosome or second chromosome, or both, has an increase in copy number. In some cases, the increase in copy number is a result of cancer or aneuploidy. In some cases, the first chromosome or second chromosome, or both, has a decrease in copy number. In some cases, the decrease in copy number is a result of cancer or aneuploidy.
  • An additional aspect of the disclosure provides a method for characterizing a fetal nucleic acid sequence.
  • the method comprises: (a) determining a maternal nucleic acid sequence, wherein the maternal nucleic acid is derived from a pregnant mother of a fetus, by: (i) fragmenting a maternal nucleic acid to provide a plurality of first maternal fragments; (ii) separating the plurality of first maternal fragments into maternal partitions; (iii) creating a plurality of second maternal fragments from each of the first maternal fragments within their respective maternal partitions, the plurality of second maternal fragments having a first barcode sequence attached thereto, wherein within a given maternal partition of the maternal partitions the second maternal fragments comprise a first common barcode sequence attached thereto; (iv) sequencing the plurality of second maternal fragments to provide a plurality of maternal fragment sequences; (v) attributing the maternal fragment sequences to an original first maternal fragment based at least in part on the presence of the first common barcode sequence to determine
  • the paternal fragment sequences and the maternal fragment sequences are each used to link sequences into one or more inferred contigs.
  • the inferred contigs are used to construct maternal and paternal phase blocks.
  • the sequence of the fetal nucleic acid is compared to the maternal and paternal phase blocks to construct fetal phase blocks.
  • the paternal fragment sequences are assembled to produce at least a portion of sequences for the plurality of first paternal fragments, thereby determining the paternal nucleic acid sequence
  • the maternal fragment sequences are assembled to produce at least a portion of sequences for the plurality of first maternal fragments, thereby determining the maternal nucleic acid sequence.
  • the determining the paternal nucleic acid sequence comprises mapping the paternal fragment sequences to a paternal reference
  • the determining the maternal nucleic acid sequence comprises mapping the maternal fragment sequences to a maternal reference.
  • the sequence of the fetal nucleic acid is determined with an accuracy of at least 99%. In some cases, the one or more genetic variations of the sequence of the fetal nucleic acid are determined with an accuracy of at least 99%. In some cases, the one or more genetic variations are selected from the group consisting of a structural variation and a single nucleotide polymorphism (SNP). In some cases, the one or more genetic variations are a structural variation selected from the group consisting of a copy number variation, an insertion, a deletion, a translocation, a retrotransposon, an inversion, a rearrangement, a repeat expansion and a duplication.
  • SNP single nucleotide polymorphism
  • the method for characterizing the fetal nucleic acid sequence further comprises, in (c), determining the one or more genetic variations of the sequence of the fetal nucleic acid using one or more genetic variations determined for the maternal nucleic acid sequence and the paternal nucleic acid sequence. In some cases, the method for characterizing the fetal nucleic acid sequence further comprises, in (c), determining one or more de novo mutations of the fetal nucleic acid. In some cases, the method for characterizing the fetal nucleic acid sequence further comprises, during or after (c), determining an aneuploidy associated with the fetal nucleic acid.
  • the method for characterizing the fetal nucleic acid sequence further comprises, during or after (v) in (a), haplotyping the maternal nucleic acid sequence to provide a haplotype-resolved maternal nucleic acid sequence and, during or after (v) in (b), haplotyping the paternal nucleic acid sequence to provide a haplotype-resolved paternal nucleic acid sequence.
  • the method for characterizing the fetal nucleic acid sequence further comprises in (c), determining the sequence of the fetal nucleic acid and/or the one or more genetic variations using the haplotype-resolved maternal nucleic acid sequence and the haplotype-resolved paternal nucleic acid sequence.
  • one or more of the maternal nucleic acid and the paternal nucleic acid is genomic deoxyribonucleic acid (DNA).
  • the fetal nucleic acid comprises cell-free nucleic acid.
  • the method for characterizing the fetal nucleic acid sequence further comprises, in (a), determining the maternal nucleic acid sequence with an accuracy of at least 99%. In some cases, the method for characterizing the fetal nucleic acid sequence further comprises, in (b), determining the paternal nucleic acid sequence with an accuracy of at least 99%.
  • the maternal nucleic acid sequence and/or the paternal nucleic acid sequence has a length greater than 10 kilobases (kb).
  • the maternal and paternal partitions comprise droplets in an emulsion.
  • the first barcode sequence is provided in the given maternal partition releasably attached to a first particle.
  • the second barcode sequence is provided in the given paternal partition releasably attached to a second particle.
  • An additional aspect of the disclosure provides a method for characterizing a sample nucleic acid.
  • the method comprises: (a) obtaining a biological sample from a subject, which biological sample includes a cell-free sample nucleic acid; (b) in a droplet, attaching a barcode sequence to fragments of the cell-free sample nucleic acid or to copies of portions of the sample nucleic acid, to provide barcoded sample fragments; (c) determining nucleic acid sequences of the barcoded sample fragments and providing a sample nucleic acid sequence based on the nucleic acid sequences of the barcoded sample fragments; (d) using a programmed computer processor to generate a comparison of the sample nucleic acid sequence to a reference nucleic acid sequence, which reference nucleic acid sequence has a length greater 10 kilobases (kb) and an accuracy of at least 99%; and (e) using the comparison to identify one or more genetic variations in the sample nucleic acid sequence, thereby associating the sample nucleic acid
  • the one or more genetic variations in the sample nucleic acid sequence are selected from the group consisting of a structural variation and a single nucleotide polymorphism (SNP).
  • the one or more genetic variations of the sample nucleic acid sequence are a structural variation selected from the group consisting of a copy number variation, an insertion, a deletion, a retrotransposon, a translocation, an inversion, a rearrangement, a repeat expansion and a duplication.
  • the sample nucleic acid sequence is provided with an accuracy of at least 99%.
  • the barcode sequence is provided in the droplet releasably attached to a particle, and wherein (b) further comprises releasing the barcode sequence from the particle into the droplet prior to the attaching the barcode sequence.
  • the barcode sequence is provided as a portion of a primer sequence releasably attached to the particle, wherein the primer sequence also includes a random N-mer sequence, and wherein (b) further comprises releasing the primer sequence from the particle into the droplet prior to the attaching the barcode sequence.
  • the method for characterizing the sample nucleic acid further comprises: (i) in an additional droplet, attaching an additional barcode sequence to fragments of a reference nucleic acid or to copies of portions of the reference nucleic acid to provide barcoded reference fragments; and (ii) determining nucleic acid sequences of the barcoded reference fragments and determining the reference nucleic acid sequence based on the nucleic acid sequences of the barcoded reference fragments.
  • the determining the reference nucleic acid sequence comprises assembling the nucleic acid sequences of the barcoded reference fragments.
  • the method for characterizing the sample nucleic acid further comprises providing the additional barcode sequence in the additional droplet releasably attached to a particle and releasing the additional barcode sequence from the particle into the additional partition prior to the attaching the additional barcode sequence. In some cases, the method for characterizing the sample nucleic acid further comprises providing the additional barcode sequence as a portion of a primer sequence releasably attached to the particle, wherein the primer sequence also includes a random N-mer sequence, and releasing the primer from the particle into the additional droplet prior to the attaching the additional barcode sequence.
  • the method for characterizing the sample nucleic acid further comprises attaching the additional barcode sequence to the fragments of the reference nucleic acid or to the copies of portions of the reference nucleic acid in an amplification reaction using the primer. In some cases, the method for characterizing the sample nucleic acid further comprises determining one or more genetic variations in the reference nucleic acid sequence.
  • the one or more genetic variations in the reference nucleic acid sequence are selected from the group consisting of a structural variation and a single nucleotide polymorphism (SNP). In some cases, the one or more genetic variations in the reference nucleic acid sequence are a structural variation selected from the group consisting of a copy number variation, an insertion, a deletion, a retrotransposon, a translocation, an inversion, a rearrangement, a repeat expansion and a duplication. In some cases, the reference nucleic acid comprises a germline nucleic acid sequence. In some cases, the reference nucleic acid comprises a cancer nucleic acid sequence. In some cases, the sample nucleic acid sequence has a length of greater than 10 kb.
  • the reference nucleic acid is derived from a genome indicative of an absence of a disease state. In some cases, the reference nucleic acid is a derived from a genome indicative of a disease state. In some cases, the disease state comprises cancer. In some cases, the disease state comprises an aneuploidy. In some cases, the cell-free sample nucleic acid comprises tumor nucleic acid. In some cases, the tumor nucleic acid comprises a circulating tumor nucleic acid.
  • FIG. 1 provides a schematic illustration of identification and analysis of phased variants using conventional processes versus example processes and systems described herein.
  • FIG. 2 provides a schematic illustration of the identification and analysis of structural variations using conventional processes versus example processes and systems described herein.
  • FIG. 3 illustrates an example workflow for performing an assay to detect copy number or haplotype using methods and compositions disclosed herein.
  • FIG. 4 provides a schematic illustration of an example process for combining a nucleic acid sample with beads and partitioning the nucleic acids and beads into discrete droplets
  • FIG. 5 provides a schematic illustration of an example process for barcoding and amplification of chromosomal nucleic acid fragments.
  • FIG. 6 provides a schematic illustration of an example use of barcoding of chromosomal nucleic acid fragments in attributing sequence data to individual chromosomes.
  • FIG. 7 provides a schematic illustration of an example of phased sequencing processes.
  • FIG. 8 provides a schematic illustration of an example subset of the genome of a healthy patient (top panel) and a cancer patient with a gain in haplotype copy number (central panel) or loss of haplotype copy number (bottom panel).
  • FIGS. 9A-B provides: (a) a schematic illustration showing a relative contribution of tumor DNA and (b) a representation of detecting such copy gains and losses by ordinary sequencing methods.
  • FIG. 10 provides a schematic illustration of an example of detecting copy gains and losses using a single variant position (left panel) and combined variant positions (right panel).
  • FIG. 11 provides a schematic illustration of the potential of described methods and systems to identify gains and losses in copy number.
  • FIG. 12 illustrates an example workflow for performing an aneuploidy test based on determination of chromosome number and copy number variation using methods and compositions described herein.
  • FIGS. 13A-B illustrate an example overview of a process for identifying structural variations such as translocations and gene fusions in genetic samples.
  • FIG. 14 illustrates an example workflow for performing a cancer diagnostic test based on determination of copy number variation using the methods and compositions described herein.
  • FIG. 15 provides a schematic illustration of an EML-4-ALK structural variation from an NCI-H2228 cancer cell line.
  • FIGS. 16A and 16B provide barcode mapping data using the systems described herein for identifying the presence of the EML-4-ALK variant structure shown in FIG. 15 , in the cancer cell line ( FIG. 16A ), as compared to a negative control cell line ( FIG. 16B ).
  • FIG. 17 schematically depicts an example workflow of analyzing a paternal nucleic acid sequence as described herein.
  • FIG. 18 schematically depicts an example workflow of analyzing a maternal nucleic acid sequence as described herein.
  • FIG. 19 schematically depicts an example workflow of analyzing a fetal nucleic acid sequence as described herein.
  • FIG. 20 schematically depicts an example workflow of analyzing a reference nucleic acid sequence as described herein.
  • FIG. 21 schematically depicts an example workflow of analyzing a sample nucleic acid sequence as described herein.
  • FIG. 22 schematically depicts an example computer control system.
  • organism generally refers to a contiguous living system.
  • Non-limiting examples of organisms includes animals (e.g., humans, other types of mammals, birds, reptiles, insects, other example types of animals described elsewhere herein), plants, fungi and bacterium.
  • the term “contig” generally refers to a contiguous nucleic acid sequence of a given length.
  • the contiguous sequence may be derived from an individual sequence read, including either a short or long read sequence read, or from an assembly of sequence reads that are aligned and assembled based upon overlapping sequences within the reads, or that are defined as linked within a fragment based upon other known linkage data, e.g., the tagging with common barcodes as described elsewhere herein.
  • overlapping sequence reads may likewise include short reads, e.g., less than 500 bases, e.g., in some cases from approximately 100 to 500 bases, and in some cases from 100 to 250 bases, or based upon longer sequence reads, e.g., greater than 500 bases, 1000 bases or even greater than 10,000 bases.
  • This disclosure provides methods and systems useful in providing significant advances in the characterization of genetic material.
  • the methods and systems can be useful in providing genetic characterizations that are very difficult or even impossible using generally available technologies, including, for example, haplotype phasing, identifying structural variations, e.g., deletions, duplications, copy-number variants, insertions, inversions, retrotransposons, translocations, LTRs, STRs, and a variety of other useful characterizations.
  • the methods and systems described herein accomplish the above goals by providing for the sequencing of long individual nucleic acid molecules, which permit the identification and use of long range variant information, e.g., relating variations to different sequence segments, including sequence segments containing other variations, that are separated by significant distances in the originating sequence, e.g., longer than is provided by short read sequencing technologies.
  • long range variant information e.g., relating variations to different sequence segments, including sequence segments containing other variations, that are separated by significant distances in the originating sequence, e.g., longer than is provided by short read sequencing technologies.
  • these methods and systems achieve these objectives with the advantage of extremely low sequencing error rates of short read sequencing technologies, and far below those of the reported long read-length sequencing technologies, e.g., single molecule sequencing, such as SMRT Sequencing and nanopore sequencing technologies.
  • the methods and systems described herein segment long nucleic acid molecules into smaller fragments that are sequenceable using high-throughput, higher accuracy short-read sequencing technologies, but do such segmentation in a manner that allows the sequence information derived from the smaller fragments to be attributed to the originating longer individual nucleic acid molecules.
  • sequence information derived from the smaller fragments can be attributed to the originating longer individual nucleic acid molecules.
  • characterization information can include haplotype phasing, identification of structural variations, and identifying copy number variations.
  • FIG. 1 schematically illustrates the challenges of phased variant calling and the solutions presented by the methods described herein.
  • nucleic acids 102 and 104 in Panel I represent two haploid sequences of the same region of different chromosomes, e.g., maternally and paternally inherited chromosomes.
  • Each sequence includes a series of variants, e.g., variants 106 - 114 on nucleic acid 102 , and variants 116 - 122 on nucleic acid 104 , at different alleles that characterize each haploid sequence.
  • pooled fragments from both haploid sequences are sequenced, resulting in a large number of short sequence reads 124 , and the resulting sequence 126 is assembled (shown in Panel IIIa).
  • the resulting assembly shown in Panel IIIa results in single consensus sequence assembly 126 , including all of variants 106 - 122 .
  • Panel IIb of FIG. 1 the methods and systems described herein breakdown or segment the longer nucleic acids 102 and 104 into shorter, sequenceable fragments, as with the above described approach, but retain with those fragments the ability to attribute them to their originating molecular context.
  • This is schematically illustrated in Panel IIb, in which different fragments are grouped or “compartmentalized” according to their originating molecular context. In the context of the disclosure, this grouping can be accomplished through one or both of physically partitioning the fragments into groups that retain the molecular context, as well as tagging those fragments in order to subsequently be able to elucidate that context.
  • This grouping is schematically illustrated as the allocation of the shorter sequence reads as between groups 128 and 130 , representing short sequence reads from nucleic acids 102 and 104 , respectively. Because the originating sequence context is retained through the sequencing process, one can employ that context in resolving the original molecular context, e.g., the phasing, of the various variants 106 - 114 and 116 - 122 as between sequences 102 and 104 , respectively.
  • the original molecular context e.g., the phasing
  • the methods and systems are useful in characterizing structural variants that are generally unidentifiable or at least difficult to identify, using short read sequence technologies.
  • a genomic sample may include nucleic acids that include a translocation event, e.g., a translocation of genetic element 206 from sequence 202 to sequence 204 .
  • translocations may be any of a variety of different translocation types, including, for example, translocations between different chromosomes, whether to the same or different regions, between different regions of the same chromosome.
  • the short sequence reads derived from sequences 202 and 204 are provided with a compartmentalization, shown in Panel IIb as groups 214 and 216 , that retain the original molecular grouping of the smaller sequence fragments, allowing their assembly as sequences 218 and 220 , shown in Panel IIIb, allowing attribution back to the originating sequences 202 and 204 , and identification of the translocation variation, e.g., translocated sequence segment 206 a in correct sequence assemblies 218 and 220 , as illustrated in Panel Mb.
  • a compartmentalization shown in Panel IIb as groups 214 and 216 , that retain the original molecular grouping of the smaller sequence fragments, allowing their assembly as sequences 218 and 220 , shown in Panel IIIb, allowing attribution back to the originating sequences 202 and 204 , and identification of the translocation variation, e.g., translocated sequence segment 206 a in correct sequence assemblies 218 and 220 , as illustrated in Panel Mb.
  • individual molecular context refers to sequence context beyond the specific sequence read, e.g., relation to adjacent or proximal sequences, that are not included within the sequence read itself, and as such, will generally be such that they would not be included in whole or in part in a short sequence read, e.g., a read of about 150 bases, or about 300 bases for paired reads.
  • a short sequence read e.g., a read of about 150 bases, or about 300 bases for paired reads.
  • the methods and systems provide long range sequence context for short sequence reads.
  • Such long range context includes relationship or linkage of a given sequence read to sequence reads that are within a distance of each other of longer than 1 kilobase (kb), longer than 5 kb, longer than 10 kb, longer than 15 kb, longer than 20 kb, longer than 30 kb, longer than 40 kb, longer than 50 kb, longer than 60 kb, longer than 70 kb, longer than 80 kb, longer than 90 kb or even longer than 100 kb, or longer.
  • kb kilobase
  • Sequence context can include lower resolution context, e.g., from mapping the short sequence reads to the individual longer molecules or contigs of linked molecules, as well as the higher resolution sequence context, e.g., from long range sequencing of large portions of the longer individual molecules, e.g., having contiguous determined sequences of individual molecules where such determined sequences are longer than 1 kb, longer than 5 kb, longer than 10 kb, longer than 15 kb, longer than 20 kb, longer than 30 kb, longer than 40 kb, longer than 50 kb, longer than 60 kb, longer than 70 kb, longer than 80 kb, longer than 90 kb or even longer than 100 kb.
  • the attribution of short sequences to longer nucleic acids may include both mapping of short sequences against longer nucleic acid stretches to provide high level sequence context, as well as providing assembled sequences from the short sequences through these longer nucleic acids.
  • long range sequence context associated with long individual molecules
  • having such long range sequence context also allows one to infer even longer range sequence context.
  • long range molecular context described above, one can identify overlapping variant portions, e.g., phased variants, translocated sequences, etc., among long sequences from different originating molecules, allowing the inferred linkage between those molecules.
  • inferred linkages or molecular contexts are referred to herein as “inferred contigs”.
  • phase blocks may represent commonly phased sequences, e.g., where by virtue of overlapping phased variants, one can infer a phased contig of substantially greater length than the individual originating molecules.
  • phase blocks are referred to herein as “phase blocks”.
  • contig or phase block lengths having an N50 (the contig or phase block length for which the collection of all phase blocks or contigs of that length or longer contain at least half of the sum of the lengths of all contigs or phase blocks, and for which the collection of all contigs or phase blocks of that length or shorter also contains at least half the sum of the lengths of all contigs or phase blocks), mode, mean, or median of at least about 10 kilobases (kb), at least about 20 kb, at least about 50 kb.
  • N50 the contig or phase block length for which the collection of all phase blocks or contigs of that length or longer contain at least half of the sum of the lengths of all contigs or phase blocks, and for which the collection of all contigs or phase blocks of that length or shorter also contains at least half the sum of the lengths of all contigs or phase blocks
  • mode mean, or median of at least about 10 kilobases (kb), at least about 20 kb, at least about 50 kb.
  • inferred contig or phase block lengths have an N50, mode, mean, or median of at least about 100 kb, at least about 150 kb, at least about 200 kb, and in some cases, at least about 250 kb, at least about 300 kb, at least about 350 kb, at least about 400 kb, and in some cases, at least about 500 kb, at least about 750 kb, at least about 1 Mb, at least about 1.75 Mb, at least about 2.5 Mb or more, are attained.
  • maximum inferred contig or phase block lengths of at least or in excess of 20 kb, 40 kb, 50 kb, 100 kb, 200 kb, 300 kb, 400 kb, 500 kb, 750 kb, 1 megabase (Mb), 1.75 Mb, 2 Mb or 2.5 Mb may be obtained.
  • inferred contigs or phase blocks lengths can be at least about 20 kb, at least about 40 kb, at least about 50 kb, at least about 100 kb, at least about 200 kb, and in some cases, at least about 500 kb, at least about 750 kb, at least about 1 Mb, and in some cases at least about 1.75 Mb, at least about 2.5 Mb or more.
  • the methods and systems described herein provide for the compartmentalization, depositing or partitioning of sample nucleic acids, or fragments thereof, into discrete compartments or partitions (referred to interchangeably herein as partitions), where each partition maintains separation of its own contents from the contents of other partitions.
  • Unique identifiers e.g., barcodes
  • the partitions that hold the compartmentalized or partitioned sample nucleic acids may be previously, subsequently or concurrently delivered to the partitions that hold the compartmentalized or partitioned sample nucleic acids, in order to allow for the later attribution of the characteristics, e.g., nucleic acid sequence information, to the sample nucleic acids included within a particular compartment, and particularly to relatively long stretches of contiguous sample nucleic acids that may be originally deposited into the partitions.
  • the sample nucleic acids can be partitioned such that the nucleic acids are present in the partitions in relatively long fragments or stretches of contiguous nucleic acid molecules. These fragments can represent a number of overlapping fragments of the overall sample nucleic acids to be analyzed, e.g., an entire chromosome, exome, or other large genomic fragment. These sample nucleic acids may include whole genomes, individual chromosomes, exomes, amplicons, or any of a variety of different nucleic acids of interest.
  • these fragments of the sample nucleic acids may be longer than 100 bases, longer 500 bases, longer than 1 kb, longer than 5 kb, longer than 10 kb, longer than 15 kb, longer than 20 kb, longer than 30 kb, longer than 40 kb, longer than 50 kb, longer than 60 kb, longer than 70 kb, longer than 80 kb, longer than 90 kb or even longer than 100 kb, which permits the longer range molecular context described above.
  • the sample nucleic acids can also be partitioned at a level whereby a given partition has a very low probability of including two overlapping fragments of the starting sample nucleic acid. This can be accomplished by providing the sample nucleic acid at a low input amount and/or concentration during the partitioning process. As a result, in some cases, a given partition may include a number of long, but non-overlapping fragments of the starting sample nucleic acids.
  • the sample nucleic acids in the different partitions are then associated with unique identifiers, where for any given partition, nucleic acids contained therein possess the same unique identifier, but where different partitions may include different unique identifiers.
  • the partitioning allocates the sample components into very small volume partitions or droplets, it will be appreciated that in order to achieve the allocation as set forth above, one need not conduct substantial dilution of the sample, as would can be required in higher volume processes, e.g., in tubes, or wells of a multiwell plate. Further, because the systems described herein employ such high levels of barcode diversity, one can allocate diverse barcodes among higher numbers of genomic equivalents, as provided above. In particular, previously described, multiwell plate approaches (see, e.g., U.S. Patent Publication No.
  • 2013/0079231 and 2013/0157870 may only operate with a hundred to a few hundred different barcode sequences, and employ a limiting dilution process of their sample in order to be able to attribute barcodes to different cells/nucleic acids. As such, they generally operate with far fewer than 100 cells, which would can provide a ratio of genomes:(barcode type) on the order of 1:10, and certainly well above 1:100.
  • diverse barcode types can operate at genome:(barcode type) ratios that are on the order of 1:50 or less, 1:100 or less, 1:1000 or less, or even smaller ratios, while also allowing for loading higher numbers of genomes (e.g., on the order of greater than 100 genomes per assay, greater than 500 genomes per assay, 1000 genomes per assay, or even more) while still providing for far improved barcode diversity per genome.
  • the oligonucleotides may comprise at least a first and second region.
  • the first region may be a barcode region that, as between oligonucleotides within a given partition, may be substantially the same barcode sequence, but as between different partitions, may and, in most cases is a different barcode sequence.
  • the second region may be a an N-mer (e.g., either a random N-mer or an N-mer designed to target a particular sequence) that can be used to prime the nucleic acids within the sample within the partitions.
  • the N-mer may be designed to target a particular chromosome (e.g., chromosome 1, 13, 18, or 21), or region of a chromosome, e.g., an exome or other targeted region.
  • the N-mer may be designed to target a particular gene or genetic region, such as a gene or region associated with a disease or disorder (e.g., cancer).
  • an amplification reaction may be conducted using the second N-mer to prime the nucleic acid sample at different places along the length of the nucleic acid.
  • each partition may contain amplified products of the nucleic acid that are attached to an identical or near-identical barcode, and that may represent overlapping, smaller fragments of the nucleic acids in each partition.
  • the bar-code can serve as a marker that signifies that a set of nucleic acids originated from the same partition, and thus potentially also originated from the same strand of nucleic acid.
  • the nucleic acids may be pooled, sequenced, and aligned using a sequencing algorithm.
  • shorter sequence reads may, by virtue of their associated barcode sequences, be aligned and attributed to a single, long fragment of the sample nucleic acid, all of the identified variants on that sequence can be attributed to a single originating fragment and single originating chromosome. Further, by aligning multiple co-located variants across multiple long fragments, one can further characterize that chromosomal contribution. Accordingly, conclusions regarding the phasing of particular genetic variants may then be drawn. Such information may be useful for identifying haplotypes, which are generally a specified set of genetic variants that reside on the same nucleic acid strand or on different nucleic acid strands. Copy number variations may also be identified in this manner.
  • Haplotype phasing and copy number variation data are generally not available by sequencing genomic DNA because biological samples (blood, cells, or tissue samples, for example) are processed en masse to extract the genetic material from an ensemble of cells, and convert it into sequencing libraries that are configured specifically for a given sequencing technology.
  • sequencing data generally provides non-phased genotypes, in which it is not possible to determine whether genetic information is present on the same or different chromosomes.
  • such ensemble sample preparation and sequencing methods are also predisposed towards primarily identifying and characterizing the majority constituents in the sample, and are not designed to identify and characterize minority constituents, e.g., genetic material contributed by one chromosome, or by one or a few cells, or fragmented tumor cell DNA molecule circulating in the bloodstream, that constitute a small percentage of the total DNA in the extracted sample.
  • the described methods and systems also provide a significant advantage for detecting minor populations that are present in a larger sample. As such, they can be useful for assessing copy number variations in a sample since often only a small portion of a clinical sample contains tissue with copy number variations. For example, if the sample is a blood sample from a pregnant woman, only a small fraction of the sample would contain circulating cell-free fetal DNA.
  • the use of the barcoding technique disclosed herein confers the unique capability of providing individual molecular context for a given set of genetic markers, i.e., attributing a given set of genetic markers (as opposed to a single marker) to individual sample nucleic acid molecules, and through variant coordinated assembly, to provide a broader or even longer range inferred individual molecular context, among multiple sample nucleic acid molecules, and/or to a specific chromosome.
  • These genetic markers may include specific genetic loci, e.g., variants, such as SNPs, or they may include short sequences.
  • the use of barcoding confers the additional advantages of facilitating the ability to discriminate between minority constituents and majority constituents of the total nucleic acid population extracted from the sample, e.g.
  • implementation in a microfluidics format confers the ability to work with extremely small sample volumes and low input quantities of DNA, as well as the ability to rapidly process large numbers of sample partitions (e.g., droplets) to facilitate genome-wide tagging.
  • an advantage of the methods and systems described herein is that they can achieve results through the use of ubiquitously available, short read sequencing technologies.
  • Such technologies have the advantages of being readily available and widely dispersed within the research community, with protocols and reagent systems that are well characterized and highly effective.
  • These short read sequencing technologies include those available from, e.g., Illumina, Inc. (e.g., GXII, NextSeq, MiSeq, HiSeq, X10), Ion Torrent division of Thermo-Fisher (e.g., Ion Proton and Ion PGM), pyrosequencing methods, as well as others.
  • the methods and systems described herein utilize these short read sequencing technologies and do so with their associated low error rates.
  • the methods and systems described herein achieve individual molecular read lengths or context, as described above, but with individual sequencing reads, excluding mate pair extensions, that are shorter than 1000 bp, shorter than 500 bp, shorter than 300 bp, shorter than 200 bp, shorter than 150 bp or even shorter; and with sequencing error rates for such individual molecular read lengths that are less than 5%, less than 1%, less than 0.5%, less than 0.1%, less than 0.05%, less than 0.01%, less than 0.005%, or even less than 0.001%.
  • the methods and systems described in the disclosure provide for depositing or partitioning individual samples (e.g., nucleic acids) into discrete partitions, where each partition maintains separation of its own contents from the contents in other partitions.
  • the partitions refer to containers or vessels that may include a variety of different forms, e.g., wells, tubes, micro or nanowells, through holes, or the like. In some aspects, however, the partitions are flowable within fluid streams. These vessels may be comprised of, e.g., microcapsules or micro-vesicles that have an outer barrier surrounding an inner fluid center or core, or they may be a porous matrix that is capable of entraining and/or retaining materials within its matrix.
  • these partitions may comprise droplets of aqueous fluid within a non-aqueous continuous phase, e.g., an oil phase.
  • a non-aqueous continuous phase e.g., an oil phase.
  • a variety of different vessels are described in, for example, U.S. patent application Ser. No. 13/966,150, filed Aug. 13, 2013.
  • emulsion systems for creating stable droplets in non-aqueous or oil continuous phases are described in detail in, e.g., U.S. Patent Publication No. 2010/0105112, the full disclosure of which is herein incorporated by reference in its entirety.
  • microfluidic channel networks can be suited for generating partitions as described herein. Examples of such microfluidic devices include those described in detail in U.S. Provisional Patent Application No.
  • partitioning of sample materials into discrete partitions may generally be accomplished by flowing an aqueous, sample containing stream, into a junction into which is also flowing a non-aqueous stream of partitioning fluid, e.g., a fluorinated oil, such that aqueous droplets are created within the flowing stream partitioning fluid, where such droplets include the sample materials.
  • partitions e.g., droplets
  • the partitions can also include co-partitioned barcode oligonucleotides.
  • the relative amount of sample materials within any particular partition may be adjusted by controlling a variety of different parameters of the system, including, for example, the concentration of sample in the aqueous stream, the flow rate of the aqueous stream and/or the non-aqueous stream, and the like.
  • the partitions described herein are often characterized by having extremely small volumes.
  • the droplets may have overall volumes that are less than 1000 picoliters (pL), less than 900 pL, less than 800 pL, less than 700 pL, less than 600 pL, less than 500 pL, less than 400 pL, less than 300 pL, less than 200 pL, less than 100 pL, less than 50 pL, less than 20 pL, less than 10 pL, or even less than 1 pL.
  • pL picoliters
  • the sample fluid volume within the partitions may be less than 90% of the above described volumes, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, or even less than 10% the above described volumes.
  • the use of low reaction volume partitions can be advantageous in performing reactions with very small amounts of starting reagents, e.g., input nucleic acids.
  • the sample nucleic acids within partitions are generally provided with unique identifiers such that, upon characterization of those nucleic acids they may be attributed as having been derived from their respective origins. Accordingly, the sample nucleic acids can be co-partitioned with the unique identifiers (e.g., barcode sequences).
  • the unique identifiers are provided in the form of oligonucleotides that comprise nucleic acid barcode sequences that may be attached to those samples.
  • the oligonucleotides are partitioned such that as between oligonucleotides in a given partition, the nucleic acid barcode sequences contained therein are the same, but as between different partitions, the oligonucleotides can have differing barcode sequences. In some aspects, only one nucleic acid barcode sequence may be associated with a given partition, although in some cases, two or more different barcode sequences may be present.
  • the nucleic acid barcode sequences can include from 6 to about 20 or more nucleotides within the sequence of the oligonucleotides. These nucleotides may be completely contiguous, i.e., in a single stretch of adjacent nucleotides, or they may be separated into two or more separate subsequences that are separated by one or more nucleotides. In some cases, separated subsequences may be from about 4 to about 16 nucleotides in length.
  • the co-partitioned oligonucleotides can also comprise other functional sequences useful in the processing of the partitioned nucleic acids. These sequences include, e.g., targeted or random/universal amplification primer sequences for amplifying the genomic DNA from the individual nucleic acids within the partitions while attaching the associated barcode sequences, sequencing primers, hybridization or probing sequences, e.g., for identification of presence of the sequences, or for pulling down barcoded nucleic acids, or any of a number of other potential functional sequences.
  • sequences include, e.g., targeted or random/universal amplification primer sequences for amplifying the genomic DNA from the individual nucleic acids within the partitions while attaching the associated barcode sequences, sequencing primers, hybridization or probing sequences, e.g., for identification of presence of the sequences, or for pulling down barcoded nucleic acids, or any of a number of other potential functional sequences.
  • beads are provided that each may include large numbers of the above described oligonucleotides releasably attached to the beads, where all of the oligonucleotides attached to a particular bead may include the same nucleic acid barcode sequence, but where a large number of diverse barcode sequences may be represented across the population of beads used.
  • the population of beads may provide a diverse barcode sequence library that may include at least 1000 different barcode sequences, at least 10,000 different barcode sequences, at least 100,000 different barcode sequences, or in some cases, at least 1,000,000 different barcode sequences.
  • each bead may be provided with large numbers of oligonucleotide molecules attached.
  • the number of molecules of oligonucleotides including the barcode sequence on an individual bead may be at least bout 10,000 oligonucleotides, at least 100,000 oligonucleotide molecules, at least 1,000,000 oligonucleotide molecules, at least 100,000,000 oligonucleotide molecules, and in some cases at least 1 billion oligonucleotide molecules.
  • the oligonucleotides may be releasable from the beads upon the application of a particular stimulus to the beads.
  • the stimulus may be a photo-stimulus, e.g., through cleavage of a photo-labile linkage that may release the oligonucleotides.
  • a thermal stimulus may be used, where elevation of the temperature of the beads environment may result in cleavage of a linkage or other release of the oligonucleotides form the beads.
  • a chemical stimulus may be used that cleaves a linkage of the oligonucleotides to the beads, or otherwise may result in release of the oligonucleotides from the beads.
  • the beads including the attached oligonucleotides may be co-partitioned with the individual samples, such that a single bead and a single sample are contained within an individual partition.
  • the relative flow rates of the fluids can be controlled such that, on average, the partitions contain less than one bead per partition, in order to ensure that those partitions that are occupied, are primarily singly occupied.
  • the flows and channel architectures are controlled as to ensure a desired number of singly occupied partitions, less than a certain level of unoccupied partitions and less than a certain level of multiply occupied partitions.
  • FIG. 3 illustrates an example method for barcoding and subsequently sequencing a sample nucleic acid, such as for use for a copy number variation or haplotype assay.
  • a sample comprising nucleic acid may be obtained from a source, 300 , and a set of barcoded beads may also be obtained, 310 .
  • the beads can be linked to oligonucleotides containing one or more barcode sequences, as well as a primer, such as a random N-mer or other primer.
  • the barcode sequences are releasable from the barcoded beads, e.g., through cleavage of a linkage between the barcode and the bead or through degradation of the underlying bead to release the barcode, or a combination of the two.
  • the barcoded beads can be degraded or dissolved by an agent, such as a reducing agent to release the barcode sequences.
  • an agent such as a reducing agent to release the barcode sequences.
  • a low quantity of the sample comprising nucleic acid, 305 , barcoded beads, 315 , and, in some cases, other reagents, e.g., a reducing agent, 320 are combined and subject to partitioning.
  • such partitioning may involve introducing the components to a droplet generation system, such as a microfluidic device, 325 .
  • a droplet generation system such as a microfluidic device, 325 .
  • a water-in-oil emulsion 330 may be formed, where the emulsion contains aqueous droplets that contain sample nucleic acid, 305 , reducing agent, 320 , and barcoded beads, 315 .
  • the reducing agent may dissolve or degrade the barcoded beads, thereby releasing the oligonucleotides with the barcodes and random N-mers from the beads within the droplets, 335 .
  • the random N-mers may then prime different regions of the sample nucleic acid, resulting in amplified copies of the sample after amplification, where each copy is tagged with a barcode sequence, 340 .
  • each droplet contains a set of oligonucleotides that contain identical barcode sequences and different random N-mer sequences.
  • additional sequences e.g., sequences that aid in particular sequencing methods, additional barcodes, etc.
  • Sequencing may then be performed, 355 , and an algorithm applied to interpret the sequencing data, 360 .
  • Sequencing algorithms are generally capable, for example, of performing analysis of barcodes to align sequencing reads and/or identify the sample from which a particular sequence read belongs.
  • FIG. 4 An example of a microfluidic channel structure for co-partitioning samples and beads comprising barcode oligonucleotides is schematically illustrated in FIG. 4 . As shown, channel segments 402 , 404 , 406 , 408 and 410 are provided in fluid communication at channel junction 412 . An aqueous stream comprising the individual samples 414 is flowed through channel segment 402 toward channel junction 412 . As described elsewhere herein, these samples may be suspended within an aqueous fluid prior to the partitioning process.
  • an aqueous stream comprising the barcode carrying beads 416 is flowed through channel segment 404 toward channel junction 412 .
  • a non-aqueous partitioning fluid is introduced into channel junction 412 from each of side channels 406 and 408 , and the combined streams are flowed into outlet channel 410 .
  • the two combined aqueous streams from channel segments 402 and 404 are combined, and partitioned into droplets 418 , that include co-partitioned samples 414 and beads 416 .
  • each of the fluids combining at channel junction 412 can optimize the combination and partitioning to achieve a desired occupancy level of beads, samples or both, within the partitions 418 that are generated.
  • reagents may be co-partitioned along with the samples and beads, including, for example, chemical stimuli, nucleic acid extension, transcription, and/or amplification reagents such as polymerases, reverse transcriptases, nucleoside triphosphates or NTP analogues, primer sequences and additional cofactors such as divalent metal ions used in such reactions, ligation reaction reagents, such as ligase enzymes and ligation sequences, dyes, labels, or other tagging reagents.
  • chemical stimuli such as nucleic acid extension, transcription, and/or amplification reagents such as polymerases, reverse transcriptases, nucleoside triphosphates or NTP analogues, primer sequences and additional cofactors such as divalent metal ions used in such reactions, ligation reaction reagents, such as ligase enzymes and ligation sequences, dyes, labels, or other tagging reagents.
  • nucleic acid extension such as
  • the oligonucleotides disposed upon the bead may be used to barcode and amplify the partitioned samples.
  • An example process for use of these barcode oligonucleotides in amplifying and barcoding samples is described in detail in U.S. Patent Application Nos. 61/940,318, filed Feb. 7, 2014, 61/991,018, Filed May 9, 2014, and U.S. patent application Ser. No. 14/316,383, filed on Jun. 26, 2014, the full disclosures of which are hereby incorporated by reference in their entireties.
  • the oligonucleotides present on the beads that are co-partitioned with the samples and released from their beads into the partition with the samples.
  • the oligonucleotides can include, along with the barcode sequence, a primer sequence at its 5′end.
  • This primer sequence may be a random oligonucleotide sequence intended to randomly prime numerous different regions of the samples, or it may be a specific primer sequence targeted to prime upstream of a specific targeted region of the sample.
  • the primer portion of the oligonucleotide can anneal to a complementary region of the sample.
  • Extension reaction reagents e.g., DNA polymerase, nucleoside triphosphates, co-factors (e.g., Mg 2+ or Mn 2+ etc.), that are also co-partitioned with the samples and beads, then extend the primer sequence using the sample as a template, to produce a complementary fragment to the strand of the template to which the primer annealed, with complementary fragment includes the oligonucleotide and its associated barcode sequence.
  • Annealing and extension of multiple primers to different portions of the sample may result in a large pool of overlapping complementary fragments of the sample, each possessing its own barcode sequence indicative of the partition in which it was created.
  • these complementary fragments may themselves be used as a template primed by the oligonucleotides present in the partition to produce a complement of the complement that again, includes the barcode sequence.
  • this replication process is configured such that when the first complement is duplicated, it produces two complementary sequences at or near its termini, to allow the formation of a hairpin structure or partial hairpin structure, that reduces the ability of the molecule to be the basis for producing further iterative copies. A schematic illustration of one example of this is shown in FIG. 5 .
  • oligonucleotides that include a barcode sequence are co-partitioned in, e.g., a droplet 502 in an emulsion, along with a sample nucleic acid 504 .
  • the oligonucleotides 508 may be provided on a bead 506 that is co-partitioned with the sample nucleic acid 504 , which oligonucleotides can be releasable from the bead 506 , as shown in panel A.
  • the oligonucleotides 508 include a barcode sequence 512 , in addition to one or more functional sequences, e.g., sequences 510 , 514 and 516 .
  • oligonucleotide 508 is shown as comprising barcode sequence 512 , as well as sequence 510 that may function as an attachment or immobilization sequence for a given sequencing system, e.g., a P5 sequence used for attachment in flow cells of an Illumina Hiseq or Miseq system.
  • the oligonucleotides also include a primer sequence 516 , which may include a random or targeted N-mer for priming replication of portions of the sample nucleic acid 504 .
  • oligonucleotide 508 Also included within oligonucleotide 508 is a sequence 514 which may provide a sequencing priming region, such as a “read1” or R1 priming region, that is used to prime polymerase mediated, template directed sequencing by synthesis reactions in sequencing systems.
  • a sequencing priming region such as a “read1” or R1 priming region
  • the barcode sequence 512 , immobilization sequence 510 and R1 sequence 514 may be common to all of the oligonucleotides attached to a given bead.
  • the primer sequence 516 may vary for random N-mer primers, or may be common to the oligonucleotides on a given bead for certain targeted applications.
  • the oligonucleotides are able to prime the sample nucleic acid as shown in panel B, which allows for extension of the oligonucleotides 508 and 508 a using polymerase enzymes and other extension reagents also co-portioned with the bead 506 and sample nucleic acid 504 .
  • panel C following extension of the oligonucleotides that, for random N-mer primers, would anneal to multiple different regions of the sample nucleic acid 504 ; multiple overlapping complements or fragments of the nucleic acid are created, e.g., fragments 518 and 520 .
  • sequence portions that are complementary to portions of sample nucleic acid e.g., sequences 522 and 524
  • these constructs are generally referred to herein as comprising fragments of the sample nucleic acid 504 , having the attached barcode sequences.
  • the replicated portions of the template sequences as described above are often referred to herein as “fragments” of that template sequence.
  • fragment encompasses any representation of a portion of the originating nucleic acid sequence, e.g., a template or sample nucleic acid, including those created by other mechanisms of providing portions of the template sequence, such as actual fragmentation of a given molecule of sequence, e.g., through enzymatic, chemical or mechanical fragmentation.
  • fragments of a template or sample nucleic acid sequence may denote replicated portions of the underlying sequence or complements thereof.
  • the barcoded nucleic acid fragments may then be subjected to characterization, e.g., through sequence analysis, or they may be further amplified in the process, as shown in panel D.
  • additional oligonucleotides e.g., oligonucleotide 508 b , also released from bead 306 , may prime the fragments 518 and 520 .
  • the oligonucleotide based upon the presence of the random N-mer primer 516 b in oligonucleotide 508 b (which in some cases can be different from other random N-mers in a given partition, e.g., primer sequence 516 ), the oligonucleotide anneals with the fragment 518 , and is extended to create a complement 526 to at least a portion of fragment 518 which includes sequence 528 , that comprises a duplicate of a portion of the sample nucleic acid sequence. Extension of the oligonucleotide 508 b continues until it has replicated through the oligonucleotide portion 508 of fragment 518 .
  • the oligonucleotides may be configured to prompt a stop in the replication by the polymerase at a desired point, e.g., after replicating through sequences 516 and 514 of oligonucleotide 508 that is included within fragment 518 .
  • this may be accomplished by different methods, including, for example, the incorporation of different nucleotides and/or nucleotide analogues that are not capable of being processed by the polymerase enzyme used.
  • this may include the inclusion of uracil containing nucleotides within the sequence region 512 to prevent a non-uracil tolerant polymerase to cease replication of that region.
  • a fragment 526 is created that includes the full-length oligonucleotide 508 b at one end, including the barcode sequence 512 , the attachment sequence 510 , the R1 primer region 514 , and the random N-mer sequence 516 b .
  • the complement 516 ′ to the random N-mer of the first oligonucleotide 508 can be included, as well as a complement to all or a portion of the R1 sequence, shown as sequence 514 ′.
  • the R1 sequence 514 and its complement 514 ′ are then able to hybridize together to form a partial hairpin structure 528 .
  • sequence 516 ′ which is the complement to random N-mer 516
  • sequence 516 b which is the complement to random N-mer 516
  • the N-mers would be common among oligonucleotides within a given partition.
  • partial hairpin structures By forming these partial hairpin structures, it allows for the removal of first level duplicates of the sample sequence from further replication, e.g., preventing iterative copying of copies.
  • the partial hairpin structure also provides a useful structure for subsequent processing of the created fragments, e.g., fragment 526 .
  • a nucleic acid 604 originated from a first source 600 (e.g., individual chromosome, strand of nucleic acid, etc.) and a nucleic acid 606 derived from a different chromosome 602 or strand of nucleic acid are each partitioned along with their own sets of barcode oligonucleotides as described above.
  • a first source 600 e.g., individual chromosome, strand of nucleic acid, etc.
  • a nucleic acid 606 derived from a different chromosome 602 or strand of nucleic acid are each partitioned along with their own sets of barcode oligonucleotides as described above.
  • each nucleic acid 604 and 606 is then processed to separately provide overlapping set of second fragments of the first fragment(s), e.g., second fragment sets 608 and 610 .
  • This processing also provides the second fragments with a barcode sequence that is the same for each of the second fragments derived from a particular first fragment.
  • the barcode sequence for second fragment set 608 is denoted by “1” while the barcode sequence for fragment set 610 is denoted by “2”.
  • a diverse library of barcodes may be used to differentially barcode large numbers of different fragment sets. However, it is not necessary for every second fragment set from a different first fragment to be barcoded with different barcode sequences. In some cases, multiple different first fragments may be processed concurrently to include the same barcode sequence. Diverse barcode libraries are described in detail elsewhere herein.
  • the barcoded fragments may then be pooled for sequencing using, for example, sequence by synthesis technologies available from Illumina or Ion Torrent division of Thermo Fisher, Inc.
  • sequence reads 612 can be attributed to their respective fragment set, e.g., as shown in aggregated reads 614 and 616 , at least in part based upon the included barcodes, and in some cases, in part based upon the sequence of the fragment itself.
  • genomic sequences are assembled by de novo assembly and/or reference based assembly (e.g., mapping to a reference).
  • the ability to attribute sequence reads to longer originating molecules is used in determining phase information about the sequence.
  • barcodes associated with sequences that reveal two or more specific gene variant sequences e.g., alleles, genetic markers
  • Such phasing information can be used in order to determine the relative copy number of certain target chromosomes or genes in a sample.
  • An advantage of the described methods and symptoms is that multiple locations, loci, variants, etc. can be used to identify individual chromosomes or nucleic acid strands from which they originate in order to determine phasing and copy number information.
  • multiple locations e.g., greater than 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 500, 1000, 5000, 10000, 50000, 100000, or 500000
  • locations e.g., greater than 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 500, 1000, 5000, 10000, 50000, 100000, or 500000
  • the methods and systems described herein can be useful at providing effective long sequence reads from individual nucleic acid fragments, e.g., individual nucleic acid molecules, despite utilizing sequencing technology that may provide relatively shorter sequence reads. Because these long sequence reads may be attributed to single starting fragments or molecules, variant locations in the sequence can, likewise, be attributed to a single molecule, and by extrapolation, to a single chromosome. In addition, one may employ the multiple locations on any given fragment, as alignment features for adjacent fragments, to provide aligned sequences that can be inferred as originating from the same chromosome.
  • a first fragment may be sequenced, and by virtue of the attribution methods and systems described above, the variants present on that sequence may all be attributed to a single chromosome.
  • a second fragment that shares a plurality of these variants that are determined to be present only on one chromosome, may then be assumed to be derived from the same chromosome, and thus aligned with the first, to create a phased alignment of the two fragments. Repeating this allows for the identification of long range phase information. Identification of variants on a single chromosome can be obtained from either known references, e.g., HapMap, or from an aggregation of the sequencing data, e.g., showing differing variants on an otherwise identical sequence stretch.
  • FIG. 7 provides a schematic illustration of an example phased sequencing process.
  • an originating nucleic acid 702 such as, for example, a chromosome, a chromosome fragment, an exome, or other large, single nucleic acid molecule, can be fragmented into multiple large fragments 704 , 706 , 708 .
  • the originating nucleic acid 702 may include a number of sequence variants (A, B, C, D, E, F, and G) that are specific to the particular nucleic acid molecule, e.g., chromosome.
  • the originating nucleic acid can be fragmented into multiple large, overlapping fragments 704 , 706 and 708 , that include subsets of the associated sequence variants. Each fragment can then be partitioned, further fragmented into subfragments, and barcoded, as described herein to provide multiple overlapping, barcoded subfragments of the larger fragments, where subfragments of a given larger fragment bear the same barcode sequence.
  • subfragments associated with barcode sequence “1” and barcode sequence “2” are shown in partitions 710 and 712 , respectively.
  • the barcoded subfragments can then be pooled, sequenced, and the sequenced subfragments assembled to provide long fragment sequences 714 , 716 , and 717 .
  • One or more of the long fragment sequences 714 , 716 , and 717 can include multiple variants.
  • the long fragment sequences may then be further assembled, based upon overlapping phased variant information from sequences 714 , 716 , and 717 to provide a phased sequence 718 , from which phased locations can be determined.
  • phased locations are determined, one may further exploit that information in a variety of ways. For example, one can utilize knowledge of phased variants in assessing genetic risk for certain disorders, identify paternal vs. maternal characteristics, identify aneuploidies, or identify haplotyping information.
  • copy number variation assays are performed using simultaneous detection of two or more phased genetic markers to improve the accuracy of copy number counting.
  • Utilizing the phasing information can increase the relative strength of the signal compared to the variance under a na ⁇ ve method just based on counting reads over multiple loci and across haplotypes. Additionally, utilizing phasing information allows for normalization of position-specific biases, boosting the signal substantially further.
  • Copy number variation (CNV) accuracy may depend on myriad factors including sequencing depth, length of CNV, number of copies, etc).
  • the methods and systems provided herein may determine CNV with an accuracy of at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 99%, 99.1%, 99.2%, 99.3% 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 99.95%, 99.99%, 99.995%, or 99.999%.
  • the methods and systems provided herein determine CNV with an error rate of less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.1%, 0.05%, 0.01%, 0.005%, 0.001%, 0.0005%, 0.0001%, 0.00005%, 0.00001%, or 0.000005%.
  • the methods and systems provided herein may detect phasing/haplotype information of two or more genetic variants with an accuracy of at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 99%, 99.1%, 99.2%, 99.3% 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 99.95%, 99.99%, 99.995%, or 99.999%.
  • the methods and systems provided herein determine phasing or haplotype information with an error rate of less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.1%, 0.05%, 0.01%, 0.005%, 0.001%, 0.0005%, 0.0001%, 0.00005%, 0.00001%, or 0.000005%.
  • This disclosure also provides methods of removing locus-specific biases, where the locus-specific variance are reduced by at least 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold, 200-fold, 500-fold, 1000-fold, 5000-fold, or 10000-fold.
  • the methods and systems provided herein can be used to detect variations in copy number, such as where the change in copy number reflects a change in the number of chromosomes, or portions of chromosomes. In some cases, the methods and systems provided herein can be used to detect variations in copy number of a gene present on the same chromosome.
  • FIG. 8 is a schematic illustrating a subset of a healthy patient's genome. This patient has a heterozygous genotype at the indicated loci and two separate haplotypes ( 1 and 2 ) 805 , 810 located on separate chromosome strands. The patient's naturally-occurring variations (such as SNPs or indels) are depicted as circles.
  • FIG. 8 also depicts the genome of a patient with cancer 815 . Certain cancers are associated with a gain in haplotype copy number. The middle panel depicts a gain in a haplotype 2 , 810 . Cancers may also be associated with a loss in haplotype number, as depicted in the bottom panel of FIG.
  • the distribution of results of the copy number assay in replicate testing can be distributed around the correct answer in a manner approximating a Poisson distribution, where the width of the distribution is dependent on various sources of random error in the assay. Since for a give sample the change in copy number may be relatively small portion of the sample, broad probability distributions for monitoring of single genetic markers can mask the correct result. This difficulty is due to the fact that normal sequencing techniques only look at one single variant position of a haplotype at a time, as shown in FIG. 10 (left panel). Using such techniques, there can be significant overlap between peaks representing copy loss 1025 , normal copy 1020 , and copy gain 1030 .
  • the techniques disclosed herein allow for detection of whole (or partial) haplotypes, increasing the resolution and improving the detection of copy gain and loss, FIG. 10 (right panel). This improvement is schematically shown in FIG. 11 , where normal detection 1100 results in spread out, overlapping peaks while the techniques herein 1110 allow for finer peaks and improved resolution of copy gain or loss.
  • the use of simultaneous monitoring of two or more phased genetic markers, particularly markers that are known to be co-located on a single chromosome, and which can therefore most likely always appear in greater or lesser number in a synchronized, non-random fashion has the effect of narrowing the width of the expected results distribution and simultaneously improving the accuracy of the count.
  • the methods and systems provided herein also provide more accurate and sensitive processes for detecting fetal aneuploidy.
  • Fetal aneuploidies are aberrations in fetal chromosome number. Aneuploidies commonly result in significant physical and neurological impairments. For example, a reduction in the number of X chromosomes is responsible for Turner's syndrome. An increase in copy number of chromosome number 21 results in Down Syndrome. Invasive testing such as amniocentesis or Chorionic Villus Sampling (CVS) can lead to risk of pregnancy loss and less invasive methods of testing the maternal blood are used here.
  • CVS Chorionic Villus Sampling
  • FIG. 12 An exemplary process is shown in FIG. 12 .
  • a pregnant woman at risk of carrying a fetus with an aneuploid genome is tested, 1200 .
  • a maternal blood sample containing fetal genetic material is collected, 1205 .
  • Genetic material e.g., cell-free nucleic acids
  • a set of barcoded beads may also be obtained, 1215 .
  • the beads can be linked to oligonucleotides containing one or more barcode sequences, as well as a primer, such as a random N-mer or other primer.
  • the barcode sequences are releasable from the barcoded beads, e.g., through cleavage of a linkage between the barcode and the bead or through degradation of the underlying bead to release the barcode, or a combination of the two.
  • the barcoded beads can be degraded or dissolved by an agent, such as a reducing agent to release the barcode sequences.
  • an agent such as a reducing agent to release the barcode sequences.
  • a sample, 1210 , barcoded beads, 1220 , and, in some cases, other reagents, e.g., a reducing agent, are combined and subjected to partitioning.
  • such partitioning may involve introducing the components to a droplet generation system, such as a microfluidic device, 1225 .
  • a droplet generation system such as a microfluidic device, 1225 .
  • a water-in-oil emulsion 1230 may be formed, where the emulsion contains aqueous droplets that contain sample nucleic acid, 1210 , barcoded beads, 1215 , and, in some cases, a reducing agent.
  • the reducing agent may dissolve or degrade the barcoded beads, thereby releasing the oligonucleotides with the barcodes and random N-mers from the beads within the droplets, 1235 .
  • the random N-mers may then prime different regions of the sample nucleic acid, resulting in amplified copies of the sample after amplification, where each copy is tagged with a barcode sequence, 1240 .
  • each droplet contains a set of oligonucleotides that contain identical barcode sequences and different random N-mer sequences.
  • individual droplets comprise unique bar-code sequences; or, in some cases, a certain proportion of the total population of droplets has unique sequences.
  • additional sequences e.g., sequences that aid in particular sequencing methods, additional barcodes, etc.
  • additional sequences e.g., sequences that aid in particular sequencing methods, additional barcodes, etc.
  • Sequencing may then be performed via any suitable type of sequencing platform (e.g., Illumina, Ion Torrent, Pacific Biosciences SMRT, Roche 454 sequencing SOLiD sequencing, etc.), 1250 , and an algorithm applied to interpret the sequencing data, 1255 .
  • Sequencing algorithms are generally capable, for example, of performing analysis of barcodes to align sequencing reads and/or identify the sample from which a particular sequence read belongs.
  • the aligned sequences may be further attributed to their respective genetic origins (e.g., chromosomes) based upon, the unique barcodes attached.
  • the number of chromosome copies is then compared to that of a normal diploid chromosome, 1260 .
  • the patient is informed of any copy number aberrations for different chromosomes and the associated risks/disease, 1265 .
  • Phasing e.g. determining whether genetic variants are linked or reside on different chromosomes can provide useful information for a variety of applications.
  • phasing is useful for determining if certain translocations of a genome associated with diseases are present. Detection of such translocations can also allow for differential diagnosis and modified treatment. Determination of which alleles in a genome are linked can be useful for considering how genes are inherited.
  • the method and systems described herein are highly useful in obtaining the long range molecular sequence information for identification and characterization of a wide range of different genetic structural variations.
  • these variations include a wide variety of different variant events, including insertions, deletions, duplications, retrotransposons, translocations, inversions short and long tandem repeats, and the like.
  • These structural variations are of significant scientific interest, as they are believed to be associated with a range of diverse genetic diseases.
  • the methods and systems described herein are capable of providing long range sequence information that is attributable to individual originating nucleic acid molecules, and further, in possessing this long range sequence information, inferring even longer range sequence context, through the comparing and overlapping of these longer sequence information.
  • Such long range sequence information and/or inferred sequence context allows the identification and characterization numerous structural variations not easily identified using available techniques.
  • FIGS. 13A and 13B provide a more detailed example process for identifying certain types of structural variations using the methods and systems described herein.
  • the genome of an organism, or tissue from an organism might ordinarily include the first genotype illustrated in FIG. 13A , where a first gene region 1302 including first gene 1304 is separated from a second gene region 1306 including second gene 1208 .
  • This separation may reflect a range of distances between the genes, including, e.g., different regions in the same exon, different exons on the same chromosome, different chromosomes, etc.
  • a genotype is shown that reflects a translocation event having occurred in which gene 1308 is inserted into gene region 1304 such that it creates a gene fusion between genes 1304 and 1308 as gene fusion 1312 in variant sequence 1314 .
  • the loci to the left and to the right of a breakpoint can tend to be on a common fragment of genomic DNA and therefore be maintained within a single partition, and thus barcoded with a common or shared barcode sequence. Due to the stochastic nature of shearing, this sharing of barcodes decreases as the sequences are more distant from the breakpoint. Using statistical methods one can determine whether the barcode overlap between two genomic loci is significantly larger than what would be expected by chance. Such an overlap suggests the presence of a breakpoint.
  • the barcode information complements information provided by traditional sequencing such as information from reads spanning the breakpoint) if such information is available.
  • the genomic material from the organism, including the relevant gene regions is fragmented such that it includes relatively long fragments, as described above. This is illustrated with respect to the non-translocated genotype in FIG. 13A .
  • two long individual first molecule fragments 1316 and 1318 are created that include gene regions 1302 and 1306 respectively. These fragments are separately partitioned into partitions 1320 and 1322 , respectively, and each of the first fragments is fragmented into a number of second fragments 1324 and 1326 , respectively within the partition, which fragmenting process attaches a unique identifier tag or barcode sequence to the second fragments that is common to all of the second fragments within a given partition.
  • the tag or barcode is indicated by “1” or “2”, for each of partitions 1320 and 1322 , respectively.
  • the second fragments may then be pooled and subjected to nucleic acid sequencing processes, which can provide both the sequence of the second fragment as well as the barcode sequence for that fragment. Based upon the presence of a particular barcode, e.g., 1 or 2, a the second fragment sequences may then be attributed to a certain originating sequence, e.g., gene 1304 or 1308 , as shown by the attribution of barcodes to each sequence. In some cases, mapping of barcoded second fragment sequences as to separate originating first fragment sequences may be sufficiently definitive to determine that no translocation has occurred. However, in some cases, one may assemble the second fragment sequences to provide an assembled sequence for all or a portion of the originating first fragment sequence, e.g., as shown by assembled sequences 1330 and 1332 .
  • FIG. 13B shows a schematic illustration of the same process applied to a translocation containing genotype.
  • a first long nucleic acid fragment 1352 is generated from the variant sequence 1314 , and includes at least a portion of the translocation variant, e.g., gene fusion 1312 .
  • the first fragment 1352 is then partitioned into discrete partition 1354 .
  • first fragment 1352 is further fragmented into second fragments 1356 that again, include unique barcodes that are the same for all second fragments 1356 within the partition 1354 (shown as barcode “1”).
  • pooling the second fragments and sequencing provides the underlying sequences of the second fragments as well as their associated barcodes. These barcoded sequences can then be attributed to their respective gene sequences. As shown, however, both genes can reflect attributed second fragment sequences that include the same barcode sequences, indicating that they originated from the same partition, and potentially the same originating molecule, indicating a gene fusion. This may be further validated by providing a number of overlapping first fragments that also include at least portions of the gene fusion, but processed in different partitions with different barcodes.
  • the presence of multiple different barcode sequences (and their underlying fragment sequences) that attribute to each of the originally separated genes can be indicative of the presence of a gene fusion or other translocation event.
  • attribution of at least 2 barcodes, at least 3 different barcodes, at least 4 different barcodes, at least 5 different barcodes, at least 10 different barcodes, at least 20 different barcodes or more, to two genetic regions that would have been expected to have been separated based upon a reference sequence may provide indication of a translocation event that has placed those regions proximal to, adjacent to or otherwise integrated with each other.
  • the size of the fragments that are partitioned can indicate the sensitivity with which one can identify variant linkage. In particular, where the fragments in a given droplet are 10 kb in length, it would be expected that linkages that are within that 10 kb size range would be detectable.
  • fragment size selection may be used to adjust the relative proximity of detected linked sequences, whether as wild type or variants.
  • proximal sequences that are normally separated by more than 100 bases, more than 500 bases, more than 1 kb, 10 kb, more than 20 kb, more than 30 kb, more than 40 kb, more than 50 kb, more than 60 kb, more than 70 kb, more than 80 kb, more than 90 kb, more than 100 kb, more than 200 kb or even greater, may be readily identified herein by identifying the linkage between those unlinked sequence segments in variant genomes, which linkage is indicated by shared or common barcodes, and/or, as noted, by sequence data that spans a breakpoint.
  • Such linkage is generally identifiable when those linked sequences are separated within the genomic sequence by less than 50 kb, less than 40 kb, less than 30 kb, less than 20 kb, less than 10 kb, less than 5 kb, less than 4 kb, less than 3 kb, less than 2 kb, less than 1 kb, less than 500 bases, less than 200 bases or even less.
  • a structural variation resulting in two sequences being positioned proximal to each other or linked, where they would normally be separated by, e.g., more than 10 kb, more than 20 kb, more than 30 kb, more than 40 kb, or more than 50 kb or more, may be identified by the percentage of the total number of mappable barcoded sequences that include barcodes that are common to the two sequence portions.
  • the processes described herein can ensure that sequences that are within a certain sequence distance will be included, whether as wild type or variant sequences, within a single partition, e.g., as a single nucleic acid fragment.
  • sequences that are within a certain sequence distance will be included, whether as wild type or variant sequences, within a single partition, e.g., as a single nucleic acid fragment.
  • common or overlapping barcode sequences are greater than 1% of the total number of barcodes mapped to the two sequences, it may be used to identify linkage as between two sequence segments, and particularly, as between two sequence segments that would not normally be linked, e.g., a structural variation.
  • the shared or common barcodes can be more than 2%, more than 3%, more than 4%, more than 5%, more than 6%, more than 7%, more than 8%, and in some cases more than 9% or even more than 10% of the total mappable barcodes to two normally separated sequences, in order to identify a structural linkage that constitutes a structural variation within the genome.
  • the shared or common barcodes can be detected at a proportion or number that is statistically significantly greater than a control genome that is known not to have the structural variation. Additionally, where second sequence fragments span the point where the variant sequence meets the “normal” sequence, or “breakpoint”, e.g., as in second fragment 1358 one can use this information as additional evidence of the gene fusion.
  • barcode sequences allows the assembly of the short sequences into sequences for the longer originating fragments
  • these longer fragments also permit the inference of longer range sequence information from overlapping long fragments assembled from different, overlapping originating long fragments. This resulting assembly allows for longer range sequence level identification and characterization of gene fusion 1312 .
  • Retrotransposons can be created by transcription followed by reverse transcription of spliced messenger RNA (mRNA) and insertion into a new location in the genome. Hence, these structural variants lack introns and are often interchromosomal but otherwise have diverse features.
  • retrotransposons introduce functional copies of genes they are referred to as retrogenes, which have been reported in human and Drosophila genomes.
  • retrocopies may contain the entire transcript, specific transcript isoforms or an incomplete transcript.
  • alternative transcription start sites and promoter sequences sometimes reside within a transcript so retrotransposons sometimes introduce promotor sequences within the reinserted region of the genome that could drive expression of downstream sequences.
  • retrotransposons insert far away from the parental gene within exons or introns. When inserted near genes retrotransposons can exploit local regulatory sequences for expression. Insertions near genes can also inactivate the receiving gene or create new chimera transcripts. Retrotransposon mediated chimeric gene transcripts have been reported in RNA-Seq data from human samples.
  • Retrotransposons can be identified from whole genome libraries using the systems and methods described herein, and their insertion site can be mapped using the barcode mapping discussed above.
  • the Ceph NA12878 genome has a SKA3-DDX10 chimeric retrotransposon.
  • the SKA3 intron-less transcript is inserted in between exons 10 and 11 of DDX10.
  • the CBX3-C15ORF17 retrotransposon can also be detected in NA12878 using the methods described herein. Isoform 2 of CBX3 is inserted in between exons 2 and 3 of C15ORF17. This chimeric transcript has been observed in 20% of European RNA-Seq samples from the HapMap project (D.R. Schrider et al. PLoS Genetics 2013).
  • Retrotransposons can also be detected in whole exome libraries prepared using the methods and systems described herein. While retrotransposons are easily enriched with exome targeting it can be difficult or not possible to differentiate between a translocation event and a retrotransposon since introns are removed during capture. However, using the systems and methods described herein, one may identify retrotransposons in whole exome sequencing (WES) libraries by introducing intronic baits for suspected retrotransposons (see also U.S. Provisional Patent Application No. 62/072,164, filed Oct. 29, 2014, incorporated herein by reference in its entirety for all purposes). Lack of intron signal can be indicative of retrotransposon structural variants whereas intron signal can be indicative of a translocation.
  • WES whole exome sequencing
  • Diseases associated with copy number variations can include, for example, DiGeorge/velocardiofacial syndrome (22q11.2 deletion), Prader-Willi syndrome (15q11-q13 deletion), Williams-Beuren syndrome (7q11.23 deletion), Miller-Dieker syndrome (MDLS) (17p13.3 microdeletion), Smith-Magenis syndrome (SMS) (17p11.2 microdeletion), Neurofibromatosis Type 1 (NF1) (17q11.2 microdeletion), Phelan-McErmid Syndrome (22q13 deletion), Rett syndrome (loss-of-function mutations in MECp2 on chromosome Xq28), Merzbacher disease (CNV of PLP1), spinal muscular atrophy (SMA) (homozygous absence of telomerec SMN1 on chromosome 5q13), Potocki-Lupski Syndrome (PTLS, duplication of chromosome 17p
  • PMP22 Additional copies of the PMP22 gene can be associated with Charcot-Marie-Tooth neuropathy type IA (CMT1A) and hereditary neuropathy with liability to pressure palsies (HNPP).
  • CMT1A Charcot-Marie-Tooth neuropathy type IA
  • HNPP hereditary neuropathy with liability to pressure palsies
  • the disease can be a disease described in Lupski J. (2007) Nature Genetics 39: S43-S47.
  • the methods and systems provided herein can also accurately detect or diagnose a wide range of fetal aneuploidies. Often, the methods provided herein comprise analyzing a sample (e.g., blood sample) taken from a pregnant woman in order to evaluate the fetal nucleic acids within the sample.
  • a sample e.g., blood sample
  • Fetal aneuploidies can include, e.g., trisomy 13 (Patau syndrome), trisomy 18 (Edwards syndrome), trisomy 21 (Down Syndrome), Klinefelter Syndrome (XXY), monosomy of one or more chromosomes (X chromosome monosomy, Turner's syndrome), trisomy X, trisomy of one or more chromosomes, tetrasomy or pentasomy of one or more chromosomes (e.g., XXXX, XXYY, XXXY, XYYYY, XXXXXY, XXXYY, XYYYY and XXYYY), triploidy (three of every chromosome, e.g.
  • an aneuploidy can be a segmental aneuploidy.
  • Segmental aneuploidies can include, e.g., 1p36 duplication, dup(17)(p11.2p11.2) syndrome, Down syndrome, Pelizaeus-Merzbacher disease, dup(22)(q11.2q11.2) syndrome, and cat-eye syndrome.
  • an abnormal genotype e.g., fetal genotype
  • a decrease in chromosomal number results in a condition such as Cri-du-chat syndrome, Wolf-Hirschhorn, Williams-Beuren syndrome, Charcot-Marie-Tooth disease, Hereditary neuropathy with liability to pressure palsies, Smith-Magenis syndrome, Neurofibromatosis, Alagille syndrome, Velocardiofacial syndrome, DiGeorge syndrome, Steroid sulfatase deficiency, Kallmann syndrome, Microphthalmia with linear skin defects, Adrenal hypoplasia, Glycerol kinase deficiency, Pelizaeus-Merzbacher disease, Testis-determining factor on Y, Azospermia (factor a), Azospermia (factor b), Azospermia (factor c), or 1p36 deletion.
  • a decrease in chromosomal number results in a condition such as Cri-du-chat syndrome, Wolf-Hirschhorn, Williams
  • CNV is associated with malformation syndromes, including CHARGE (coloboma, heart anomaly, choanal atresia, retardation, genital, and ear anomalies), Peters-Plus, Pitt-Hopkins, and thrombocytopenia-absent radius syndrome (see e.g., Ropers HH (2007) Am J of Hum Genetics 81: 199-207).
  • CHARGE coloboma, heart anomaly, choanal atresia, retardation, genital, and ear anomalies
  • Peters-Plus Pitt-Hopkins
  • thrombocytopenia-absent radius syndrome see e.g., Ropers HH (2007) Am J of Hum Genetics 81: 199-207.
  • the relationship between copy number variations and cancer is described, e.g., in Shlien A. and Malkin D. (2009) Genome Med. 1(6): 62.
  • Copy number variations are associated with, e.g., autism, schizophrenia, and idiopathic learning
  • the methods and systems provided herein are also useful to detect CNVs associated with different types of cancer.
  • the methods and systems can be used to detect EGFR copy number, which can be increased in non-small cell lung cancer.
  • the methods and systems provided herein can also be used to determine a subject's level of susceptibility to a particular disease or disorder, including susceptibility to infection from a pathogen (e.g., viral, bacterial, microbial, fungal, etc.).
  • a pathogen e.g., viral, bacterial, microbial, fungal, etc.
  • the methods can be used to determine a subject's susceptibility to HIV infection by analyzing the copy number of CCL3L1, given that a relatively high level of CCL3L1 is associated with lower susceptibility to HIV infection (Gonzalez E. et al. (2005) Science 307: 1434-1440).
  • the methods can be used to determine a subject's susceptibility to system lupus erythematosus.
  • the methods can be used to detect copy number of FCGR3B (CD16 cell surface immunoglobulin receptor) since a low copy number of this molecule is associated with an increased susceptibility to systemic lupus erythematosus (Aitman T. J. et al. (2006) Nature 439: 851-855).
  • FCGR3B CD16 cell surface immunoglobulin receptor
  • the methods and systems provided herein can also be used to detect CNVs associated with other diseases or disorders, such as CNVs associated with autism, schizophrenia, or idiopathic learning disability (Kinght et al., (1999) The Lancet 354 (9191): 1676-81.).
  • the methods and systems can be used to detect autosomal-dominant microtia, which is linked to five tandem copies of a copy-number-variable region at chromosome 4p16 (Balikova I. (2008) Am J. Hum Genet. 82: 181-187).
  • a method comprises detecting a disease or disorder using a system or method described herein and further providing a treatment to a subject based on the detection of the disease. For example, if a cancer is detected, the subject may be treated by a surgical intervention, by administering a drug designed to treat such cancer, by providing a hormonal therapy, and/or by administering radiation or more generalized chemotherapy.
  • differential diagnosis of a disease or disorder can be achieved by determining and characterizing a sequence of a sample nucleic acid obtained from a subject suspected of having the disease or disorder and further characterizing the sample nucleic acid as indicative of a disorder or disease state (or absence thereof) by comparing it to a sequence and/or sequence characterization of a reference nucleic acid indicative of the presence (or absence) of the disorder or disease state.
  • the reference nucleic acid sequence may be derived from a genome that is indicative of an absence of a disease or disorder state (e.g., germline nucleic acid) or may be derived from a genome that is indicative of a disease or disorder state (e.g., cancer nucleic acid, nucleic acid indicative of an aneuploidy, etc.).
  • a disease or disorder state e.g., germline nucleic acid
  • a disease or disorder state e.g., cancer nucleic acid, nucleic acid indicative of an aneuploidy, etc.
  • the reference nucleic acid sequence (e.g., having lengths of longer than 1 kb, longer than 5 kb, longer than 10 kb, longer than 15 kb, longer than 20 kb, longer than 30 kb, longer than 40 kb, longer than 50 kb, longer than 60 kb, longer than 70 kb, longer than 80 kb, longer than 90 kb or even longer than 100 kb) may be characterized in one or more respects, with non-limiting examples that include determining the presence (or absence) of a particular sequence, determining the presence (or absence) of a particular haplotype, determining the presence (or absence) of one or more genetic variations (e.g., structural variations (e.g., a copy number variation, an insertion, a deletion, a translocation, an inversion, a retrotransposon, a rearrangement, a repeat expansion, a duplication, etc.), single nucleotide polymorphisms (SNPs), etc.
  • any suitable type and number of sequence characteristics of the reference sequence can be used to characterize the sequence of the sample nucleic acid.
  • one or more genetic variations (or lack thereof) or structural variations (or lack thereof) of a reference nucleic acid sequence may be used as a sequence signature to identify the reference nucleic acid as indicative of the presence (or absence) of a disorder or disease state.
  • the sample nucleic acid sequence can be characterized in a similar manner and further characterized/identified as derived (or not derived) from a nucleic acid indicative of the disorder or disease based upon whether or not it displays a similar character to the reference nucleic acid sequence.
  • characterizations of sample nucleic acid sequence and/or the reference nucleic acid sequence and their comparisons may be completed with the aid of a programmed computer processor.
  • a programmed computer processor can be included in a computer control system, such as in an example computer control system described elsewhere herein.
  • the sample nucleic acid may be obtained from any suitable source, including sample sources and biological sample sources described elsewhere herein.
  • the sample nucleic acid may comprise cell-free nucleic acid.
  • the sample nucleic acid may comprise tumor nucleic acid (e.g., tumor DNA).
  • the sample nucleic acid may comprise circulating tumor nucleic acid (e.g., circulating tumor DNA (ctDNA)). Circulating tumor nucleic acid may be derived from a circulating tumor cell (CTC) and/or may be obtained, for example, from a subject's blood, plasma, other bodily fluid or tissue.
  • CTC circulating tumor cell
  • FIGS. 20-21 illustrate an example method for characterizing a sample nucleic acid in the context of disease detection and diagnosis.
  • FIG. 20 demonstrates an example method by which long range sequence context can be determined for a reference nucleic acid (e.g., germline nucleic acid (e.g., germline genomic DNA), nucleic acid associated with a particular disorder or disease state) from shorter barcoded fragments, such as, for example in a manner analogous to that shown in FIG. 6 .
  • a reference nucleic acid may be obtained 2000
  • a set of barcoded beads may also be obtained, 2010 .
  • the beads can be linked to oligonucleotides containing one or more barcode sequences, as well as a primer, such as a random N-mer or other primer.
  • the barcode sequences are releasable from the barcoded beads, e.g., through cleavage of a linkage between the barcode and the bead or through degradation of the underlying bead to release the barcode, or a combination of the two.
  • the barcoded beads can be degraded or dissolved by an agent, such as a reducing agent to release the barcode sequences.
  • reference nucleic acid, 2005 , barcoded beads, 2015 , and, in some cases, other reagents, e.g., a reducing agent, 2020 , are combined and subject to partitioning.
  • the reference nucleic acid 2000 may be fragmented prior to partitioning and at least some of the resulting fragments are partitioned as 2005 for barcoding.
  • partitioning may involve introducing the components to a droplet generation system, such as a microfluidic device, 2025 .
  • a water-in-oil emulsion 2030 may be formed, where the emulsion contains aqueous droplets that contain reference nucleic acid, 2005 , reducing agent, 2020 , and barcoded beads, 2015 .
  • the reducing agent may dissolve or degrade the barcoded beads, thereby releasing the oligonucleotides with the barcodes and random N-mers from the beads within the droplets, 2035 .
  • the random N-mers may then prime different regions of the reference nucleic acid, resulting in amplified copies of the reference nucleic acid after amplification, where each copy is tagged with a barcode sequence, 2040 .
  • amplification 2040 may be achieved by a method analogous to that described elsewhere herein and schematically depicted in FIG. 5 .
  • each droplet contains a set of oligonucleotides that contain identical barcode sequences and different random N-mer sequences.
  • additional sequences e.g., sequences that aid in particular sequencing methods, additional barcodes, etc.
  • amplification methods 2050 (e.g., PCR).
  • Sequencing may then be performed, 2055 , and an algorithm applied to interpret the sequencing data, 2060 .
  • interpretation of the sequencing data 2060 may include providing a sequence for at least a portion of the reference nucleic acid.
  • long range sequence context for the reference nucleic acid is obtained and characterized such as, for example, in the case where the reference nucleic acid is derived from a disease state (e.g., determination of one or more haplotypes as described elsewhere herein, determination of one or more structural variations (e.g., a copy number variation, an insertion, a deletion, a translocation, an inversion, a rearrangement, a repeat expansion, a duplication, retrotransposon, a gene fusion, etc.), calling of one or more SNPs, etc.).
  • variants can be called for various reference nucleic acids obtained from a source and inferred contigs generated to provide longer range sequence context, such as is described elsewhere herein with respect to FIG. 7 .
  • FIG. 21 demonstrates an example of characterizing a sample nucleic acid sequence from the reference 2060 characterization obtained as shown in FIG. 20 .
  • Long range sequence context can be obtained for the sample nucleic acid from sequencing of shorter barcoded fragments as is described elsewhere herein, such as, for example, via the method schematically depicted in FIG. 6 .
  • a nucleic acid sample e.g., a sample comprising a circulating tumor nucleic acid
  • a set of barcoded beads may also be obtained, 2110 .
  • the beads can be linked to oligonucleotides containing one or more barcode sequences, as well as a primer, such as a random N-mer or other primer.
  • the barcode sequences are releasable from the barcoded beads, e.g., through cleavage of a linkage between the barcode and the bead or through degradation of the underlying bead to release the barcode, or a combination of the two.
  • the barcoded beads can be degraded or dissolved by an agent, such as a reducing agent to release the barcode sequences.
  • sample nucleic acid, 2105 , barcoded beads, 2115 , and, in some cases, other reagents, e.g., a reducing agent, 2120 , are combined and subject to partitioning.
  • the fetal sample 2100 is fragmented prior to partitioning and at least some of the resulting fragments are partitioned as 2105 for barcoding.
  • partitioning may involve introducing the components to a droplet generation system, such as a microfluidic device, 2125 .
  • a water-in-oil emulsion 2130 may be formed, where the emulsion contains aqueous droplets that contain sample nucleic acid, 2105 , reducing agent, 2120 , and barcoded beads, 2115 .
  • the reducing agent may dissolve or degrade the barcoded beads, thereby releasing the oligonucleotides with the barcodes and random N-mers from the beads within the droplets, 2135 .
  • the random N-mers may then prime different regions of the sample nucleic acid, resulting in amplified copies of the sample nucleic acid after amplification, where each copy is tagged with a barcode sequence, 2140 .
  • amplification 2140 may be achieved by a method analogous to that described elsewhere herein and schematically depicted in FIG. 5 .
  • each droplet contains a set of oligonucleotides that contain identical barcode sequences and different random N-mer sequences.
  • additional sequences e.g., sequences that aid in particular sequencing methods, additional barcodes, etc.
  • sequences may be added, via, for example, amplification methods, 2150 (e.g., PCR).
  • Sequencing may then be performed, 2155 , and an algorithm applied to interpret the sequencing data, 2160 .
  • interpretation of the sequencing data 2160 may include providing a sequence of the sample nucleic acid.
  • sample nucleic acid sequence can be characterized 2160 (e.g., determination of one or more haplotypes as described elsewhere herein, determination of one or more structural variations (e.g., a copy number variation, an insertion, a deletion, a translocation, an inversion, a rearrangement, a repeat expansion, a duplication, retrotransposon, a gene fusion, etc.) using the characterization of the reference nucleic acid sequence 2060 . Based on the comparison of the sample nucleic acid sequence and its characterization with the sequence and characterization of the reference nucleic acid, a differential diagnosis 2170 regarding the presence (or absence) of the disorder or disease state can be made.
  • sample and reference nucleic acids may be added to the same device and barcoded sample and reference fragments generated in droplets according to FIGS. 20 and 21 , where an emulsion comprises the droplets for both types of nucleic acid.
  • the emulsion can then be broken and the contents of the droplets pooled, further processed (e.g., bulk addition of additional sequences via PCR) and sequenced as described elsewhere herein.
  • Individual sequencing reads from the barcoded fragments can be attributed to their respective sample sequence via barcode sequences. Sequences obtained from the sample nucleic acid can be characterized based upon the characterization of the reference nucleic acid sequence.
  • Utilizing methods and systems herein can improve accuracy in determining long range sequence context of nucleic acids, including the long-range sequence context of reference and sample nucleic acid sequences as described herein.
  • the methods and systems provided herein may determine long-range sequence context of reference and/or sample nucleic acids with accuracy of at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 99%, 99.1%, 99.2%, 99.3% 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 99.95%, 99.99%, 99.995%, or 99.999%.
  • the methods and systems provided herein may determine long-range sequence context of reference and/or sample nucleic acids with an error rate of less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.1%, 0.05%, 0.01%, 0.005%, 0.001%, 0.0005%, 0.0001%, 0.00005%, 0.00001%, or 0.000005%.
  • methods and systems herein can also improve accuracy in characterizing a reference nucleic acid sequence and/or sample nucleic acid sequence in one or more aspects (e.g., determination of a sequence, determination of one or more genetic variations, determination of haplotypes, etc.). Accordingly, the methods and systems provided herein may characterize a reference nucleic acid sequence and/or sample nucleic acid sequence in one or more aspects with an accuracy of at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 99%, 99.1%, 99.2%, 99.3% 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 99.95%, 99.99%, 99.995%, or 99.999%.
  • the methods and systems provided herein may characterize a reference nucleic acid sequence and/or sample nucleic acid sequence in one or more aspects with an error rate of less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.1%, 0.05%, 0.01%, 0.005%, 0.001%, 0.0005%, 0.0001%, 0.00005%, 0.00001%, or 0.000005%.
  • a sample nucleic acid sequence (including long-range sequence context) can be provided from analysis of a reference nucleic acid sequence with an error rate of less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.1%, 0.05%, 0.01%, 0.005%, 0.001%, 0.0005%, 0.0001%, 0.00005%, 0.00001%, or 0.000005%.
  • a sample nucleic acid sequence can be used for differential diagnosis of a disorder or disease (or absence thereof) by comparison with a sequence and/or characterization of a sequence of a reference nucleic acid with accuracy of at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 99%, 99.1%, 99.2%, 99.3% 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 99.95%, 99.99%, 99.995%, or 99.999%.
  • a sample nucleic acid sequence can be used for differential diagnosis of a disorder or disease (or absence thereof) by comparison with a sequence and/or characterization of a sequence of a reference nucleic acid with an error rate of less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.1%, 0.05%, 0.01%, 0.005%, 0.001%, 0.0005%, 0.0001%, 0.00005%, 0.00001%, or 0.000005%.
  • the methods and systems may be used to detect copy number variation in a patient with lung cancer in order to determine whether the lung cancer is Non-Small Cell Lung Cancer, which is associated with a variation in the EGFR gene.
  • a patient's treatment regimen may be refined to correlate with the differential diagnosis.
  • Targeted therapy or molecularly targeted therapy is one of the major modalities of medical treatment (pharmacotherapy) for cancer, others being hormonal therapy and cytotoxic chemotherapy.
  • Targeted therapy blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth, rather than by simply interfering with all rapidly dividing cells (e.g. with traditional chemotherapy).
  • FIG. 14 shows an exemplary process for differentially diagnosing Non-Small Cell Lung Cancer.
  • a patient with chromic cough, weight loss and shortness of breath is tested for lung cancer 1400 .
  • Blood is drawn from the patient 1405 and samples (e.g., circulating tumor cells, cell-free DNA, circulating nucleic acid (e.g., circulating tumor nucleic acid), etc.) are derived from the blood 1410 .
  • samples e.g., circulating tumor cells, cell-free DNA, circulating nucleic acid (e.g., circulating tumor nucleic acid), etc.
  • a set of barcoded beads may also be obtained, 1415 .
  • the beads can be linked to oligonucleotides containing one or more barcode sequences, as well as a primer, such as a random N-mer or other primer.
  • the barcode sequences are releasable from the barcoded beads, e.g., through cleavage of a linkage between the barcode and the bead or through degradation of the underlying bead to release the barcode, or a combination of the two.
  • the barcoded beads can be degraded or dissolved by an agent, such as a reducing agent to release the barcode sequences.
  • an agent such as a reducing agent to release the barcode sequences.
  • a sample, 1410 , barcoded beads, 1420 , and, in some cases, other reagents, e.g., a reducing agent, are combined and subject to partitioning.
  • such partitioning may involve introducing the components to a droplet generation system, such as a microfluidic device, 1425 .
  • a droplet generation system such as a microfluidic device, 1425 .
  • a water-in-oil emulsion 1430 may be formed, where the emulsion contains aqueous droplets that contain sample nucleic acid, 1410 , barcoded beads, 1415 , and, in some cases, a reducing agent.
  • the reducing agent may dissolve or degrade the barcoded beads, thereby releasing the oligonucleotides with the barcodes and random N-mers from the beads within the droplets, 1435 .
  • the random N-mers may then prime different regions of the sample nucleic acid, resulting in amplified copies of the sample after amplification, where each copy is tagged with a barcode sequence, 1440 .
  • each droplet contains a set of oligonucleotides that contain identical barcode sequences and different random N-mer sequences.
  • the emulsion is broken, 1445 and additional sequences (e.g., sequences that aid in particular sequencing methods, additional barcodes, etc.) may be added, via, for example, amplification methods (e.g., PCR).
  • Sequencing may then be performed, 1450 , and an algorithm applied to interpret the sequencing data, 1455 .
  • Sequencing algorithms are generally capable, for example, of performing analysis of barcodes to align sequencing reads and/or identify the sample from which a particular sequence read belongs.
  • the analyzed sequence is then compared to a known genome reference sequence to determine the CNV of different genes 1460 . If the EGFR copy number in the DNA is higher than normal, the patient can be differentially diagnosed with non-small cell lung cancer (NSCLC) instead of small-cell lung cancer 1465 .
  • NSCLC non-small cell lung cancer
  • the CTC of non-small cell lung cancer also has other copy number variations that may further distinguish it from small-cell lung cancer.
  • surgery, chemotherapy, or radiation therapy is prescribed 1470 .
  • a patient diagnosed with NSLC is administered a drug targeted for such cancer such as an ALK inhibitor (e.g., Crizotinib).
  • an ALK inhibitor e.g., Crizotinib
  • the patient is administered cetuximab, panitumumab, lapatinib, and/or capecitabine.
  • the target may be a different gene, such as ERBB2, and the therapy comprises trastuzumab (Herceptin). (2010) Nature 466: 368-72; Cook E. H. and Scherer S. W. (2008) Nature 455: 919-923.
  • Small molecules may include tyrosine-kinase inhibitors such as Imatinib mesylate (Gleevec, also known as STI-571) (which is approved for chronic myelogenous leukemia, gastrointestinal stromal tumor and some other types of cancer); Gefitinib (Iressa, also known as ZD1839)(which targets the epidermal growth factor receptor (EGFR) tyrosine kinase and is approved in the U.S.
  • Imatinib mesylate Gleevec, also known as STI-571
  • Gefitinib Iressa, also known as ZD1839
  • EGFR epidermal growth factor receptor
  • Erlotinib for non small cell lung cancer
  • Erlotinib marketed as Tarceva
  • Bortezomib (Velcade) (which is an apoptosis-inducing proteasome inhibitor drug that causes cancer cells to undergo cell death by interfering with proteins); tamoxifen; JAK inhibitors (e.g., tofactinib), ALK inhibitors (e.g., crizotinib.); Bcl-2 inhibitors (e.g. obatoclax in clinical trials, ABT-263, and Gossypol); PARP inhibitors (e.g. Iniparib, Olaparib in clinical trials); PI3K inhibitors (e.g. perifosine in a phase III trial).
  • JAK inhibitors e.g., tofactinib
  • ALK inhibitors e.g., crizotinib.
  • Bcl-2 inhibitors e.g. obatoclax in clinical trials, ABT-2
  • Apatinib which is a selective VEGF Receptor 2 inhibitor
  • AN-152 (AEZS-108) doxorubicin linked to [D-Lys(6)]-LHRH
  • Braf inhibitors vemurafenib, dabrafenib, LGX818) (used to treat metastatic melanoma that harbors BRAF V600E mutation)
  • MEK inhibitors trametinib, MEK162
  • CDK inhibitors e.g. PD-0332991, LEE011 in clinical trials
  • Hsp90 inhibitors and Salinomycin.
  • Other therapies include Small Molecule Drug Conjugates such as Vintafolide, which is a small molecule drug conjugate consisting of a small molecule targeting the folate receptor.
  • Monoclonal antibodies are another type of therapy that may be administered as part of a method provided herein. Monoclonal drug conjugates may also be administered.
  • Exemplary monoclonal antibodies include: Rituximab (marketed as MabThera or Rituxan)(which targets CD20 found on B cells and targets non Hodgkin lymphoma); Trastuzumab (Herceptin) (which targets the Her2/neu (also known as ErbB2) receptor expressed in some types of breast cancer); Cetuximab (marketed as Erbitux) and Panitumumab Bevacizumab (marketed as Avastin) (which targets VEGF ligand).
  • Rituximab marketed as MabThera or Rituxan
  • trastuzumab Herceptin
  • Her2/neu also known as ErbB2 receptor expressed in some types of breast cancer
  • Cetuximab marketed as Erbitux
  • Panitumumab Bevacizumab marketed as Avastin
  • the methods and systems described herein may also be used to characterize circulating nucleic acids within the blood or plasma of a subject.
  • analyses include the analysis of circulating tumor DNA, for use in identification of potential disease states in a patient, or circulating fetal DNA within the blood or plasma of a pregnant female, in order to characterize the fetal DNA in a non-invasive way, e.g., without resorting to direct sampling through amniocentesis or other invasive procedures.
  • the methods may be used to characterize fetal nucleic acid sequences, e.g. circulating fetal DNA, based, at least in part, on analysis of parental nucleic acid sequences.
  • long range sequence context can be determined for both paternal and maternal nucleic acids (e.g., having lengths of longer than 1 kb, longer than 5 kb, longer than 10 kb, longer than 15 kb, longer than 20 kb, longer than 30 kb, longer than 40 kb, longer than 50 kb, longer than 60 kb, longer than 70 kb, longer than 80 kb, longer than 90 kb or even longer than 100 kb) from shorter barcoded fragments using methods and systems described herein.
  • Long range sequence context can be used to determine one or more haplotypes and one or more genetic variations, including single nucleotide polymorphisms (SNPs), structural variations in (e.g., a copy number variation, an insertion, a deletion, a translocation, an inversion, a rearrangement, a repeat expansion, a retrotransposon, a duplication, a gene fusion, etc.) in both the paternal and maternal nucleic acid sequences.
  • SNPs single nucleotide polymorphisms
  • structural variations in e.g., a copy number variation, an insertion, a deletion, a translocation, an inversion, a rearrangement, a repeat expansion, a retrotransposon, a duplication, a gene fusion, etc.
  • long range sequence context of paternal and maternal nucleic acids and any determined SNP, haplotype and/or structural variation information can be used to characterize a sequence of a fetal nucleic acid obtained from the pregnant mother (e.g., circulating fetal nucleic acid, such as, for example, cell-free fetal nucleic acid).
  • characterizations of a fetal nucleic acid, via comparison with maternal and paternal sequences and characterization may be completed with the aid of a programmed computer processor.
  • a programmed computer processor can be included in a computer control system, such as in an example computer control system described elsewhere herein.
  • a sequence and/or long range sequence context of parental and/or maternal nucleic acids may be used as a reference by which to characterize fetal nucleic acid, including a fetal nucleic acid sequence.
  • long range sequence context obtained by methods and systems described herein can provide improved, long range sequence context information for paternal and maternal nucleic acids from which fetal nucleic acid sequences can be characterized.
  • characterization of a fetal nucleic acid sequence from parental nucleic acids as references may include determining a sequence for at least a portion of a fetal nucleic acid, and/or calling one or more SNPs of a fetal nucleic acid sequence, determining one or more de novo mutations of a fetal nucleic acid sequence, determining one or more haplotypes of a fetal nucleic acid sequence, and/or determining and characterizing one or more structural variations, etc. in a sequence of the fetal nucleic acid.
  • FIGS. 17-19 illustrate an example method for characterizing fetal nucleic acid from longer range sequence context obtained for paternal and maternal nucleic acid, via sequencing of shorter barcoded fragments.
  • FIG. 17 demonstrates an example method by which longer range sequence context can be determined for a paternal nucleic acid sample (e.g., paternal genomic DNA) from shorter barcoded fragments, such as, for example, in a manner analogous to that shown in FIG. 6 .
  • a sample comprising paternal nucleic acid may be obtained from the father of a fetus, 1700 , and a set of barcoded beads may also be obtained, 1710 .
  • the beads can be linked to oligonucleotides containing one or more barcode sequences, as well as a primer, such as a random N-mer or other primer.
  • the barcode sequences are releasable from the barcoded beads, e.g., through cleavage of a linkage between the barcode and the bead or through degradation of the underlying bead to release the barcode, or a combination of the two.
  • the barcoded beads can be degraded or dissolved by an agent, such as a reducing agent to release the barcode sequences.
  • paternal sample comprising nucleic acid, 1705 , barcoded beads, 1715 , and, in some cases, other reagents, e.g., a reducing agent, 1720 , are combined and subject to partitioning.
  • the paternal sample 1700 is fragmented prior to partitioning and at least some of the resulting fragments are partitioned as 1705 for barcoding.
  • partitioning may involve introducing the components to a droplet generation system, such as a microfluidic device, 1725 .
  • a water-in-oil emulsion 1730 may be formed, where the emulsion contains aqueous droplets that contain paternal sample nucleic acid, 1705 , reducing agent, 1720 , and barcoded beads, 1715 .
  • the reducing agent may dissolve or degrade the barcoded beads, thereby releasing the oligonucleotides with the barcodes and random N-mers from the beads within the droplets, 1735 .
  • the random N-mers may then prime different regions of the paternal sample nucleic acid, resulting in amplified copies of the paternal sample after amplification, where each copy is tagged with a barcode sequence, 1740 .
  • amplification 1740 may be achieved by a method analogous to that described elsewhere herein and schematically depicted in FIG. 5 .
  • each droplet contains a set of oligonucleotides that contain identical barcode sequences and different random N-mer sequences.
  • additional sequences e.g., sequences that aid in particular sequencing methods, additional barcodes, etc.
  • amplification methods 1750 (e.g., PCR).
  • Sequencing may then be performed, 1755 , and an algorithm applied to interpret the sequencing data 1760 .
  • interpretation of sequencing data 1760 may include providing a sequence for at least a portion of the paternal nucleic acid.
  • long range sequence context for the paternal nucleic acid sample can be obtained and characterized (e.g., determination of one or more haplotypes as described elsewhere herein, determination of one or more structural variations (e.g., a copy number variation, an insertion, a deletion, a translocation, an inversion, a rearrangement, a repeat expansion, a duplication, a retrotransposon, a gene fusion, etc.), calling of one or more SNPs, determination of one or more other genetic variations, etc.).
  • variants can be called for various paternal nucleic acids and inferred contigs generated to provide longer range sequence context, such as is described elsewhere herein with respect to FIG. 7 .
  • FIG. 18 demonstrates an example method by which long range sequence context can be determined for a maternal nucleic acid sample (e.g., maternal genomic DNA) from shorter barcoded fragments, such as, for example, in a manner analogous to that shown in FIG. 6 .
  • a sample comprising maternal nucleic acid may be obtained from the pregnant mother of a fetus, 1800 , and a set of barcoded beads may also be obtained, 1810 .
  • the beads can be linked to oligonucleotides containing one or more barcode sequences, as well as a primer, such as a random N-mer or other primer.
  • the barcode sequences are releasable from the barcoded beads, e.g., through cleavage of a linkage between the barcode and the bead or through degradation of the underlying bead to release the barcode, or a combination of the two.
  • the barcoded beads can be degraded or dissolved by an agent, such as a reducing agent to release the barcode sequences.
  • an agent such as a reducing agent to release the barcode sequences.
  • maternal sample comprising nucleic acid, 1805 , barcoded beads, 1815 , and, in some cases, other reagents, e.g., a reducing agent, 1820 , are combined and subject to partitioning.
  • the maternal sample 1800 is fragmented prior to partitioning and at least some of the resulting fragments are partitioned as 1805 for barcoding.
  • partitioning may involve introducing the components to a droplet generation system, such as a microfluidic device, 1825 .
  • a droplet generation system such as a microfluidic device, 1825 .
  • a water-in-oil emulsion 1830 may be formed, where the emulsion contains aqueous droplets that contain maternal sample nucleic acid, 1805 , reducing agent, 1820 , and barcoded beads, 1815 .
  • the reducing agent may dissolve or degrade the barcoded beads, thereby releasing the oligonucleotides with the barcodes and random N-mers from the beads within the droplets, 1835 .
  • the random N-mers may then prime different regions of the maternal sample nucleic acid, resulting in amplified copies of the maternal sample after amplification, where each copy is tagged with a barcode sequence, 1840 .
  • amplification 1840 may be achieved by a method analogous to that described elsewhere herein and schematically depicted in FIG. 5 .
  • each droplet contains a set of oligonucleotides that contain identical barcode sequences and different random N-mer sequences.
  • sequences that aid in particular sequencing methods, additional barcodes, etc. may be added, via, for example, amplification methods, 1850 (e.g., PCR).
  • amplification methods 1850 (e.g., PCR).
  • Sequencing may then be performed, 1855 , and an algorithm applied to interpret the sequencing data, 1860 .
  • interpretation of sequencing data 1860 may include providing a sequence for at least a portion of the maternal nucleic acid.
  • long range sequence context for the maternal nucleic acid sample can be obtained and characterized (e.g., determination of one or more haplotypes as described elsewhere herein, determination of one or more structural variations (e.g., a copy number variation, an insertion, a deletion, a translocation, an inversion, a rearrangement, a repeat expansion, a duplication, a retrotransposon, a gene fusion, etc.), calling of one or more SNPs, determination of one or more other genetic variations, etc.
  • variants can be called for various maternal nucleic acids obtained from a sample and inferred contigs generated to provide longer range sequence context, such as is described elsewhere herein with respect to FIG. 7 .
  • FIG. 19 demonstrates an example of characterizing a fetal sample sequence from the paternal 1760 and maternal 1860 characterizations obtained as shown in FIG. 17 and FIG. 18 , respectively.
  • a fetal nucleic acid sample can be obtained from the pregnant mother 1900 .
  • Long range sequence context can be obtained for the fetal nucleic acid from sequencing of shorter barcoded fragments as is described elsewhere herein, such as, for example, via the method schematically depicted in FIG. 6 .
  • the fetal nucleic acid sample may be circulating fetal DNA and/or cell-free DNA that may be, for example, obtained from the pregnant mother's blood, plasma, other bodily fluid, or tissue.
  • a set of barcoded beads may also be obtained, 1910 .
  • the beads are can be linked to oligonucleotides containing one or more barcode sequences, as well as a primer, such as a random N-mer or other primer.
  • the barcode sequences are releasable from the barcoded beads, e.g., through cleavage of a linkage between the barcode and the bead or through degradation of the underlying bead to release the barcode, or a combination of the two.
  • the barcoded beads can be degraded or dissolved by an agent, such as a reducing agent to release the barcode sequences.
  • fetal sample comprising nucleic acid, 1905 , barcoded beads, 1915 , and, in some cases, other reagents, e.g., a reducing agent, 1920 , are combined and subject to partitioning as 1905 .
  • the fetal sample 1900 is fragmented prior to partitioning and at least some of the resulting fragments are partitioned as 1905 for barcoding.
  • partitioning may involve introducing the components to a droplet generation system, such as a microfluidic device, 1925 .
  • a water-in-oil emulsion 1930 may be formed, where the emulsion contains aqueous droplets that contain maternal sample nucleic acid, 1905 , reducing agent, 1920 , and barcoded beads, 1915 .
  • the reducing agent may dissolve or degrade the barcoded beads, thereby releasing the oligonucleotides with the barcodes and random N-mers from the beads within the droplets, 1935 .
  • the random N-mers may then prime different regions of the fetal sample nucleic acid, resulting in amplified copies of the fetal sample after amplification, where each copy is tagged with a barcode sequence, 1940 .
  • amplification 1940 may be achieved by a method analogous to that described elsewhere herein and schematically depicted in FIG. 5 .
  • each droplet contains a set of oligonucleotides that contain identical barcode sequences and different random N-mer sequences.
  • additional sequences e.g., sequences that aid in particular sequencing methods, additional barcodes, etc.
  • amplification methods 1950 (e.g., PCR).
  • Sequencing may then be performed, 1955 , and an algorithm applied to interpret the sequencing data, 1960 .
  • interpretation of sequencing data 1960 may include providing a sequence for at least a portion of the fetal nucleic acid.
  • the fetal nucleic acid sequence can be characterized 1960 (e.g., determination of one or more haplotypes as described elsewhere herein, determination of one or more structural variations (e.g., a copy number variation, an insertion, a deletion, a translocation, an inversion, a rearrangement, a repeat expansion, a duplication, retrotransposon, a gene fusion, etc.), determination of one or more de novo mutations, calling of one or more SNPs, etc.) using the long-range sequence contexts and/or characterizations of the paternal 1760 and maternal 1860 samples.
  • phase blocks of the fetal nucleic acid can be determined by comparison of the fetal nucleic acid sequence to the maternal and paternal phase blocks.
  • paternal nucleic acid, maternal nucleic acid and/or fetal nucleic acid may completed as part of separate partitioning analyses or may be completed as part of one or more combined partitioning analyses.
  • paternal, maternal and fetal nucleic acids may be added to the same device and barcoded maternal, paternal and fetal fragments generated in droplets according to FIGS. 17-19 , where an emulsion comprises the droplets for the three types of nucleic acid.
  • the emulsion can then be broken and the contents of the droplets pooled, further processed (e.g., bulk addition of additional sequences via PCR) and sequenced as described elsewhere herein.
  • Individual sequencing reads from the barcoded fragments can be attributed to their respective sample sequence via barcode sequences.
  • the sequence of a fetal nucleic acid may be determined from long range paternal and maternal sequence contexts and characterizations obtained using methods and systems described herein. For example, genome sequencing of paternal and maternal genomes, along with sequencing of circulating fetal nucleic acids, may be used to determine a corresponding fetal genome sequence.
  • An example of determining a sequence of genomic fetal nucleic acid from sequence analysis of parental genomes and cell-free fetal nucleic acid can be found in Kitzman et al. (2012 Jun. 6) Sci Transl. Med. 4(137): 137ra76, which is herein entirely incorporated by reference.
  • Determination of a fetal genome may be useful in the prenatal determination and diagnosis of genetic disorders in the fetus, including, for example, fetal aneuploidy.
  • methods and systems provided herein can be useful in resolving haplotypes in nucleic acid sequences.
  • Haplotype-resolved paternal and maternal sequences can be determined for paternal and maternal sample nucleic acid sequences, respectively which can aid in more accurately determining the sequence of a fetal genome and/or characterizing the same.
  • Utilizing methods and systems herein can improve accuracy in determining long range sequence context of nucleic acids, including the long-range sequence context of parental nucleic acid sequences (e.g., maternal nucleic acid sequences, paternal nucleic acid sequences).
  • the methods and systems provided herein may determine long-range sequence context of parental nucleic acids with accuracy of at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 99%, 99.1%, 99.2%, 99.3% 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 99.95%, 99.99%, 99.995%, or 99.999%.
  • the methods and systems provided herein may determine long-range sequence context of parental nucleic acids with an error rate of less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.1%, 0.05%, 0.01%, 0.005%, 0.001%, 0.0005%, 0.0001%, 0.00005%, 0.00001%, or 0.000005%.
  • methods and systems herein can also improve accuracy in characterizing a paternal nucleic acid sequence in one or more aspects (e.g., determination of a sequence, determination of one or more genetic variations, determination of one or more structural variants, determination of haplotypes, etc.).
  • the methods and systems provided herein may characterize a paternal nucleic acid sequence in one or more aspects with an accuracy of at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 99%, 99.1%, 99.2%, 99.3% 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 99.95%, 99.99%, 99.995%, or 99.999%.
  • the methods and systems provided herein may characterize a parental nucleic acid sequence in one or more aspects with an error rate of less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.1%, 0.05%, 0.01%, 0.005%, 0.001%, 0.0005%, 0.0001%, 0.00005%, 0.00001%, or 0.000005%.
  • a fetal nucleic acid sequence (including long-range sequence context) can be provided from analysis of parental nucleic sequences with accuracy of at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 99%, 99.1%, 99.2%, 99.3% 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 99.95%, 99.99%, 99.995%, or 99.999%.
  • a fetal nucleic acid sequence (including long-range sequence context) can be provided from analysis of parental nucleic sequences with an error rate of less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.1%, 0.05%, 0.01%, 0.005%, 0.001%, 0.0005%, 0.0001%, 0.00005%, 0.00001%, or 0.000005%.
  • a fetal nucleic acid sequence can be characterized in one or more aspects via analysis of parental nucleic acid sequences as described herein (e.g., determination of a sequence, determination of one or more genetic variations, determination of one or more structural variations, determination of haplotypes, etc.) with accuracy of at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 99%, 99.1%, 99.2%, 99.3% 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 99.95%, 99.99%, 99.995%, or 99.999%.
  • parental nucleic acid sequences as described herein (e.g., determination of a sequence, determination of one or more genetic variations, determination of one or more structural variations, determination of haplotypes, etc.) with accuracy of at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 99%, 99.1%, 99.2%, 99.3% 99.4%
  • a fetal nucleic acid sequence can be characterized in one or more aspects via analysis of parental nucleic acid sequences as described herein (e.g., determination of a sequence, determination of one or more genetic variations, determination of haplotypes, determination of one or more structural variations, etc.) with an error rate of less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.1%, 0.05%, 0.01%, 0.005%, 0.001%, 0.0005%, 0.0001%, 0.00005%, 0.00001%, or 0.000005%.
  • Detection of a disease or disorder may begin with obtaining a sample from a patient.
  • sample generally refers to a biological sample.
  • biological samples include nucleic acid molecules, amino acids, polypeptides, proteins, carbohydrates, fats, or viruses.
  • a biological sample is a nucleic acid sample including one or more nucleic acid molecules.
  • Exemplary samples may include polynucleotides, nucleic acids, oligonucleotides, cell-free nucleic acid (e.g., cell-free DNA (cfDNA)), circulating cell-free nucleic acid, circulating tumor nucleic acid (e.g., circulating tumor DNA (ctDNA)), circulating tumor cell (CTC) nucleic acids, nucleic acid fragments, nucleotides, DNA, RNA, peptide polynucleotides, complementary DNA (cDNA), double stranded DNA (dsDNA), single stranded DNA (ssDNA), plasmid DNA, cosmid DNA, chromosomal DNA, genomic DNA (gDNA), viral DNA, bacterial DNA, mtDNA (mitochondrial DNA), ribosomal RNA, cell-free DNA, cell free fetal DNA (cffDNA), mRNA, rRNA, tRNA, nRNA, siRNA, snRNA, snoRNA, sca
  • the substance may be a fluid, e.g., a biological fluid.
  • a fluidic substance may include, but not limited to, blood, cord blood, saliva, urine, sweat, serum, semen, vaginal fluid, gastric and digestive fluid, spinal fluid, placental fluid, cavity fluid, ocular fluid, serum, breast milk, lymphatic fluid, or combinations thereof.
  • the substance may be solid, for example, a biological tissue.
  • the substance may comprise normal healthy tissues, diseased tissues, or a mix of healthy and diseased tissues. In some cases, the substance may comprise tumors. Tumors may be benign (non-cancer) or malignant (cancer).
  • Non-limiting examples of tumors may include: fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's, leiomyosarcoma, rhabdomyosarcoma, gastrointestinal system carcinomas, colon carcinoma, pancreatic cancer, breast cancer, genitourinary system carcinomas, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, chor
  • the substance may be associated with various types of organs.
  • organs may include brain, liver, lung, kidney, prostate, ovary, spleen, lymph node (including tonsil), thyroid, pancreas, heart, skeletal muscle, intestine, larynx, esophagus, stomach, or combinations thereof.
  • the substance may comprise a variety of cells, including but not limited to: eukaryotic cells, prokaryotic cells, fungi cells, heart cells, lung cells, kidney cells, liver cells, pancreas cells, reproductive cells, stem cells, induced pluripotent stem cells, gastrointestinal cells, blood cells, cancer cells, bacterial cells, bacterial cells isolated from a human microbiome sample, etc.
  • the substance may comprise contents of a cell, such as, for example, the contents of a single cell or the contents of multiple cells.
  • contents of a cell such as, for example, the contents of a single cell or the contents of multiple cells.
  • Samples may be obtained from various subjects.
  • a subject may be a living subject or a dead subject. Examples of subjects may include, but not limited to, humans, mammals, non-human mammals, rodents, amphibians, reptiles, canines, felines, bovines, equines, goats, ovines, hens, avines, mice, rabbits, insects, slugs, microbes, bacteria, parasites, or fish.
  • the subject may be a patient who is having, suspected of having, or at a risk of developing a disease or disorder.
  • the subject may be a pregnant woman.
  • the subject may be a normal healthy pregnant woman.
  • the subject may be a pregnant woman who is at a risking of carrying a baby with certain birth defect.
  • a sample may be obtained from a subject by various approaches.
  • a sample may be obtained from a subject through accessing the circulatory system (e.g., intravenously or intra-arterially via a syringe or other apparatus), collecting a secreted biological sample (e.g., saliva, sputum urine, feces, etc.), surgically (e.g., biopsy) acquiring a biological sample (e.g., intra-operative samples, post-surgical samples, etc.), swabbing (e.g., buccal swab, oropharyngeal swab), or pipetting.
  • a biological sample e.g., intra-operative samples, post-surgical samples, etc.
  • swabbing e.g., buccal swab, oropharyngeal swab
  • pipetting e.g., buccal swab, oropharyngeal swab
  • CNVs can be associated with efficacy of a therapy.
  • increased HER2 gene copy number can enhance the response to gefitinib therapy in advanced non-small cell lung cancer. See Cappuzzo F. et al. (2005) J. Clin. Oncol. 23: 5007-5018.
  • High EGFR gene copy number can predict for increased sensitivity to lapatinib and capecitabine. See Fabi et al. (2010) J. Clin. Oncol. 28:15s (2010 ASCO Annual Meeting).
  • High EGFR gene copy number is associated with increased sensitivity to cetuximab and panitumumab.
  • Copy number variations can be associated with resistance of cancer patients to certain therapeutics. For example, amplification of thymidylate synthase can result in resistance to 5-fluorouracil treatment in metastatic colorectal cancer patients. See Wang et al. (2002) PNAS USA vol. 99, pp. 16156-61.
  • the present disclosure provides computer systems that are programmed or otherwise configured to implement methods provided herein, such as, for example, methods for nucleic sequencing and determination of genetic variations, storing reference nucleic acid sequences, conducting sequence analysis and/or comparing sample and reference nucleic acid sequences as described herein.
  • An example of such a computer system is shown in FIG. 22 .
  • the computer system 2201 includes a central processing unit (CPU, also “processor” and “computer processor” herein) 2205 , which can be a single core or multi core processor, or a plurality of processors for parallel processing.
  • CPU central processing unit
  • processor also “processor” and “computer processor” herein
  • the computer system 2201 also includes memory or memory location 2210 (e.g., random-access memory, read-only memory, flash memory), electronic storage unit 2215 (e.g., hard disk), communication interface 2220 (e.g., network adapter) for communicating with one or more other systems, and peripheral devices 2225 , such as cache, other memory, data storage and/or electronic display adapters.
  • the memory 2210 , storage unit 2215 , interface 2220 and peripheral devices 2225 are in communication with the CPU 2205 through a communication bus (solid lines), such as a motherboard.
  • the storage unit 2215 can be a data storage unit (or data repository) for storing data.
  • the computer system 2201 can be operatively coupled to a computer network (“network”) 2230 with the aid of the communication interface 2220 .
  • network computer network
  • the network 2230 can be the Internet, an internet and/or extranet, or an intranet and/or extranet that is in communication with the Internet.
  • the network 2230 in some cases is a telecommunication and/or data network.
  • the network 2230 can include one or more computer servers, which can enable distributed computing, such as cloud computing.
  • the network 2230 in some cases with the aid of the computer system 2201 , can implement a peer-to-peer network, which may enable devices coupled to the computer system 2201 to behave as a client or a server.
  • the CPU 2205 can execute a sequence of machine-readable instructions, which can be embodied in a program or software.
  • the instructions may be stored in a memory location, such as the memory 2210 . Examples of operations performed by the CPU 2205 can include fetch, decode, execute, and writeback.
  • the storage unit 2215 can store files, such as drivers, libraries and saved programs.
  • the storage unit 2215 can store user data, e.g., user preferences and user programs.
  • the computer system 2201 in some cases can include one or more additional data storage units that are external to the computer system 2201 , such as located on a remote server that is in communication with the computer system 2201 through an intranet or the Internet.
  • the computer system 2201 can communicate with one or more remote computer systems through the network 2230 .
  • the computer system 2201 can communicate with a remote computer system of a user (e.g., operator).
  • remote computer systems include personal computers (e.g., portable PC), slate or tablet PC's (e.g., Apple® iPad, Samsung® Galaxy Tab), telephones, Smart phones (e.g., Apple® iPhone, Android-enabled device, Blackberry®), or personal digital assistants.
  • the user can access the computer system 2201 via the network 2230 .
  • Methods as described herein can be implemented by way of machine (e.g., computer processor) executable code stored on an electronic storage location of the computer system 2201 , such as, for example, on the memory 2210 or electronic storage unit 2215 .
  • the machine executable or machine readable code can be provided in the form of software.
  • the code can be executed by the processor 2205 .
  • the code can be retrieved from the storage unit 2215 and stored on the memory 2210 for ready access by the processor 2205 .
  • the electronic storage unit 2215 can be precluded, and machine-executable instructions are stored on memory 2210 .
  • the code can be pre-compiled and configured for use with a machine have a processer adapted to execute the code, or can be compiled during runtime.
  • the code can be supplied in a programming language that can be selected to enable the code to execute in a pre-compiled or as-compiled fashion.
  • aspects of the systems and methods provided herein can be embodied in programming.
  • Various aspects of the technology may be thought of as “products” or “articles of manufacture” typically in the form of machine (or processor) executable code and/or associated data that is carried on or embodied in a type of machine readable medium.
  • Machine-executable code can be stored on an electronic storage unit, such memory (e.g., read-only memory, random-access memory, flash memory) or a hard disk.
  • “Storage” type media can include any or all of the tangible memory of the computers, processors or the like, or associated modules thereof, such as various semiconductor memories, tape drives, disk drives and the like, which may provide non-transitory storage at any time for the software programming.
  • All or portions of the software may at times be communicated through the Internet or various other telecommunication networks. Such communications, for example, may enable loading of the software from one computer or processor into another, for example, from a management server or host computer into the computer platform of an application server.
  • another type of media that may bear the software elements includes optical, electrical and electromagnetic waves, such as used across physical interfaces between local devices, through wired and optical landline networks and over various air-links.
  • the physical elements that carry such waves, such as wired or wireless links, optical links or the like, also may be considered as media bearing the software.
  • terms such as computer or machine “readable medium” refer to any medium that participates in providing instructions to a processor for execution.
  • a machine readable medium such as computer-executable code
  • a tangible storage medium such as computer-executable code
  • Non-volatile storage media include, for example, optical or magnetic disks, such as any of the storage devices in any computer(s) or the like, such as may be used to implement the databases, etc. shown in the drawings.
  • Volatile storage media include dynamic memory, such as main memory of such a computer platform.
  • Tangible transmission media include coaxial cables; copper wire and fiber optics, including the wires that comprise a bus within a computer system.
  • Carrier-wave transmission media may take the form of electric or electromagnetic signals, or acoustic or light waves such as those generated during radio frequency (RF) and infrared (IR) data communications.
  • RF radio frequency
  • IR infrared
  • Common forms of computer-readable media therefore include for example: a floppy disk, a flexible disk, hard disk, magnetic tape, any other magnetic medium, a CD-ROM, DVD or DVD-ROM, any other optical medium, punch cards paper tape, any other physical storage medium with patterns of holes, a RAM, a ROM, a PROM and EPROM, a FLASH-EPROM, any other memory chip or cartridge, a carrier wave transporting data or instructions, cables or links transporting such a carrier wave, or any other medium from which a computer may read programming code and/or data.
  • Many of these forms of computer readable media may be involved in carrying one or more sequences of one or more instructions to a processor for execution.
  • the computer system 2201 can include or be in communication with an electronic display 2235 that comprises a user interface (UI) for providing, for example, an output or readout of a nucleic acid sequencing instrument coupled to the computer system 2201 .
  • UI user interface
  • Such readout can include a nucleic acid sequencing readout, such as a sequence of nucleic acid bases that comprise a given nucleic acid sample.
  • the UI may also be used to display the results of an analysis making use of such readout. Examples of UI's include, without limitation, a graphical user interface (GUI) and web-based user interface.
  • GUI graphical user interface
  • the electronic display 2235 can be a computer monitor, or a capacitive or resistive touchscreen.
  • Genomic DNA from the NA12878 human cell line was subjected to size based separation of fragments using a Blue Pippin DNA sizing system to recover fragments that were approximately 10 kb in length.
  • the size selected sample nucleic acids were then copartitioned with barcode beads in aqueous droplets within a fluorinated oil continuous phase using a microfluidic partitioning system (see e.g., U.S. Provisional Patent Application No. 61/977,804, filed Apr.
  • aqueous droplets also included the dNTPs, thermostable DNA polymerase and other reagents for carrying out amplification within the droplets, as well as a chemical activator for releasing the barcode oligonucleotides from the beads.
  • dNTPs thermostable DNA polymerase
  • other reagents for carrying out amplification within the droplets
  • a chemical activator for releasing the barcode oligonucleotides from the beads.
  • the barcode beads were obtained as a subset of a stock library that represented barcode diversity of over 700,000 different barcode sequences.
  • the barcode containing oligonucleotides included additional sequence components and had the general structure:
  • the droplets were thermocycled to allow for primer extension of the barcode oligos against the template of the sample nucleic acids within each droplet. This resulted in copied fragments of the sample nucleic acids that included the barcode sequence representative of the originating partition, in addition to the other included sequences set forth above.
  • the emulsion of droplets including the amplified copy fragments was broken and the additional sequencer required components, e.g., read2 primer sequence and P7 attachment sequence for Illumina sequencer, were added to the copy fragments through additional amplification, which attached these sequences to the other end of the copy fragments.
  • additional sequencer required components e.g., read2 primer sequence and P7 attachment sequence for Illumina sequencer
  • the sequencing library was then sequenced on an Illumina HiSeq system at 10 ⁇ coverage, 20 ⁇ coverage and 30 ⁇ coverage, and the resulting sequence reads and their associated barcode sequences were then analyzed. Proximally mapping sequences that shared common barcodes were then assembled into larger contigs, and single nucleotide polymorphisms were identified and associated with individual starting molecules based upon their associated barcodes and sequence mapping, to identify phased SNPs. Sequences that included overlapping phased SNPs were then assembled into phase blocks or inferred contigs of phased sequence data based upon the overlapping phased SNPs. The resulting data was compared to known haplotype maps for the cell line for comparison.
  • each allele of a series of heterozygous variants is assigned to one of two to two haplotypes.
  • phasing assignment, variants) is defined that returns the log-likelihood of the observed read and barcode data, given a set of variants, and a phasing assignment of the heterozygous variants.
  • the form of the log-likelihood function derives from two main observations about barcoded sequence read data: (1) The reads from one barcode cover a small fraction of a haploid genome, so the probability of one barcode containing reads for both haplotypes in a given region of the genome is small.
  • the reads for one barcode in a local region of the genome are very likely to come from a single haplotype; (2) the probability that an observed base differs from the true base in haplotype it was derived from is described by the Phred QV of the observed base assigned by the sequencer.
  • the phasing configuration that maximizes the log-likelihood function, for a given set of barcoded reads and variants is then reported.
  • the maximum-likelihood scoring haplotype configuration is then found by a structured search procedure.
  • a beam search is used to find an optimal phasing configuration of a small block of neighboring variants (e.g., ⁇ 50 variants).
  • Second the relative phasing of the blocks is determined in a sweep over the block junctions. At this point an overall near-optimal phasing configuration is found and is used as a starting point for further optimization.
  • the haplotype assignment of individual variants is then inverted to find local improvement to the phasing, the difference in the log-likelihood between the swapped configurations provides an estimate of the confidence of that phasing assignment.
  • the phasing configuration is broken into phase blocks that have a high probability of being internally correct. It is then tested whether to break a phase block at each SNP by comparing the log-likelihoods of the optimal configuration with a configuration where all SNPs right of the current SNP have their haplotype assignment inverted.
  • the table below provides the phasing metrics obtained for the NA 12878 genome. As is apparent, extremely long phase blocks are obtained from short read sequence data, correctly identifying significant percentages of phased SNPs, with very low short or long switch errors.
  • NCI-H2228 lung cancer cell line is known to have an EML4-ALK fusion translocation within its genome.
  • the structure of the variation compared to wild type is illustrated in FIG. 15 .
  • the EML-4 gene while on the same chromosome, is relatively separate or distant from the ALK gene, is instead translocated and fused to the ALK gene (See e.g., Choi, et al., Identification of Novel Isoforms of the EML 4- LK Transforming Gene in Non - Small Cell Lung Cancer , J. Cancer Res., 68:4971 (July 2008)).
  • the EML4 gene is also inverted.
  • the translocation is further illustrated in Panel II, as compared to the wild type structure, where the translocation results in the fusion of exons 1-6 of EML-4 (shown as black boxes) to exons 20-29 of ALK (shown as white boxes), as well as the fusion of exons 7-23 of ALK fused to exons 1-19 of the EML-4.
  • genomic DNA from the NCI-H2228 cell line was subjected to size separation using a Blue Pippin® system (Sage Sciences, Inc.), to select for fragments of approximately 10 kb in length.
  • the size selected sample nucleic acids were then copartitioned with barcode beads, amplified and processed into a sequencing library as described above for Example 1, except that the DNA was subjected to hybrid capture using an Agilent SureSelect Exome capture kit after barcoding and prior to sequencing.
  • the sequencing library was then sequenced to approximately 80 ⁇ coverage on an Illumina HiSeq system and the resulting sequence reads and their associated barcode sequences were then analyzed.
  • the higher number of shared barcodes among portions of the genome that span the translocation event was clearly evident as compared to the wild type, illustrating structural proximity between the fused components where not present in the wild type. In particular, and as shown in FIG.
  • the fusion structure showed barcode overlap between EML-4 exons 1-6 and ALK exons 20-29, of 12 barcodes, and between EML-4 exons 7-23 and ALK exons 1-19, of 20 barcodes, that were comparable to the overlapping barcodes for the wild type construct for the heterozygous cell line.
  • a negative control run using a non variant cell line showed substantially only barcode overlap for the wild type vs. the variant construct, as shown in FIG. 16B , with sequence coverage of approximately 140 ⁇ , and using 3 ng of starting DNA.
  • a patient is tested for susceptibility to lupus. Blood is drawn from the patient. A cell-free DNA sample is sequenced using techniques recited herein. The sequence is then compared to a known genome reference sequence to determine the CNV of different genes. A low copy number of FCGR3B (the CD16 cell surface immunoglobulin receptor) indicates an increased susceptibility to systemic lupus erythematosus. The patient is informed of any copy number aberrations and the associated risks/disease.
  • FCGR3B the CD16 cell surface immunoglobulin receptor
  • a patient is tested for predisposition to neuroblastoma. Blood is drawn from the patient. A cell-free DNA sample is sequenced using techniques recited herein. The sequence is then compared to a known genome reference sequence to determine the CNV of different genes. CNV at 1q21.1 indicates an increased predisposition to neuroblastoma. The patient is informed of any copy number aberrations and the associated risks/disease.
  • a patient with chromic cough, weight loss and shortness of breath is tested for lung cancer.
  • Blood is drawn from the patient.
  • the circulating tumor cell (CTC) or cell-free DNA sample is sequenced using techniques recited herein.
  • the CTC sequence is then compared to a known genome reference sequence to determine the CNV of different genes. If the EGFR copy number in the DNA is higher than normal, the patient can be differentially diagnosed with non-small cell lung cancer (NSCLC) instead of small-cell lung cancer.
  • NSCLC non-small cell lung cancer
  • the CTC of non-small cell lung cancer also has other copy number variations that may further distinguish it from small-cell lung cancer.
  • surgery, chemotherapy, or radiation therapy is prescribed.
  • NSCLC non-small cell lung carcinoma
  • ALK inhibitors such as Crizotinib
  • Fetal aneuploidies are aberrations in chromosome number. Aneuploidies commonly result in significant physical and neurological impairments. A reduction in the number of X chromosomes is responsible for Turner's syndrome. An increase in copy number of chromosome number 21 results in Down's syndrome. Invasive testing such as amniocentesis or Chorionic Villus Sampling (CVS) can lead to risk of pregnancy loss and less invasive methods of testing the maternal blood are used here.
  • CVS Chorionic Villus Sampling
  • a pregnant patient with a family history of Down's syndrome or Turner's syndrome is tested.
  • a maternal blood sample containing fetal genetic material is collected.
  • the nucleic acids from different chromosomes are then separated into different partitions along with barcoded tag molecules as described herein.
  • the samples are then sequenced and the number of each chromosome copies is compared to a sequence on a normal diploid chromosome. The patient is informed of any copy number aberrations for different chromosomes and the associated risks/disease.
  • Burkitt's Lymphoma is characterized by a t(8;14) translocation in the chromosomes.
  • a patient generally diagnosed with lymphoma is tested for Burkitt's Lymphoma.
  • a tumor-biopsy specimen is collected from the lymph node.
  • the nucleic acids from different chromosomes are the separated into different partitions along with barcoded tag molecules as described herein.
  • the samples are then sequenced and compared to a control DNA sample to detect chromosomal translocation. If the patient is diagnosed as having Burkitt's Lymphoma, a more intensive chemotherapy regimen, including the CHOP or R-CHOP regimen, can be required than with other types of lymphoma.
  • CHOP consists of: Cyclophosphamide, an alkylating agent which damages DNA by binding to it and causing the formation of cross-links; Hydroxydaunorubicin (also called doxorubicin or Adriamycin), an intercalating agent which damages DNA by inserting itself between DNA bases; Oncovin (vincristine), which prevents cells from duplicating by binding to the protein tubulin; Prednisone or prednisolone, which are corticosteroids.
  • This regimen can also be combined with the monoclonal antibody rituximab since Burkitt's the lymphoma is of B cell origin; this combination is called R-CHOP.
  • a sample comprising maternal DNA from a pregnant patient and a sample comprising paternal DNA from the father of the fetus are collected.
  • the nucleic acids from each sample are separated into different partitions along with molecular barcoded tags as described herein.
  • the samples are then sequenced and the sequences are used to generate inferred contigs for each of the partitioned maternal and paternal fragments.
  • the inferred contigs are used to construct haplotype blocks for portions of each of the maternal and paternal chromosomes.
  • a maternal blood sample containing fetal genetic material is collected.
  • the cell-free DNA is sequenced to generate a sequences of both the maternal circulating DNA and the fetal circulating DNA.
  • the reads are compared to the paternal and maternal phase blocks generated above. Some phase blocks have undergone recombination during meiosis.
  • the fetal material is identified that matches the paternal phase blocks and not the maternal phase blocks. In some cases, the fetal material matches the entirety of a paternal phase block and it is determined that the fetus has that paternal phase block in the paternally inherited chromosome.
  • the fetal material matches part of a phase block and then matches a second phase block, where the two phase blocks are on homologous chromosomal regions in the paternal genome. It is determined that a meiotic recombination event occurred at this region, the most likely point of recombination is determined, and a novel fetal phase block that is a combination of two paternal phase blocks is produced.
  • the sequences of the circulating DNA are compared to the maternal phase blocks. Sites of heterozygosity in the maternal phase blocks are used to determine the most likely phase of the maternally derived fetal chromosomes.
  • the circulating DNA sequences are used to determine the copy number at the heterozygous sites of the maternal genome. Elevated copy numbers of specific maternal phase blocks indicates that the maternally derived chromosome of the fetus contains the sequence of the elevated phase block.
  • at first one phase block of a homologous region will appear elevated, and then a portion of another phase block of the same region will appear elevated, indicating that meiotic recombination has occurred. In these cases, a the most likely region of recombination is determined and a new fetal phase block is constructed from the two maternal phase blocks.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
US14/752,589 2014-06-26 2015-06-26 Analysis of nucleic acid sequences Abandoned US20150376700A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US14/752,589 US20150376700A1 (en) 2014-06-26 2015-06-26 Analysis of nucleic acid sequences
US15/985,388 US20180265928A1 (en) 2014-06-26 2018-05-21 Analysis of nucleic acid sequences
US16/898,984 US12163191B2 (en) 2014-06-26 2020-06-11 Analysis of nucleic acid sequences
US18/934,042 US20250059606A1 (en) 2014-06-26 2024-10-31 Analysis of nucleic acid sequences

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462017808P 2014-06-26 2014-06-26
US201462072214P 2014-10-29 2014-10-29
US14/752,589 US20150376700A1 (en) 2014-06-26 2015-06-26 Analysis of nucleic acid sequences

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/985,388 Continuation US20180265928A1 (en) 2014-06-26 2018-05-21 Analysis of nucleic acid sequences
US16/898,984 Continuation US12163191B2 (en) 2014-06-26 2020-06-11 Analysis of nucleic acid sequences

Publications (1)

Publication Number Publication Date
US20150376700A1 true US20150376700A1 (en) 2015-12-31

Family

ID=54929876

Family Applications (4)

Application Number Title Priority Date Filing Date
US14/752,589 Abandoned US20150376700A1 (en) 2014-06-26 2015-06-26 Analysis of nucleic acid sequences
US15/985,388 Abandoned US20180265928A1 (en) 2014-06-26 2018-05-21 Analysis of nucleic acid sequences
US16/898,984 Active 2038-07-02 US12163191B2 (en) 2014-06-26 2020-06-11 Analysis of nucleic acid sequences
US18/934,042 Pending US20250059606A1 (en) 2014-06-26 2024-10-31 Analysis of nucleic acid sequences

Family Applications After (3)

Application Number Title Priority Date Filing Date
US15/985,388 Abandoned US20180265928A1 (en) 2014-06-26 2018-05-21 Analysis of nucleic acid sequences
US16/898,984 Active 2038-07-02 US12163191B2 (en) 2014-06-26 2020-06-11 Analysis of nucleic acid sequences
US18/934,042 Pending US20250059606A1 (en) 2014-06-26 2024-10-31 Analysis of nucleic acid sequences

Country Status (10)

Country Link
US (4) US20150376700A1 (https=)
EP (1) EP3161162A4 (https=)
JP (1) JP2017522866A (https=)
KR (1) KR20170026383A (https=)
CN (1) CN106536756A (https=)
AU (1) AU2015279617A1 (https=)
CA (1) CA2953469A1 (https=)
IL (1) IL249619A0 (https=)
MX (1) MX2016016904A (https=)
WO (1) WO2015200869A1 (https=)

Cited By (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200893A2 (en) 2014-06-26 2015-12-30 10X Genomics, Inc. Methods of analyzing nucleic acids from individual cells or cell populations
US20160203196A1 (en) * 2015-01-13 2016-07-14 10X Genomics, Inc. Systems and methods for visualizing structural variation and phasing information
US9644204B2 (en) 2013-02-08 2017-05-09 10X Genomics, Inc. Partitioning and processing of analytes and other species
US9689024B2 (en) 2012-08-14 2017-06-27 10X Genomics, Inc. Methods for droplet-based sample preparation
US9694361B2 (en) 2014-04-10 2017-07-04 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US9701998B2 (en) 2012-12-14 2017-07-11 10X Genomics, Inc. Methods and systems for processing polynucleotides
WO2017165463A1 (en) 2016-03-22 2017-09-28 Counsyl, Inc. Combinatorial dna screening
US20170321270A1 (en) * 2016-05-06 2017-11-09 Counsyl, Inc. Noninvasive prenatal diagnostic methods
US9824068B2 (en) 2013-12-16 2017-11-21 10X Genomics, Inc. Methods and apparatus for sorting data
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US20180179578A1 (en) * 2014-08-22 2018-06-28 Resolution Bioscience, Inc. Methods for quantitative genetic analysis of cell free dna
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
WO2018200867A1 (en) 2017-04-26 2018-11-01 10X Genomics, Inc. Mmlv reverse transcriptase variants
US20180340169A1 (en) * 2017-05-26 2018-11-29 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10221436B2 (en) 2015-01-12 2019-03-05 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US10221442B2 (en) 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
US10227648B2 (en) 2012-12-14 2019-03-12 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10287623B2 (en) 2014-10-29 2019-05-14 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequencing
WO2019108807A1 (en) 2017-12-01 2019-06-06 Personal Genome Diagnositics Inc. Process for microsatellite instability detection
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10357771B2 (en) 2017-08-22 2019-07-23 10X Genomics, Inc. Method of producing emulsions
US10364467B2 (en) 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
WO2019157529A1 (en) 2018-02-12 2019-08-15 10X Genomics, Inc. Methods characterizing multiple analytes from individual cells or cell populations
US10386338B2 (en) * 2017-10-30 2019-08-20 Cynthia Rena Wright DNA/RNA PEMS microcantilever probe for detection of viral infection and detection of genetic variants
US10395758B2 (en) 2013-08-30 2019-08-27 10X Genomics, Inc. Sequencing methods
US10395759B2 (en) 2015-05-18 2019-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for copy number variant detection
US10400280B2 (en) 2012-08-14 2019-09-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
WO2019169028A1 (en) 2018-02-28 2019-09-06 10X Genomics, Inc. Transcriptome sequencing through random ligation
US10428326B2 (en) 2017-01-30 2019-10-01 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
EP3414341A4 (en) * 2016-02-11 2019-10-09 10X Genomics, Inc. SYSTEMS, METHODS AND MEDIA FOR DE-NOVO ARRANGEMENT OF ALL GENERIC SEQUENCE DATA
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10544413B2 (en) 2017-05-18 2020-01-28 10X Genomics, Inc. Methods and systems for sorting droplets and beads
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10590244B2 (en) 2017-10-04 2020-03-17 10X Genomics, Inc. Compositions, methods, and systems for bead formation using improved polymers
US10697000B2 (en) 2015-02-24 2020-06-30 10X Genomics, Inc. Partition processing methods and systems
US10741270B2 (en) 2012-03-08 2020-08-11 The Chinese University Of Hong Kong Size-based analysis of cell-free tumor DNA for classifying level of cancer
US10745742B2 (en) 2017-11-15 2020-08-18 10X Genomics, Inc. Functionalized gel beads
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10774370B2 (en) 2015-12-04 2020-09-15 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
US10839939B2 (en) 2014-06-26 2020-11-17 10X Genomics, Inc. Processes and systems for nucleic acid sequence assembly
US10837047B2 (en) 2017-10-04 2020-11-17 10X Genomics, Inc. Compositions, methods, and systems for bead formation using improved polymers
US10854315B2 (en) 2015-02-09 2020-12-01 10X Genomics, Inc. Systems and methods for determining structural variation and phasing using variant call data
US10995333B2 (en) 2017-02-06 2021-05-04 10X Genomics, Inc. Systems and methods for nucleic acid preparation
US11062789B2 (en) 2014-07-18 2021-07-13 The Chinese University Of Hong Kong Methylation pattern analysis of tissues in a DNA mixture
US11084036B2 (en) 2016-05-13 2021-08-10 10X Genomics, Inc. Microfluidic systems and methods of use
US11135584B2 (en) 2014-11-05 2021-10-05 10X Genomics, Inc. Instrument systems for integrated sample processing
US11155881B2 (en) 2018-04-06 2021-10-26 10X Genomics, Inc. Systems and methods for quality control in single cell processing
US11274343B2 (en) 2015-02-24 2022-03-15 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequence coverage
JP2022065157A (ja) * 2016-05-02 2022-04-26 エンコディア， インコーポレイテッド 核酸エンコーディングを使用した巨大分子解析
US11319594B2 (en) 2016-08-25 2022-05-03 Resolution Bioscience, Inc. Methods for the detection of genomic copy changes in DNA samples
US11339391B2 (en) 2015-11-11 2022-05-24 Resolution Bioscience, Inc. High efficiency construction of DNA libraries
US11365438B2 (en) 2017-11-30 2022-06-21 10X Genomics, Inc. Systems and methods for nucleic acid preparation and analysis
US11371094B2 (en) 2015-11-19 2022-06-28 10X Genomics, Inc. Systems and methods for nucleic acid processing using degenerate nucleotides
US11435339B2 (en) 2016-11-30 2022-09-06 The Chinese University Of Hong Kong Analysis of cell-free DNA in urine
US11447833B2 (en) 2019-11-06 2022-09-20 The Board Of Trustees Of The Leland Stanford Junior University Methods for preparing nucleic acid libraries for sequencing
US11459607B1 (en) 2018-12-10 2022-10-04 10X Genomics, Inc. Systems and methods for processing-nucleic acid molecules from a single cell using sequential co-partitioning and composite barcodes
US11467153B2 (en) 2019-02-12 2022-10-11 10X Genomics, Inc. Methods for processing nucleic acid molecules
WO2022236221A1 (en) * 2021-05-05 2022-11-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules
US11535891B2 (en) 2019-05-03 2022-12-27 The Regents Of The University Of California Barcoded solid supports and methods of making and using same
US11584953B2 (en) 2019-02-12 2023-02-21 10X Genomics, Inc. Methods for processing nucleic acid molecules
US11584954B2 (en) 2017-10-27 2023-02-21 10X Genomics, Inc. Methods and systems for sample preparation and analysis
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US11634709B2 (en) 2019-04-30 2023-04-25 Encodia, Inc. Methods for preparing analytes and related kits
US11639928B2 (en) 2018-02-22 2023-05-02 10X Genomics, Inc. Methods and systems for characterizing analytes from individual cells or cell populations
US11655499B1 (en) 2019-02-25 2023-05-23 10X Genomics, Inc. Detection of sequence elements in nucleic acid molecules
US11660601B2 (en) 2017-05-18 2023-05-30 10X Genomics, Inc. Methods for sorting particles
US11703427B2 (en) 2018-06-25 2023-07-18 10X Genomics, Inc. Methods and systems for cell and bead processing
US11725231B2 (en) 2017-10-26 2023-08-15 10X Genomics, Inc. Methods and systems for nucleic acid preparation and chromatin analysis
US11773389B2 (en) 2017-05-26 2023-10-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US11783912B2 (en) 2021-05-05 2023-10-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules
US11782062B2 (en) 2017-10-31 2023-10-10 Encodia, Inc. Kits for analysis using nucleic acid encoding and/or label
US11833515B2 (en) 2017-10-26 2023-12-05 10X Genomics, Inc. Microfluidic channel networks for partitioning
US11845983B1 (en) 2019-01-09 2023-12-19 10X Genomics, Inc. Methods and systems for multiplexing of droplet based assays
US11851700B1 (en) 2020-05-13 2023-12-26 10X Genomics, Inc. Methods, kits, and compositions for processing extracellular molecules
US11851683B1 (en) 2019-02-12 2023-12-26 10X Genomics, Inc. Methods and systems for selective analysis of cellular samples
US11873530B1 (en) 2018-07-27 2024-01-16 10X Genomics, Inc. Systems and methods for metabolome analysis
US11898206B2 (en) 2017-05-19 2024-02-13 10X Genomics, Inc. Systems and methods for clonotype screening
CN117580963A (zh) * 2021-05-05 2024-02-20 斯坦福大学托管董事会 用于分析核酸分子的方法和系统
US11920183B2 (en) 2019-03-11 2024-03-05 10X Genomics, Inc. Systems and methods for processing optically tagged beads
US11932882B2 (en) 2019-12-11 2024-03-19 10X Genomics, Inc. Reverse transcriptase variants
US11932899B2 (en) 2018-06-07 2024-03-19 10X Genomics, Inc. Methods and systems for characterizing nucleic acid molecules
US11952626B2 (en) 2021-02-23 2024-04-09 10X Genomics, Inc. Probe-based analysis of nucleic acids and proteins
US11999949B2 (en) 2012-12-10 2024-06-04 Resolution Bioscience, Inc. Methods for targeted genomic analysis
US12049621B2 (en) 2018-05-10 2024-07-30 10X Genomics, Inc. Methods and systems for molecular composition generation
US12065688B2 (en) 2018-08-20 2024-08-20 10X Genomics, Inc. Compositions and methods for cellular processing
US12071669B2 (en) 2016-02-12 2024-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for detection of abnormal karyotypes
US12084715B1 (en) 2020-11-05 2024-09-10 10X Genomics, Inc. Methods and systems for reducing artifactual antisense products
US12104200B2 (en) 2017-12-22 2024-10-01 10X Genomics, Inc Systems and methods for processing nucleic acid molecules from one or more cells
US12112833B2 (en) 2020-02-04 2024-10-08 10X Genomics, Inc. Systems and methods for index hopping filtering
US12163179B2 (en) 2018-08-03 2024-12-10 10X Gemomics, Inc. Methods and systems to minimize barcode exchange
US12163191B2 (en) 2014-06-26 2024-12-10 10X Genomics, Inc. Analysis of nucleic acid sequences
US12169198B2 (en) 2019-01-08 2024-12-17 10X Genomics, Inc. Systems and methods for sample analysis
US12168801B1 (en) 2020-07-02 2024-12-17 10X Genomics, Inc. Hybrid/capture probe designs for full-length cDNA
US12188014B1 (en) 2018-07-25 2025-01-07 10X Genomics, Inc. Compositions and methods for nucleic acid processing using blocking agents
US12209271B2 (en) 2018-08-20 2025-01-28 10X Genomics, Inc. Methods and systems for detection of protein-DNA interactions using proximity ligation
US12235262B1 (en) 2019-09-09 2025-02-25 10X Genomics, Inc. Methods and systems for single cell protein analysis
US12264411B2 (en) 2017-01-30 2025-04-01 10X Genomics, Inc. Methods and systems for analysis
US12275993B2 (en) 2019-02-12 2025-04-15 10X Genomics, Inc. Analysis of nucleic acid sequences
US12305239B2 (en) 2019-02-12 2025-05-20 10X Genomics, Inc. Analysis of nucleic acid sequences
US12312640B2 (en) 2014-06-26 2025-05-27 10X Genomics, Inc. Analysis of nucleic acid sequences
US12391975B2 (en) 2019-02-12 2025-08-19 10X Genomics, Inc. Systems and methods for transposon loading
US12398262B1 (en) 2021-01-22 2025-08-26 10X Genomics, Inc. Triblock copolymer-based cell stabilization and fixation system and methods of use thereof
US12411132B2 (en) 2017-12-12 2025-09-09 10X Genomics, Inc. Systems and methods for single cell processing
US12416102B2 (en) 2019-02-12 2025-09-16 10X Genomics, Inc. Systems and methods for transfer of reagents between droplets
US12421558B2 (en) 2020-02-13 2025-09-23 10X Genomics, Inc. Systems and methods for joint interactive visualization of gene expression and DNA chromatin accessibility
US12427518B2 (en) 2016-05-12 2025-09-30 10X Genomics, Inc. Microfluidic on-chip filters
US12480158B1 (en) 2020-11-05 2025-11-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US12577545B2 (en) 2017-04-26 2026-03-17 10X Genomics, Inc. MMLV reverse transcriptase variants
US12580044B1 (en) 2020-09-02 2026-03-17 10X Genomics, Inc. Systems and methods for identifying cells that are antigen-specific for an immunogenic feature
US12606860B2 (en) 2019-03-27 2026-04-21 10X Genomics, Inc. Systems and methods for processing RNA from cells

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
CA2865575C (en) 2012-02-27 2024-01-16 Cellular Research, Inc. Compositions and kits for molecular counting
KR102758333B1 (ko) 2013-08-28 2025-01-23 벡톤 디킨슨 앤드 컴퍼니 대량의 동시 단일 세포 분석
US9582877B2 (en) 2013-10-07 2017-02-28 Cellular Research, Inc. Methods and systems for digitally counting features on arrays
WO2015200541A1 (en) 2014-06-24 2015-12-30 Bio-Rad Laboratories, Inc. Digital pcr barcoding
EP3259371B1 (en) 2015-02-19 2020-09-02 Becton, Dickinson and Company High-throughput single-cell analysis combining proteomic and genomic information
WO2016138496A1 (en) 2015-02-27 2016-09-01 Cellular Research, Inc. Spatially addressable molecular barcoding
US20180073073A1 (en) * 2015-03-18 2018-03-15 Cellular Research, Inc. Methods and compositions for labeling targets and haplotype phasing
WO2016160844A2 (en) 2015-03-30 2016-10-06 Cellular Research, Inc. Methods and compositions for combinatorial barcoding
EP4582556A3 (en) 2015-04-23 2025-10-08 Becton, Dickinson and Company Methods and compositions for whole transcriptome amplification
WO2016196229A1 (en) 2015-06-01 2016-12-08 Cellular Research, Inc. Methods for rna quantification
JP6940484B2 (ja) 2015-09-11 2021-09-29 セルラー リサーチ， インコーポレイテッド ライブラリー正規化のための方法および組成物
JP7129343B2 (ja) 2016-05-02 2022-09-01 ベクトン・ディキンソン・アンド・カンパニー 正確な分子バーコーディング
US10301677B2 (en) 2016-05-25 2019-05-28 Cellular Research, Inc. Normalization of nucleic acid libraries
ES2979395T3 (es) 2016-05-26 2024-09-25 Becton Dickinson Co Métodos de ajuste del recuento de etiquetas moleculares
US10202641B2 (en) 2016-05-31 2019-02-12 Cellular Research, Inc. Error correction in amplification of samples
US10640763B2 (en) 2016-05-31 2020-05-05 Cellular Research, Inc. Molecular indexing of internal sequences
CN109791157B (zh) 2016-09-26 2022-06-07 贝克顿迪金森公司 使用具有条形码化的寡核苷酸序列的试剂测量蛋白质表达
JP7228510B2 (ja) 2016-11-08 2023-02-24 ベクトン・ディキンソン・アンド・カンパニー 細胞標識分類の方法
US11164659B2 (en) 2016-11-08 2021-11-02 Becton, Dickinson And Company Methods for expression profile classification
ES2961580T3 (es) 2017-01-13 2024-03-12 Cellular Res Inc Revestimiento hidrófilo de canales de fluidos
CN110291207A (zh) 2017-01-27 2019-09-27 豪夫迈·罗氏有限公司 用于长程测序的条形码化dna
CN110382708A (zh) 2017-02-01 2019-10-25 赛卢拉研究公司 使用阻断性寡核苷酸进行选择性扩增
CA3062248A1 (en) 2017-05-05 2018-11-08 Scipio Bioscience Methods for trapping and barcoding discrete biological units in hydrogel
CN110719959B (zh) 2017-06-05 2021-08-06 贝克顿迪金森公司 针对单细胞的样品索引
EP3728636B1 (en) 2017-12-19 2024-09-11 Becton, Dickinson and Company Particles associated with oligonucleotides
JP7358388B2 (ja) 2018-05-03 2023-10-10 ベクトン・ディキンソン・アンド・カンパニー 反対側の転写物末端における分子バーコーディング
CN112272710A (zh) 2018-05-03 2021-01-26 贝克顿迪金森公司 高通量多组学样品分析
ES2992135T3 (es) 2018-10-01 2024-12-09 Becton Dickinson Co Determinar secuencias de transcripción 5’
US11932849B2 (en) 2018-11-08 2024-03-19 Becton, Dickinson And Company Whole transcriptome analysis of single cells using random priming
US11492660B2 (en) 2018-12-13 2022-11-08 Becton, Dickinson And Company Selective extension in single cell whole transcriptome analysis
US11371076B2 (en) 2019-01-16 2022-06-28 Becton, Dickinson And Company Polymerase chain reaction normalization through primer titration
ES2945227T3 (es) 2019-01-23 2023-06-29 Becton Dickinson Co Oligonucleótidos asociados con anticuerpos
WO2020167920A1 (en) 2019-02-14 2020-08-20 Cellular Research, Inc. Hybrid targeted and whole transcriptome amplification
CN109979531B (zh) * 2019-03-29 2021-08-31 北京市商汤科技开发有限公司 一种基因变异识别方法、装置和存储介质
US11965208B2 (en) 2019-04-19 2024-04-23 Becton, Dickinson And Company Methods of associating phenotypical data and single cell sequencing data
CN120099137A (zh) 2019-07-22 2025-06-06 贝克顿迪金森公司 单细胞染色质免疫沉淀测序测定
JP7522189B2 (ja) 2019-11-08 2024-07-24 ベクトン・ディキンソン・アンド・カンパニー 免疫レパートリーシーケンシングのための完全長ｖ（ｄ）ｊ情報を得るためのランダムプライミングの使用
WO2021146219A1 (en) 2020-01-13 2021-07-22 Becton, Dickinson And Company Cell capture using du-containing oligonucleotides
US11649497B2 (en) 2020-01-13 2023-05-16 Becton, Dickinson And Company Methods and compositions for quantitation of proteins and RNA
WO2021155057A1 (en) 2020-01-29 2021-08-05 Becton, Dickinson And Company Barcoded wells for spatial mapping of single cells through sequencing
WO2021173719A1 (en) 2020-02-25 2021-09-02 Becton, Dickinson And Company Bi-specific probes to enable the use of single-cell samples as single color compensation control
US11661625B2 (en) 2020-05-14 2023-05-30 Becton, Dickinson And Company Primers for immune repertoire profiling
US12157913B2 (en) 2020-06-02 2024-12-03 Becton, Dickinson And Company Oligonucleotides and beads for 5 prime gene expression assay
US11932901B2 (en) 2020-07-13 2024-03-19 Becton, Dickinson And Company Target enrichment using nucleic acid probes for scRNAseq
US12391940B2 (en) 2020-07-31 2025-08-19 Becton, Dickinson And Company Single cell assay for transposase-accessible chromatin
KR20230091116A (ko) * 2020-10-21 2023-06-22 일루미나, 인코포레이티드 다수의 삽입체를 포함하는 시퀀싱 주형, 및 시퀀싱 처리량을 개선하기 위한 조성물 및 방법
EP4247967A1 (en) 2020-11-20 2023-09-27 Becton, Dickinson and Company Profiling of highly expressed and lowly expressed proteins
WO2022114732A1 (ko) * 2020-11-27 2022-06-02 연세대학교 산학협력단 Pcr 과정 동안 생성되는 가닥들의 정보를 연결하여 하나의 클러스터를 만들고, 생성된 가닥들의 생성 순서를 추적할 수 있는 방법
CN116685850A (zh) 2020-12-15 2023-09-01 贝克顿迪金森公司 单细胞分泌组分析
EP4430206A1 (en) 2021-11-10 2024-09-18 Encodia, Inc. Methods for barcoding macromolecules in individual cells
CN114121160B (zh) * 2021-11-25 2022-06-21 广东美格基因科技有限公司 一种检测样本中宏病毒组的方法和系统
EP4272764A1 (en) 2022-05-03 2023-11-08 Scipio Bioscience Method of complexing biological units with particles
WO2024129712A1 (en) * 2022-12-12 2024-06-20 Flagship Pioneering Innovations, Vi, Llc Phased sequencing information from circulating tumor dna
WO2026006435A1 (en) * 2024-06-26 2026-01-02 Genedx, Llc Ultra-long context genomic language modeling

Family Cites Families (760)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2797149A (en) 1953-01-08 1957-06-25 Technicon International Ltd Methods of and apparatus for analyzing liquids containing crystalloid and non-crystalloid constituents
US3047367A (en) 1959-12-01 1962-07-31 Technicon Instr Automatic analysis with fluid segmentation
US3479141A (en) 1967-05-17 1969-11-18 Technicon Corp Method and apparatus for analysis
US4124638A (en) 1977-09-12 1978-11-07 Hansen John N Solubilizable polyacrylamide gels containing disulfide cross-linkages
US4377057A (en) * 1978-06-14 1983-03-22 Lortone, Inc. Hand cabbing apparatus
US4253846A (en) 1979-11-21 1981-03-03 Technicon Instruments Corporation Method and apparatus for automated analysis of fluid samples
GB2097692B (en) 1981-01-10 1985-05-22 Shaw Stewart P D Combining chemical reagents
DE3230289A1 (de) 1982-08-14 1984-02-16 Bayer Ag, 5090 Leverkusen Herstellung von pharmazeutischen oder kosmetischen dispersionen
US4582802A (en) 1983-09-30 1986-04-15 The United States Of America As Represented By The Department Of Health And Human Services Stimulation of enzymatic ligation of DNA by high concentrations of nonspecific polymers
JPS60227826A (ja) 1984-04-27 1985-11-13 Sogo Yatsukou Kk ｐＨに応答するグラフトカプセル
US4916070A (en) 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies
US5418149A (en) 1990-07-24 1995-05-23 Hoffmann-La Roche Inc. Reduction of non-specific amplification glycosylase using DUTP and DNA uracil
US5618711A (en) 1986-08-22 1997-04-08 Hoffmann-La Roche Inc. Recombinant expression vectors and purification methods for Thermus thermophilus DNA polymerase
US4872895A (en) 1986-12-11 1989-10-10 American Telephone And Telegraph Company, At&T Bell Laboratories Method for fabricating articles which include high silica glass bodies
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5149625A (en) 1987-08-11 1992-09-22 President And Fellows Of Harvard College Multiplex analysis of DNA
US5137829A (en) 1987-10-05 1992-08-11 Washington University DNA transposon TN5SEQ1
US5185099A (en) 1988-04-20 1993-02-09 Institut National De Recherche Chimique Appliquee Visco-elastic, isotropic materials based on water, fluorinate sufactants and fluorinated oils, process for their preparation, and their use in various fields, such as optics, pharmacology and electrodynamics
US5237016A (en) 1989-01-05 1993-08-17 Siska Diagnostics, Inc. End-attachment of oligonucleotides to polyacrylamide solid supports for capture and detection of nucleic acids
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
US5756334A (en) 1990-04-26 1998-05-26 New England Biolabs, Inc. Thermostable DNA polymerase from 9°N-7 and methods for producing the same
US5489523A (en) 1990-12-03 1996-02-06 Stratagene Exonuclease-deficient thermostable Pyrococcus furiosus DNA polymerase I
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US5270183A (en) 1991-02-08 1993-12-14 Beckman Research Institute Of The City Of Hope Device and method for the automated cycling of solutions between two or more temperatures
US5994056A (en) 1991-05-02 1999-11-30 Roche Molecular Systems, Inc. Homogeneous methods for nucleic acid amplification and detection
DK0594772T3 (https=) 1991-07-04 1997-02-24 Immunodex K S
DE69228247T2 (de) 1991-08-10 1999-07-08 Medical Research Council, London Behandlung von Zellpopulationen
US5770358A (en) 1991-09-18 1998-06-23 Affymax Technologies N.V. Tagged synthetic oligomer libraries
US5413924A (en) 1992-02-13 1995-05-09 Kosak; Kenneth M. Preparation of wax beads containing a reagent for release by heating
WO1993019205A1 (en) 1992-03-19 1993-09-30 The Regents Of The University Of California Multiple tag labeling method for dna sequencing
CA2134474C (en) 1992-05-01 1999-07-06 The Trustees Of The University Of Pennsylvania Microfabricated sperm handling devices
US5587128A (en) 1992-05-01 1996-12-24 The Trustees Of The University Of Pennsylvania Mesoscale polynucleotide amplification devices
US5840865A (en) 1992-09-14 1998-11-24 Institute Of Molecular Biology And Biotechnology/Forth Eukaryotic transposable element
US5897783A (en) 1992-09-24 1999-04-27 Amersham International Plc Magnetic separation method
US5569364A (en) 1992-11-05 1996-10-29 Soane Biosciences, Inc. Separation media for electrophoresis
CA2155186A1 (en) 1993-02-01 1994-08-18 Kevin M. Ulmer Methods and apparatus for dna sequencing
AU6175594A (en) 1993-02-16 1994-09-14 Alliance Pharmaceutical Corporation Method of microemulsifying fluorinated oils
AU6637394A (en) 1993-04-19 1994-11-08 Medisorb Technologies International L.P. Long-acting treatment by slow-release delivery of antisense oligodeoxyribonucleotides from biodegradable microparticles
DE69429038T2 (de) 1993-07-28 2002-03-21 Pe Corporation (Ny), Norwalk Vorrichtung und Verfahren zur Nukleinsäurevervielfältigung
US5874239A (en) 1993-07-30 1999-02-23 Affymax Technologies N.V. Biotinylation of proteins
US5512131A (en) 1993-10-04 1996-04-30 President And Fellows Of Harvard College Formation of microstamped patterns on surfaces and derivative articles
US20030044777A1 (en) 1993-10-28 2003-03-06 Kenneth L. Beattie Flowthrough devices for multiple discrete binding reactions
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5558071A (en) 1994-03-07 1996-09-24 Combustion Electromagnetics, Inc. Ignition system power converter and controller
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
NZ285139A (en) 1994-05-11 1998-10-28 Genera Technologies Ltd Use of electromagnetism and antibodies to capture microorganisms
US5705628A (en) 1994-09-20 1998-01-06 Whitehead Institute For Biomedical Research DNA purification and isolation using magnetic particles
US5846719A (en) 1994-10-13 1998-12-08 Lynx Therapeutics, Inc. Oligonucleotide tags for sorting and identification
US5585069A (en) 1994-11-10 1996-12-17 David Sarnoff Research Center, Inc. Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis
EP0812434B1 (en) 1995-03-01 2013-09-18 President and Fellows of Harvard College Microcontact printing on surfaces and derivative articles
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
EP0832287B1 (en) 1995-06-07 2007-10-10 Solexa, Inc Oligonucleotide tags for sorting and identification
AU718357B2 (en) 1995-06-07 2000-04-13 Lynx Therapeutics, Inc. Oligonucleotide tags for sorting and identification
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US6866760B2 (en) 1998-08-27 2005-03-15 E Ink Corporation Electrophoretic medium and process for the production thereof
US5872010A (en) 1995-07-21 1999-02-16 Northeastern University Microscale fluid handling system
US6057149A (en) 1995-09-15 2000-05-02 The University Of Michigan Microscale devices and reactions in microscale devices
US5851769A (en) 1995-09-27 1998-12-22 The Regents Of The University Of California Quantitative DNA fiber mapping
US5736330A (en) 1995-10-11 1998-04-07 Luminex Corporation Method and compositions for flow cytometric determination of DNA sequences
US5736332A (en) 1995-11-30 1998-04-07 Mandecki; Wlodek Method of determining the sequence of nucleic acids employing solid-phase particles carrying transponders
US6051377A (en) 1995-11-30 2000-04-18 Pharmaseq, Inc. Multiplex assay for nucleic acids employing transponders
US6001571A (en) 1995-11-30 1999-12-14 Mandecki; Wlodek Multiplex assay for nucleic acids employing transponders
US6355198B1 (en) 1996-03-15 2002-03-12 President And Fellows Of Harvard College Method of forming articles including waveguides via capillary micromolding and microtransfer molding
EP0832436A1 (en) 1996-04-15 1998-04-01 Dade Behring Inc. Apparatus and method for analysis
EP2369007B1 (en) 1996-05-29 2015-07-29 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US5846727A (en) 1996-06-06 1998-12-08 Board Of Supervisors Of Louisiana State University And Agricultural & Mechanical College Microsystem for rapid DNA sequencing
WO1998002237A1 (en) 1996-07-15 1998-01-22 Kemgas Limited Production of powders
US5965443A (en) 1996-09-09 1999-10-12 Wisconsin Alumni Research Foundation System for in vitro transposition
US6133436A (en) 1996-11-06 2000-10-17 Sequenom, Inc. Beads bound to a solid support and to nucleic acids
US5900481A (en) 1996-11-06 1999-05-04 Sequenom, Inc. Bead linkers for immobilizing nucleic acids to solid supports
CA2276251A1 (en) 1996-11-20 1998-05-28 The Regents Of The University Of Michigan Microfabricated isothermal nucleic acid amplification devices and methods
US5958703A (en) 1996-12-03 1999-09-28 Glaxo Group Limited Use of modified tethers in screening compound libraries
US20020172965A1 (en) 1996-12-13 2002-11-21 Arcaris, Inc. Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
US20050042625A1 (en) 1997-01-15 2005-02-24 Xzillion Gmbh & Co. Mass label linked hybridisation probes
US20020034737A1 (en) 1997-03-04 2002-03-21 Hyseq, Inc. Methods and compositions for detection or quantification of nucleic acid species
US6297006B1 (en) 1997-01-16 2001-10-02 Hyseq, Inc. Methods for sequencing repetitive sequences and for determining the order of sequence subfragments
WO1998035012A2 (en) 1997-02-12 1998-08-13 Chan Eugene Y Methods and products for analyzing polymers
US7622294B2 (en) 1997-03-14 2009-11-24 Trustees Of Tufts College Methods for detecting target analytes and enzymatic reactions
US6327410B1 (en) 1997-03-14 2001-12-04 The Trustees Of Tufts College Target analyte sensors utilizing Microspheres
US6391622B1 (en) 1997-04-04 2002-05-21 Caliper Technologies Corp. Closed-loop biochemical analyzers
US6143496A (en) 1997-04-17 2000-11-07 Cytonix Corporation Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly
EP0975807B1 (en) 1997-05-02 2006-09-27 Gen-Probe Incorporated Two-step hybridization and capture of a polynucleotide
DE69823347T2 (de) 1997-05-16 2005-05-12 Alberta Research Council, Edmonton Mikrofluidisches system und verfahren zu dessen betrieb
JP4294740B2 (ja) 1997-05-23 2009-07-15 ソレクサ・インコーポレイテッド 分析物の系列的プロセシングのためのシステムおよび装置
US6969488B2 (en) 1998-05-22 2005-11-29 Solexa, Inc. System and apparatus for sequential processing of analytes
US20040241759A1 (en) 1997-06-16 2004-12-02 Eileen Tozer High throughput screening of libraries
ES2230701T3 (es) 1997-07-07 2005-05-01 Medical Research Council Procedimiento de seleccion in vitro.
GB9714716D0 (en) 1997-07-11 1997-09-17 Brax Genomics Ltd Characterising nucleic acids
FI103809B1 (fi) 1997-07-14 1999-09-30 Finnzymes Oy In vitro -menetelmä templaattien tuottamiseksi DNA-sekventointia varten
US20050037397A1 (en) 2001-03-28 2005-02-17 Nanosphere, Inc. Bio-barcode based detection of target analytes
US6974669B2 (en) 2000-03-28 2005-12-13 Nanosphere, Inc. Bio-barcodes based on oligonucleotide-modified nanoparticles
US6368871B1 (en) 1997-08-13 2002-04-09 Cepheid Non-planar microstructures for manipulation of fluid samples
EP1012335A4 (en) 1997-08-15 2004-06-09 Hyseq Inc EXPERIENCE AND COMPOSITIONS FOR DETECTING OR QUANTIFYING NUCLEIC ACID SPECIES
WO1999014368A2 (en) 1997-09-15 1999-03-25 Whitehead Institute For Biomedical Research Methods and apparatus for processing a sample of biomolecular analyte using a microfabricated device
US20020092767A1 (en) 1997-09-19 2002-07-18 Aclara Biosciences, Inc. Multiple array microfluidic device units
US7214298B2 (en) 1997-09-23 2007-05-08 California Institute Of Technology Microfabricated cell sorter
AU9673198A (en) 1997-10-02 1999-04-27 Aclara Biosciences, Inc. Capillary assays involving separation of free and bound species
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
US6485944B1 (en) 1997-10-10 2002-11-26 President And Fellows Of Harvard College Replica amplification of nucleic acid arrays
JP2001519538A (ja) 1997-10-10 2001-10-23 プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 核酸アレイのレプリカ増幅
US6511803B1 (en) 1997-10-10 2003-01-28 President And Fellows Of Harvard College Replica amplification of nucleic acid arrays
CA2306501C (en) 1997-10-14 2011-03-29 Luminex Corporation Precision fluorescently dyed particles and methods of making and using same
DE69830854T2 (de) 1997-12-04 2006-04-20 Amersham Biosciences Uk Ltd., Amersham Mehrfaches testverfahren
AU1726199A (en) 1997-12-31 1999-07-19 Chiron Corporation Metastatic cancer regulated gene
JP2002504342A (ja) 1998-02-19 2002-02-12 プレジデント アンド フェローズ オブ ハーバード カレッジ 一価ｍｈｃ結合ドメイン融合タンパク質および接合体、多価ｍｈｃ結合ドメイン融合タンパク質および接合体、ならびに多量体ｍｈｃ結合ドメイン融合タンパク質および接合体、そしてそれらのための使用
WO1999050402A1 (en) 1998-03-27 1999-10-07 President And Fellows Of Harvard College Systematic identification of essential genes by in vitro transposon mutagenesis
US6022716A (en) 1998-04-10 2000-02-08 Genset Sa High throughput DNA sequencing vector
WO1999052708A1 (en) 1998-04-13 1999-10-21 Luminex Corporation Liquid labeling with fluorescent microparticles
US5997636A (en) 1998-05-01 1999-12-07 Instrumentation Technology Associates, Inc. Method and apparatus for growing crystals
US6780591B2 (en) 1998-05-01 2004-08-24 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US6123798A (en) 1998-05-06 2000-09-26 Caliper Technologies Corp. Methods of fabricating polymeric structures incorporating microscale fluidic elements
US6306590B1 (en) 1998-06-08 2001-10-23 Caliper Technologies Corp. Microfluidic matrix localization apparatus and methods
WO2000008212A1 (en) 1998-08-07 2000-02-17 Cellay, Llc Gel microdrops in genetic analysis
US6159736A (en) 1998-09-23 2000-12-12 Wisconsin Alumni Research Foundation Method for making insertional mutations using a Tn5 synaptic complex
AR021833A1 (es) 1998-09-30 2002-08-07 Applied Research Systems Metodos de amplificacion y secuenciacion de acido nucleico
EP1125129A1 (en) 1998-10-13 2001-08-22 Biomicro Systems, Inc. Fluid circuit components based upon passive fluid dynamics
US6489096B1 (en) 1998-10-15 2002-12-03 Princeton University Quantitative analysis of hybridization patterns and intensities in oligonucleotide arrays
SE9803614L (sv) 1998-10-19 2000-04-20 Muhammed Mamoun Förfarande och anordning för framställning av nanopartiklar
WO2000026412A1 (en) 1998-11-02 2000-05-11 Kenneth Loren Beattie Nucleic acid analysis using sequence-targeted tandem hybridization
US5942609A (en) 1998-11-12 1999-08-24 The Porkin-Elmer Corporation Ligation assembly and detection of polynucleotides on solid-support
US6569631B1 (en) 1998-11-12 2003-05-27 3-Dimensional Pharmaceuticals, Inc. Microplate thermal shift assay for ligand development using 5-(4″dimethylaminophenyl)-2-(4′-phenyl)oxazole derivative fluorescent dyes
WO2000034527A2 (en) 1998-12-11 2000-06-15 The Regents Of The University Of California Targeted molecular bar codes
NO986133D0 (no) 1998-12-23 1998-12-23 Preben Lexow FremgangsmÕte for DNA-sekvensering
GB9900298D0 (en) 1999-01-07 1999-02-24 Medical Res Council Optical sorting method
US6416642B1 (en) 1999-01-21 2002-07-09 Caliper Technologies Corp. Method and apparatus for continuous liquid flow in microscale channels using pressure injection, wicking, and electrokinetic injection
US6635419B1 (en) 1999-02-16 2003-10-21 Applera Corporation Polynucleotide sequencing method
US20030027214A1 (en) 1999-02-17 2003-02-06 Kamb Carl Alexander Methods for substrate-ligand interaction screening
ATE556149T1 (de) 1999-02-23 2012-05-15 Caliper Life Sciences Inc Manipulation von mikropartikeln in mikrofluidischen systemen
US6171850B1 (en) 1999-03-08 2001-01-09 Caliper Technologies Corp. Integrated devices and systems for performing temperature controlled reactions and analyses
US6303343B1 (en) 1999-04-06 2001-10-16 Caliper Technologies Corp. Inefficient fast PCR
US6908737B2 (en) 1999-04-15 2005-06-21 Vitra Bioscience, Inc. Systems and methods of conducting multiplexed experiments
US20060275782A1 (en) 1999-04-20 2006-12-07 Illumina, Inc. Detection of nucleic acid reactions on bead arrays
WO2000065042A1 (en) 1999-04-28 2000-11-02 The Board Of Trustees Of The Leland Stanford Junior University P element derived vector and methods for its use
JP3815969B2 (ja) 1999-05-12 2006-08-30 アクララ バイオサイエンシーズ， インコーポレイテッド 微量流体デバイスにおける多重方式蛍光検出
WO2000070095A2 (en) 1999-05-17 2000-11-23 Dade Behring Inc. Homogeneous isothermal amplification and detection of nucleic acids using a template switch oligonucleotide
US20020051971A1 (en) 1999-05-21 2002-05-02 John R. Stuelpnagel Use of microfluidic systems in the detection of target analytes using microsphere arrays
US6846622B1 (en) 1999-05-26 2005-01-25 Oregon Health & Science University Tagged epitope protein transposable element
US20030124509A1 (en) 1999-06-03 2003-07-03 Kenis Paul J.A. Laminar flow patterning and articles made thereby
US6372813B1 (en) 1999-06-25 2002-04-16 Motorola Methods and compositions for attachment of biomolecules to solid supports, hydrogels, and hydrogel arrays
WO2001002850A1 (en) 1999-07-06 2001-01-11 Caliper Technologies Corp. Microfluidic systems and methods for determining modulator kinetics
US6977145B2 (en) 1999-07-28 2005-12-20 Serono Genetics Institute S.A. Method for carrying out a biochemical protocol in continuous flow in a microreactor
US6524456B1 (en) 1999-08-12 2003-02-25 Ut-Battelle, Llc Microfluidic devices for the controlled manipulation of small volumes
WO2001013086A2 (en) 1999-08-13 2001-02-22 Brandeis University Detection of nucleic acids
AU6788100A (en) 1999-08-20 2001-03-19 Luminex Corporation Liquid array technology
DE60040794D1 (de) 1999-08-27 2008-12-24 Matrix Technologies Corp Verfahren zur Immobilisierung von Oligonukleotiden auf festem Trägermaterial
US6982146B1 (en) 1999-08-30 2006-01-03 The United States Of America As Represented By The Department Of Health And Human Services High speed parallel molecular nucleic acid sequencing
AU8023500A (en) 1999-10-13 2001-04-23 Mds Sciex System and method for detecting and identifying molecular events in a test sample
US6958225B2 (en) 1999-10-27 2005-10-25 Affymetrix, Inc. Complexity management of genomic DNA
WO2001030965A2 (en) 1999-10-28 2001-05-03 The Board Of Trustees Of The Leland Stanford Junior University Methods of in vivo gene transfer using a sleeping beauty transposon system
JP4721603B2 (ja) 1999-11-08 2011-07-13 栄研化学株式会社 変異および／または多型の検出方法
US6432290B1 (en) 1999-11-26 2002-08-13 The Governors Of The University Of Alberta Apparatus and method for trapping bead based reagents within microfluidic analysis systems
ATE382858T1 (de) 2000-02-23 2008-01-15 Caliper Life Sciences Inc Mehrfach-reservoir-drucksteuersystem
US6454924B2 (en) 2000-02-23 2002-09-24 Zyomyx, Inc. Microfluidic devices and methods
IL134830A0 (en) 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
CN1487836A (zh) 2000-03-14 2004-04-07 埃米林药品公司 胰高糖素样肽1(7-36)对胃窦幽门十二指肠能动性的影响
WO2001075415A2 (en) 2000-03-31 2001-10-11 Micronics, Inc. Protein crystallization in microfluidic structures
WO2001077683A1 (en) 2000-04-06 2001-10-18 Caliper Technologies Corp. Methods and devices for achieving long incubation times in high-throughput systems
EP2278030B1 (en) 2000-04-10 2017-05-24 Taxon Biosciences, Inc. Methods for the survey and genetic analysis of populations
US6481453B1 (en) 2000-04-14 2002-11-19 Nanostream, Inc. Microfluidic branch metering systems and methods
US6800298B1 (en) 2000-05-11 2004-10-05 Clemson University Biological lubricant composition and method of applying lubricant composition
US20060008799A1 (en) 2000-05-22 2006-01-12 Hong Cai Rapid haplotyping by single molecule detection
CA2408574A1 (en) 2000-05-24 2001-11-29 Micronics, Inc. Microfluidic concentration gradient loop
US6645432B1 (en) 2000-05-25 2003-11-11 President & Fellows Of Harvard College Microfluidic systems including three-dimensionally arrayed channel networks
US20060263888A1 (en) 2000-06-02 2006-11-23 Honeywell International Inc. Differential white blood count on a disposable card
US6632606B1 (en) 2000-06-12 2003-10-14 Aclara Biosciences, Inc. Methods for single nucleotide polymorphism detection
DE60117556T2 (de) 2000-06-21 2006-11-02 Bioarray Solutions Ltd. Multianalytische molekularanalyse durch verwendung anwendungsspezifischer zufallspartikelarrays
EP1309404A2 (en) 2000-08-07 2003-05-14 Nanostream, Inc. Fluidic mixer in microfluidic system
US6610499B1 (en) 2000-08-31 2003-08-26 The Regents Of The University Of California Capillary array and related methods
US6773566B2 (en) 2000-08-31 2004-08-10 Nanolytics, Inc. Electrostatic actuators for microfluidics and methods for using same
DE60140553D1 (de) 2000-09-14 2009-12-31 Caliper Life Sciences Inc MIKROFLUIDISCHE VORRICHTUNGEN UND METHODEN UM TEMPERATUR-VERMITTELTE REAKTIONEN DURCHZUFüHREN
WO2002023163A1 (en) 2000-09-15 2002-03-21 California Institute Of Technology Microfabricated crossflow devices and methods
AU2002211389A1 (en) 2000-10-03 2002-04-15 California Institute Of Technology Microfluidic devices and methods of use
JP2005501217A (ja) 2000-10-10 2005-01-13 ディベルサ コーポレーション 生体活性または生体分子のハイスループットスクリーニングまたはキャピラリーに基づくスクリーニング
JP2002155305A (ja) 2000-11-14 2002-05-31 Akira Kawasaki 単分散粒子の製造装置及び単分散粒子の製造方法及びその製造方法で製造された単分散粒子
US6492154B2 (en) 2001-01-31 2002-12-10 Applera Corporation Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
CA2332186A1 (en) 2001-02-08 2002-08-08 Her Majesty In Right Of Canada As Represented By The Minister Of Agricul Ture And Agri-Food Canada Replicative in vivo gene targeting
US7670559B2 (en) 2001-02-15 2010-03-02 Caliper Life Sciences, Inc. Microfluidic systems with enhanced detection systems
ATE312076T1 (de) 2001-02-22 2005-12-15 Anika Therapeutics Inc Thiol-modifizierte hyaluronan-derivate
DE60221036T2 (de) 2001-02-23 2007-10-11 Japan Science And Technology Agency, Kawaguchi Vorrichtung zum Erzeugen von Emulsionen und Mikrokapseln
US20150329617A1 (en) 2001-03-14 2015-11-19 Dynal Biotech Asa Novel MHC molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of MHC molecules
US7211654B2 (en) 2001-03-14 2007-05-01 Regents Of The University Of Michigan Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports
WO2002081934A2 (en) 2001-04-03 2002-10-17 Micronics, Inc. Pneumatic valve interface for use in microfluidic structures
US7138267B1 (en) 2001-04-04 2006-11-21 Epicentre Technologies Corporation Methods and compositions for amplifying DNA clone copy number
US20030027221A1 (en) 2001-04-06 2003-02-06 Scott Melissa E. High-throughput screening assays by encapsulation
US7572642B2 (en) 2001-04-18 2009-08-11 Ambrigen, Llc Assay based on particles, which specifically bind with targets in spatially distributed characteristic patterns
ATE410680T1 (de) 2001-05-26 2008-10-15 One Cell Systems Inc Sekretion von proteinen durch verkapselte zellen
US6880576B2 (en) 2001-06-07 2005-04-19 Nanostream, Inc. Microfluidic devices for methods development
US7179423B2 (en) 2001-06-20 2007-02-20 Cytonome, Inc. Microfluidic system including a virtual wall fluid interface port for interfacing fluids with the microfluidic system
US7262063B2 (en) 2001-06-21 2007-08-28 Bio Array Solutions, Ltd. Directed assembly of functional heterostructures
US6613523B2 (en) 2001-06-29 2003-09-02 Agilent Technologies, Inc. Method of DNA sequencing using cleavable tags
US7077152B2 (en) 2001-07-07 2006-07-18 Nanostream, Inc. Microfluidic metering systems and methods
US7799552B2 (en) 2001-07-20 2010-09-21 California Institute Of Technology Protein and nucleic acid expression systems
US6767731B2 (en) 2001-08-27 2004-07-27 Intel Corporation Electron induced fluorescent method for nucleic acid sequencing
US7297485B2 (en) 2001-10-15 2007-11-20 Qiagen Gmbh Method for nucleic acid amplification that results in low amplification bias
JP2005509872A (ja) 2001-10-19 2005-04-14 ウエスト バージニア ユニバーシティ リサーチ コーポレーション プロテオーム解析のための微小流体システム
US6783647B2 (en) 2001-10-19 2004-08-31 Ut-Battelle, Llc Microfluidic systems and methods of transport and lysis of cells and analysis of cell lysate
US20030149307A1 (en) 2001-10-24 2003-08-07 Baxter International Inc. Process for the preparation of polyethylene glycol bis amine
WO2003038558A2 (en) 2001-10-30 2003-05-08 Nanomics Biosystems Pty, Ltd. Device and methods for directed synthesis of chemical libraries
US7262056B2 (en) 2001-11-08 2007-08-28 Mirus Bio Corporation Enhancing intermolecular integration of nucleic acids using integrator complexes
GB0127564D0 (en) 2001-11-16 2002-01-09 Medical Res Council Emulsion compositions
DE60235491D1 (de) 2001-11-28 2010-04-08 Bio Rad Laboratories Paralleles scoring von polymorphismen mittels amplifikation und fehlerkorrektur
US7335153B2 (en) 2001-12-28 2008-02-26 Bio Array Solutions Ltd. Arrays of microparticles and methods of preparation thereof
WO2003057010A2 (en) 2002-01-04 2003-07-17 Board Of Regents, The University Of Texas System Droplet-based microfluidic oligonucleotide synthesis engine
CN1617938A (zh) 2002-01-16 2005-05-18 戴诺生物技术有限公司 从单个样品中分离核酸和蛋白质的方法
KR100459870B1 (ko) 2002-02-22 2004-12-04 한국과학기술원 트랜스포존과 Cre/loxP 부위 특이적 재조합 방법을 이용하는 염색체의 특정부위가 제거된 미생물 변이주 제조방법
EP1488006B1 (en) 2002-03-20 2008-05-28 InnovativeBio.Biz Microcapsules with controlable permeability encapsulating a nucleic acid amplification reaction mixture and their use as reaction compartments for parallels reactions
EP2283917B1 (en) 2002-05-09 2021-12-15 The University of Chicago Device for pressure-driven plug transport and reaction
US7901939B2 (en) 2002-05-09 2011-03-08 University Of Chicago Method for performing crystallization and reactions in pressure-driven fluid plugs
US7527966B2 (en) 2002-06-26 2009-05-05 Transgenrx, Inc. Gene regulation in transgenic animals using a transposon-based vector
JP2006507921A (ja) 2002-06-28 2006-03-09 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 流体分散のための方法および装置
AU2003252136A1 (en) 2002-07-24 2004-02-09 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
IL151660A0 (en) 2002-09-09 2003-04-10 Univ Ben Gurion Method for isolating and culturing unculturable microorganisms
DE60229890D1 (de) 2002-09-30 2008-12-24 Hoffmann La Roche Oligonukleotide zur genotypisierung des thymidylat-synthase gens
US20040081962A1 (en) 2002-10-23 2004-04-29 Caifu Chen Methods for synthesizing complementary DNA
US6979713B2 (en) 2002-11-25 2005-12-27 3M Innovative Properties Company Curable compositions and abrasive articles therefrom
US20050266582A1 (en) 2002-12-16 2005-12-01 Modlin Douglas N Microfluidic system with integrated permeable membrane
US20040248299A1 (en) 2002-12-27 2004-12-09 Sumedha Jayasena RNA interference
US20040224331A1 (en) 2003-01-17 2004-11-11 The Trustees Of Boston University Haplotype analysis
CA2513899C (en) 2003-01-29 2013-03-26 454 Corporation Methods of amplifying and sequencing nucleic acids
DK1594973T3 (da) 2003-02-10 2012-02-13 Max Delbrueck Centrum Transposonbaseret målretningssystem
US7041481B2 (en) 2003-03-14 2006-05-09 The Regents Of The University Of California Chemical amplification based on fluid partitioning
US7316903B2 (en) 2003-03-28 2008-01-08 United States Of America As Represented By The Department Of Health And Human Services Detection of nucleic acid sequence variations using phase Mu transposase
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
AU2004226591B2 (en) 2003-04-04 2009-06-04 Zoetis Services Llc Microfluidized oil-in-water emulsions and vaccine compositions
US20100035254A1 (en) 2003-04-08 2010-02-11 Pacific Biosciences Of California, Inc. Composition and method for nucleic acid sequencing
AU2004229440B2 (en) 2003-04-10 2010-08-12 President And Fellows Of Harvard College Formation and control of fluidic species
US20060275915A1 (en) 2003-05-16 2006-12-07 Global Technologies (Nz) Ltd. Method and apparatus for mixing sample and reagent in a suspension fluid
DE112004001376D2 (de) 2003-05-19 2006-04-13 Knoell Hans Forschung Ev Vorrichtung und Verfahren zur Strukturierung von Flüssigkeiten und zum zudosieren von Reaktionsflüssigkeiten zu in Separationsmedium eingebetteten Flüssigkeitskompartimenten
WO2004105734A1 (en) 2003-05-28 2004-12-09 Valorisation Recherche, Societe En Commandite Method of preparing microcapsules
GB0313170D0 (en) 2003-06-09 2003-07-16 Qinetiq Ltd Method and apparatus for spore disruption and/or detection
EP1636564A1 (en) 2003-06-13 2006-03-22 The General Hospital Corporation Microfluidic systems for size based removal of red blood cells and platelets from blood
GB2403475B (en) 2003-07-01 2008-02-06 Oxitec Ltd Stable integrands
GB0315438D0 (en) 2003-07-02 2003-08-06 Univ Manchester Analysis of mixed cell populations
US8048627B2 (en) 2003-07-05 2011-11-01 The Johns Hopkins University Method and compositions for detection and enumeration of genetic variations
WO2005021151A1 (en) 2003-08-27 2005-03-10 President And Fellows Of Harvard College Electronic control of fluidic species
EP1660153A2 (en) 2003-09-04 2006-05-31 The United States of America as represented by the Department of Veterans Affairs Hydrogel nanocompsites for ophthalmic applications
WO2005023427A1 (en) 2003-09-05 2005-03-17 Stokes Bio Limited A microfluidic analysis system
US7354706B2 (en) 2003-09-09 2008-04-08 The Regents Of The University Of Colorado, A Body Corporate Use of photopolymerization for amplification and detection of a molecular recognition event
JP4353945B2 (ja) 2003-09-22 2009-10-28 独立行政法人理化学研究所 効率的なｄｎａ逆位反復構造の調製方法
EP2381255A1 (en) 2003-09-25 2011-10-26 Toyama Prefecture Microwell array chip and its manufacturing method
WO2005047521A2 (en) 2003-11-10 2005-05-26 Investigen, Inc. Methods of preparing nucleic acid for detection
EP1691792A4 (en) 2003-11-24 2008-05-28 Yeda Res & Dev COMPOSITIONS AND PROCESSES FOR SORTING IN VITRO OF MOLECULE AND CELL LIBRARIES
US8071364B2 (en) 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
US7927797B2 (en) 2004-01-28 2011-04-19 454 Life Sciences Corporation Nucleic acid amplification with continuous flow emulsion
US20050181379A1 (en) 2004-02-18 2005-08-18 Intel Corporation Method and device for isolating and positioning single nucleic acid molecules
AU2005216549A1 (en) 2004-02-27 2005-09-09 President And Fellows Of Harvard College Polony fluorescent in situ sequencing beads
US20100216153A1 (en) * 2004-02-27 2010-08-26 Helicos Biosciences Corporation Methods for detecting fetal nucleic acids and diagnosing fetal abnormalities
KR100552706B1 (ko) 2004-03-12 2006-02-20 삼성전자주식회사 핵산 증폭 방법 및 장치
EP1757357B1 (en) 2004-03-23 2013-04-24 Japan Science and Technology Agency Method and device for producing micro-droplets
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US20060020371A1 (en) 2004-04-13 2006-01-26 President And Fellows Of Harvard College Methods and apparatus for manipulation and/or detection of biological samples and other objects
WO2005111242A2 (en) 2004-05-10 2005-11-24 Parallele Bioscience, Inc. Digital profiling of polynucleotide populations
US7799553B2 (en) 2004-06-01 2010-09-21 The Regents Of The University Of California Microfabricated integrated DNA analysis system
US7700281B2 (en) 2004-06-30 2010-04-20 Usb Corporation Hot start nucleic acid amplification
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
CN1648671B (zh) 2005-02-06 2012-09-26 成都夸常医学工业有限公司 多反应器分析芯片检测方法和分析芯片及检测装置
US7608434B2 (en) 2004-08-04 2009-10-27 Wisconsin Alumni Research Foundation Mutated Tn5 transposase proteins and the use thereof
US20080268431A1 (en) 2004-09-14 2008-10-30 Jin-Ho Choy Information Code System Using Dna Sequences
US7892731B2 (en) 2004-10-01 2011-02-22 Radix Biosolutions, Ltd. System and method for inhibiting the decryption of a nucleic acid probe sequence used for the detection of a specific nucleic acid
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US20080004436A1 (en) 2004-11-15 2008-01-03 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Directed Evolution and Selection Using in Vitro Compartmentalization
US7329493B2 (en) 2004-12-22 2008-02-12 Asiagen Corporation One-tube nested PCR for detecting Mycobacterium tuberculosis
WO2006071770A2 (en) 2004-12-23 2006-07-06 I-Stat Corporation Molecular diagnostics system and methods
WO2006078841A1 (en) 2005-01-21 2006-07-27 President And Fellows Of Harvard College Systems and methods for forming fluidic droplets encapsulated in particles such as colloidal particles
WO2006081222A2 (en) 2005-01-25 2006-08-03 Compass Genetics, Llc. Isothermal dna amplification
US7407757B2 (en) 2005-02-10 2008-08-05 Population Genetics Technologies Genetic analysis by sequence-specific sorting
US7393665B2 (en) 2005-02-10 2008-07-01 Population Genetics Technologies Ltd Methods and compositions for tagging and identifying polynucleotides
AU2006214085A1 (en) 2005-02-18 2006-08-24 Canon U.S. Life Sciences, Inc. Devices and methods for identifying genomic DNA of organisms
WO2006088123A1 (ja) 2005-02-21 2006-08-24 Kagoshima University バイオディーゼル燃料の精製方法
WO2006096571A2 (en) 2005-03-04 2006-09-14 President And Fellows Of Harvard College Method and apparatus for forming multiple emulsions
US20070054119A1 (en) 2005-03-04 2007-03-08 Piotr Garstecki Systems and methods of forming particles
US9040237B2 (en) 2005-03-04 2015-05-26 Intel Corporation Sensor arrays and nucleic acid sequencing applications
JP2006289250A (ja) 2005-04-08 2006-10-26 Kao Corp マイクロミキサー及びそれを用いた流体混合方法
US8407013B2 (en) 2005-06-07 2013-03-26 Peter K. Rogan AB initio generation of single copy genomic probes
EP3257949A1 (en) 2005-06-15 2017-12-20 Complete Genomics Inc. Nucleic acid analysis by random mixtures of non-overlapping fragments
JP2006349060A (ja) 2005-06-16 2006-12-28 Ntn Corp ボールねじ
US8828209B2 (en) 2005-06-22 2014-09-09 The Research Foundation For The State University Of New York Massively parallel 2-dimensional capillary electrophoresis
WO2007002567A2 (en) 2005-06-23 2007-01-04 Nanosphere, Inc. Selective isolation and concentration of nucleic acids from complex samples
EP2392657B1 (en) 2005-07-05 2013-09-25 The Chemo-Sero-Therapeutic Research Institute Modified transposon vector and its use
JP5051490B2 (ja) 2005-07-08 2012-10-17 独立行政法人産業技術総合研究所 マクロ生体材料を内包する無機マイクロカプセルおよびその製造方法
US20070020640A1 (en) 2005-07-21 2007-01-25 Mccloskey Megan L Molecular encoding of nucleic acid templates for PCR and other forms of sequence analysis
FR2888912B1 (fr) 2005-07-25 2007-08-24 Commissariat Energie Atomique Procede de commande d'une communication entre deux zones par electromouillage, dispositif comportant des zones isolables les unes des autres et procede de realisation d'un tel dispositif
WO2007018601A1 (en) 2005-08-02 2007-02-15 Rubicon Genomics, Inc. Compositions and methods for processing and amplification of dna, including using multiple enzymes in a single reaction
DE102005037401B4 (de) 2005-08-08 2007-09-27 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Bildung einer Emulsion in einem fluidischen Mikrosystem
WO2007024840A2 (en) 2005-08-22 2007-03-01 Critical Therapeutics, Inc. Method of quantitating nucleic acids by flow cytometry microparticle-based array
US7556776B2 (en) 2005-09-08 2009-07-07 President And Fellows Of Harvard College Microfluidic manipulation of fluids and reactions
JP2007074967A (ja) 2005-09-13 2007-03-29 Canon Inc 識別子プローブ及びそれを用いた核酸増幅方法
CN101523156A (zh) 2005-09-16 2009-09-02 加利福尼亚大学董事会 用于分析物检测的比色生物条形码扩增测定
US7960104B2 (en) 2005-10-07 2011-06-14 Callida Genomics, Inc. Self-assembled single molecule arrays and uses thereof
US20070111241A1 (en) 2005-10-14 2007-05-17 Nezih Cereb System and method for accessing, tracking, and editing sequence analysis and software to accomplish the same
WO2007120265A2 (en) 2005-11-14 2007-10-25 Applera Corporation Coded molecules for detecting target analytes
US20070134277A1 (en) 2005-12-09 2007-06-14 Children's Medical Center Corporation Pharmaceutical formulation for sulfur-containing drugs in liquid dosage forms
US7932037B2 (en) 2007-12-05 2011-04-26 Perkinelmer Health Sciences, Inc. DNA assays using amplicon probes on encoded particles
WO2007081385A2 (en) 2006-01-11 2007-07-19 Raindance Technologies, Inc. Microfluidic devices and methods of use in the formation and control of nanoreactors
WO2007087310A2 (en) 2006-01-23 2007-08-02 Population Genetics Technologies Ltd. Nucleic acid analysis using sequence tokens
WO2007087312A2 (en) 2006-01-23 2007-08-02 Population Genetics Technologies Ltd. Molecular counting
DE602007009811D1 (de) 2006-01-27 2010-11-25 Harvard College Koaleszenz fluider tröpfchen
EP3591068A1 (en) 2006-02-02 2020-01-08 The Board of Trustees of the Leland Stanford Junior University Non-invasive fetal genetic screening by digital analysis
WO2007092538A2 (en) 2006-02-07 2007-08-16 President And Fellows Of Harvard College Methods for making nucleotide probes for sequencing and synthesis
GB0603251D0 (en) 2006-02-17 2006-03-29 Isis Innovation DNA conformation
SG170028A1 (en) 2006-02-24 2011-04-29 Callida Genomics Inc High throughput genome sequencing on dna arrays
CN101432439B (zh) 2006-02-24 2013-07-24 考利达基因组股份有限公司 Dna阵列上的高通量基因组测序
WO2007111937A1 (en) 2006-03-23 2007-10-04 Applera Corporation Directed enrichment of genomic dna for high-throughput sequencing
JP4921829B2 (ja) 2006-03-30 2012-04-25 株式会社東芝 微粒子の製造装置、乳化剤保持部、微粒子の製造方法および分子膜の製造方法
US20090181864A1 (en) 2006-03-31 2009-07-16 Nam Trung Nguyen Active control for droplet-based microfluidics
CN101495654A (zh) 2006-04-19 2009-07-29 阿普里拉股份有限公司 无凝胶珠基测序的试剂、方法和文库
US7811603B2 (en) 2006-05-09 2010-10-12 The Regents Of The University Of California Microfluidic device for forming monodisperse lipoplexes
EP2530167A1 (en) 2006-05-11 2012-12-05 Raindance Technologies, Inc. Microfluidic Devices
CA2653095C (en) 2006-05-22 2013-07-16 Nanostring Technologies, Inc. Systems and methods for analyzing nanoreporters
RU2321638C2 (ru) 2006-05-23 2008-04-10 Закрытое акционерное общество "Молекулярно-медицинские технологии" Способ изготовления многофункционального мультичипа, мультичип для последовательного или параллельного скрининга биополимеров, способ анализа биополимеров и набор для осуществления способа
CA2653321A1 (en) 2006-05-26 2007-12-06 Althea Technologies, Inc. Biochemical analysis of partitioned cells
FR2901717A1 (fr) 2006-05-30 2007-12-07 Centre Nat Rech Scient Procede de traitement de gouttes dans un circuit microfluidique.
WO2007147079A2 (en) 2006-06-14 2007-12-21 Living Microsystems, Inc. Rare cell analysis using sample splitting and dna tags
CA2656022C (en) 2006-06-19 2017-10-17 The Johns Hopkins University Single-molecule pcr on microparticles in water-in-oil emulsions
US20080076909A1 (en) 2006-06-30 2008-03-27 Applera Corporation Emulsion pcr and amplicon capture
EP1878501A1 (en) 2006-07-14 2008-01-16 Roche Diagnostics GmbH Instrument for heating and cooling
US8394590B2 (en) 2006-08-02 2013-03-12 California Institute Of Technology Capture agents and related methods and systems for detecting and/or sorting targets
EP2077912B1 (en) 2006-08-07 2019-03-27 The President and Fellows of Harvard College Fluorocarbon emulsion stabilizing surfactants
JP5553602B2 (ja) 2006-09-06 2014-07-16 キヤノン ユー．エス． ライフ サイエンシズ， インコーポレイテッド マイクロ流体アッセイを実施するためのチップ及びカートリッジ設計構成
JP5765884B2 (ja) 2006-09-25 2015-08-19 アーチャー−ダニエルズ−ミッドランド カンパニー 超吸収性表面処理カルボキシアルキル化多糖類及びその製造方法
US7935518B2 (en) 2006-09-27 2011-05-03 Alessandra Luchini Smart hydrogel particles for biomarker harvesting
US20080166720A1 (en) 2006-10-06 2008-07-10 The Regents Of The University Of California Method and apparatus for rapid nucleic acid analysis
US8841116B2 (en) 2006-10-25 2014-09-23 The Regents Of The University Of California Inline-injection microdevice and microfabricated integrated DNA analysis system using same
US7910354B2 (en) 2006-10-27 2011-03-22 Complete Genomics, Inc. Efficient arrays of amplified polynucleotides
US8709787B2 (en) 2006-11-14 2014-04-29 Handylab, Inc. Microfluidic cartridge and method of using same
CA2669728C (en) 2006-11-15 2017-04-11 Biospherex Llc Multitag sequencing and ecogenomics analysis
US20080242560A1 (en) 2006-11-21 2008-10-02 Gunderson Kevin L Methods for generating amplified nucleic acid arrays
US8598328B2 (en) 2006-12-13 2013-12-03 National University Corporation Nagoya University Tol1 factor transposase and DNA introduction system using the same
JP2008167722A (ja) 2007-01-15 2008-07-24 Konica Minolta Medical & Graphic Inc 磁性支持体上での加熱による核酸単離方法
US7844658B2 (en) 2007-01-22 2010-11-30 Comcast Cable Holdings, Llc System and method for providing an application to a device
US20080176768A1 (en) 2007-01-23 2008-07-24 Honeywell Honeywell International Hydrogel microarray with embedded metal nanoparticles
WO2008093098A2 (en) 2007-02-02 2008-08-07 Illumina Cambridge Limited Methods for indexing samples and sequencing multiple nucleotide templates
US8003312B2 (en) 2007-02-16 2011-08-23 The Board Of Trustees Of The Leland Stanford Junior University Multiplex cellular assays using detectable cell barcodes
FI20075124A0 (fi) 2007-02-21 2007-02-21 Valtion Teknillinen Menetelmä ja testikitti nukleotidivariaatioiden toteamiseksi
US9029085B2 (en) 2007-03-07 2015-05-12 President And Fellows Of Harvard College Assays and other reactions involving droplets
US20080228268A1 (en) 2007-03-15 2008-09-18 Uluru, Inc. Method of Formation of Viscous, Shape Conforming Gels and Their Uses as Medical Prosthesis
EP2136786B8 (en) 2007-03-28 2012-11-14 President and Fellows of Harvard College Apparatus for forming droplets
US20100130369A1 (en) 2007-04-23 2010-05-27 Advanced Liquid Logic, Inc. Bead-Based Multiplexed Analytical Methods and Instrumentation
CN101293191B (zh) 2007-04-25 2011-11-09 中国科学院过程工程研究所 一种琼脂糖凝胶微球的制备方法
JP2010528608A (ja) 2007-06-01 2010-08-26 ４５４ ライフ サイエンシーズ コーポレイション 複合的な混合物から個々の試料を特定するためのシステムおよび方法
EP2162205A1 (en) 2007-06-05 2010-03-17 Eugenia Kumacheva Multiple continuous microfluidic reactors for the scaled up synthesis of gel or polymer particles
WO2009005680A1 (en) 2007-06-29 2009-01-08 President And Fellows Of Harvard College Methods and apparatus for manipulation of fluidic species
WO2009011808A1 (en) 2007-07-13 2009-01-22 President And Fellows Of Harvard College Droplet-based selection
US8454906B2 (en) 2007-07-24 2013-06-04 The Regents Of The University Of California Microfabricated droplet generator for single molecule/cell genetic analysis in engineered monodispersed emulsions
US20130084243A1 (en) 2010-01-27 2013-04-04 Liliane Goetsch Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
US20090076735A1 (en) 2007-08-15 2009-03-19 Opgen, Inc. Method, system and software arrangement for comparative analysis and phylogeny with whole-genome optical maps
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US8268564B2 (en) 2007-09-26 2012-09-18 President And Fellows Of Harvard College Methods and applications for stitched DNA barcodes
WO2009048532A2 (en) 2007-10-05 2009-04-16 President And Fellows Of Harvard College Formation of particles for ultrasound application, drug release, and other uses, and microfluidic methods of preparation
US20090099040A1 (en) 2007-10-15 2009-04-16 Sigma Aldrich Company Degenerate oligonucleotides and their uses
US20100086914A1 (en) 2008-10-03 2010-04-08 Roche Molecular Systems, Inc. High resolution, high throughput hla genotyping by clonal sequencing
US8334013B2 (en) 2007-11-02 2012-12-18 Stc.Unm Mesoporous metal oxide microspheres and method for forming same
WO2009061372A1 (en) 2007-11-02 2009-05-14 President And Fellows Of Harvard College Systems and methods for creating multi-phase entities, including particles and/or fluids
US8592150B2 (en) 2007-12-05 2013-11-26 Complete Genomics, Inc. Methods and compositions for long fragment read sequencing
WO2009076485A2 (en) 2007-12-10 2009-06-18 Xiaolian Gao Sequencing of nucleic acids
US7771944B2 (en) 2007-12-14 2010-08-10 The Board Of Trustees Of The University Of Illinois Methods for determining genetic haplotypes and DNA mapping
JP5738597B2 (ja) 2007-12-21 2015-06-24 プレジデント アンド フェローズ オブ ハーバード カレッジ 核酸の配列決定のためのシステムおよび方法
WO2009091934A1 (en) 2008-01-17 2009-07-23 Sequenom, Inc. Single molecule nucleic acid sequence analysis processes and compositions
WO2009100382A1 (en) 2008-02-07 2009-08-13 Pacific Biosciences Of California, Inc. Cis reactive oxygen quenchers integrated into linkers
JP5468271B2 (ja) 2008-02-08 2014-04-09 花王株式会社 微粒子分散液の製造方法
US8034568B2 (en) 2008-02-12 2011-10-11 Nugen Technologies, Inc. Isothermal nucleic acid amplification methods and compositions
AU2009224170B2 (en) 2008-03-11 2012-03-29 National Cancer Center Method for measuring chromosome, gene or specific nucleotide sequence copy numbers using SNP array
US9011777B2 (en) 2008-03-21 2015-04-21 Lawrence Livermore National Security, Llc Monodisperse microdroplet generation and stopping without coalescence
US8961902B2 (en) 2008-04-23 2015-02-24 Bioscale, Inc. Method and apparatus for analyte processing
US9068181B2 (en) 2008-05-23 2015-06-30 The General Hospital Corporation Microfluidic droplet encapsulation
DE102008025656B4 (de) 2008-05-28 2016-07-28 Genxpro Gmbh Verfahren zur quantitativen Analyse von Nukleinsäuren, Marker dafür und deren Verwendung
GB0810051D0 (en) 2008-06-02 2008-07-09 Oxford Biodynamics Ltd Method of diagnosis
EP2303246A1 (en) 2008-06-05 2011-04-06 President and Fellows of Harvard College Polymersomes, colloidosomes, liposomes, and other species associated with fluidic droplets
WO2010003132A1 (en) 2008-07-02 2010-01-07 Illumina Cambridge Ltd. Using populations of beads for the fabrication of arrays on surfaces
US8388945B2 (en) 2008-07-11 2013-03-05 Eth Zurich Degradable microcapsules
EP4047367A1 (en) 2008-07-18 2022-08-24 Bio-Rad Laboratories, Inc. Method for detecting target analytes with droplet libraries
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
US20100062494A1 (en) 2008-08-08 2010-03-11 President And Fellows Of Harvard College Enzymatic oligonucleotide pre-adenylation
US8383345B2 (en) 2008-09-12 2013-02-26 University Of Washington Sequence tag directed subassembly of short sequencing reads into long sequencing reads
WO2010033200A2 (en) 2008-09-19 2010-03-25 President And Fellows Of Harvard College Creation of libraries of droplets and related species
US9764322B2 (en) 2008-09-23 2017-09-19 Bio-Rad Laboratories, Inc. System for generating droplets with pressure monitoring
US8709762B2 (en) 2010-03-02 2014-04-29 Bio-Rad Laboratories, Inc. System for hot-start amplification via a multiple emulsion
US8663920B2 (en) 2011-07-29 2014-03-04 Bio-Rad Laboratories, Inc. Library characterization by digital assay
US9417190B2 (en) 2008-09-23 2016-08-16 Bio-Rad Laboratories, Inc. Calibrations and controls for droplet-based assays
US20120252015A1 (en) 2011-02-18 2012-10-04 Bio-Rad Laboratories Methods and compositions for detecting genetic material
US9822393B2 (en) 2013-03-08 2017-11-21 Bio-Rad Laboratories, Inc. Compositions, methods and systems for polymerase chain reaction assays
WO2013016459A1 (en) 2011-07-25 2013-01-31 Bio-Rad Laboratories, Inc. Breakage of an emulsion containing nucleic acid
US9156010B2 (en) 2008-09-23 2015-10-13 Bio-Rad Laboratories, Inc. Droplet-based assay system
CA2735899A1 (en) 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
US8361299B2 (en) 2008-10-08 2013-01-29 Sage Science, Inc. Multichannel preparative electrophoresis system
CA2750054C (en) 2008-10-24 2018-05-29 Epicentre Technologies Corporation Transposon end compositions and methods for modifying nucleic acids
US9080211B2 (en) 2008-10-24 2015-07-14 Epicentre Technologies Corporation Transposon end compositions and methods for modifying nucleic acids
US20100113296A1 (en) 2008-11-05 2010-05-06 Joel Myerson Methods And Kits For Nucleic Acid Analysis
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US20100136559A1 (en) 2008-12-02 2010-06-03 Bio-Rad Laboratories, Inc. Chromatin structure detection
EP3150724A1 (en) 2008-12-19 2017-04-05 President and Fellows of Harvard College Particle-assisted nucleic acid sequencing
WO2010075570A2 (en) 2008-12-24 2010-07-01 New York University Methods, computer-accessible medium, and systems for score-driven whole-genome shotgun sequence assemble
KR101065807B1 (ko) 2009-01-23 2011-09-19 충남대학교산학협력단 액적 기반의 미세유체 칩을 이용한 마이크로 캡슐 제조방법
JP5457222B2 (ja) 2009-02-25 2014-04-02 エフ．ホフマン−ラ ロシュ アーゲー 小型化ハイスループット核酸分析
US9347092B2 (en) 2009-02-25 2016-05-24 Roche Molecular System, Inc. Solid support for high-throughput nucleic acid analysis
WO2010104604A1 (en) 2009-03-13 2010-09-16 President And Fellows Of Harvard College Method for the controlled creation of emulsions, including multiple emulsions
US9056299B2 (en) 2009-03-13 2015-06-16 President And Fellows Of Harvard College Scale-up of flow-focusing microfluidic devices
EP2230312A1 (en) 2009-03-19 2010-09-22 Helmholtz-Zentrum für Infektionsforschung GmbH Probe compound for detecting and isolating enzymes and means and methods using the same
WO2010111231A1 (en) 2009-03-23 2010-09-30 Raindance Technologies, Inc. Manipulation of microfluidic droplets
EP2414548B1 (en) 2009-03-30 2015-10-21 Illumina, Inc. Gene expression analysis in single cells
SG174617A1 (en) 2009-04-02 2011-10-28 Fluidigm Corp Multi-primer amplification method for barcoding of target nucleic acids
US9085798B2 (en) 2009-04-30 2015-07-21 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
WO2010127304A2 (en) 2009-05-01 2010-11-04 Illumina, Inc. Sequencing methods
US9334531B2 (en) 2010-12-17 2016-05-10 Life Technologies Corporation Nucleic acid amplification
FR2945545B1 (fr) 2009-05-14 2011-08-05 Univ Aix Marseille Ii Methode de detection d'adn procaryote extrait d'un echantillon de selles
FR2945819B1 (fr) 2009-05-19 2011-06-17 Commissariat Energie Atomique Dispositif et procede d'isolement de cibles biologiques ou chimiques
US8574835B2 (en) 2009-05-29 2013-11-05 Life Technologies Corporation Scaffolded nucleic acid polymer particles and methods of making and using
US9524369B2 (en) * 2009-06-15 2016-12-20 Complete Genomics, Inc. Processing and analysis of complex nucleic acid sequence data
EP2977455B1 (en) 2009-06-15 2020-04-15 Complete Genomics, Inc. Method for long fragment read sequencing
CN102483424B (zh) 2009-06-26 2014-11-05 哈佛学院院长等 用于流体操作的方法以及微流体装置
US20110028412A1 (en) 2009-08-03 2011-02-03 Cappellos, Inc. Herbal enhanced analgesic formulations
US20110033548A1 (en) 2009-08-05 2011-02-10 E.I. Du Pont De Nemours And Company Degradable crosslinked aminated dextran microspheres and methods of use
EP3029141A1 (en) 2009-08-20 2016-06-08 Population Genetics Technologies Ltd. Compositions and methods for intramolecular nucleic acid rearrangement
WO2011027268A2 (en) 2009-09-01 2011-03-10 Koninklijke Philips Electronics N.V. Devices and methods for microarray selection
CA2767056C (en) 2009-09-02 2018-12-04 Bio-Rad Laboratories, Inc. System for mixing fluids by coalescence of multiple emulsions
WO2011028764A2 (en) 2009-09-02 2011-03-10 President And Fellows Of Harvard College Multiple emulsions created using jetting and other techniques
US9625454B2 (en) 2009-09-04 2017-04-18 The Research Foundation For The State University Of New York Rapid and continuous analyte processing in droplet microfluidic devices
GB0918564D0 (en) 2009-10-22 2009-12-09 Plasticell Ltd Nested cell encapsulation
JP5791621B2 (ja) 2009-10-27 2015-10-07 プレジデント アンド フェローズ オブ ハーバード カレッジ 液滴生成技術
US10207240B2 (en) 2009-11-03 2019-02-19 Gen9, Inc. Methods and microfluidic devices for the manipulation of droplets in high fidelity polynucleotide assembly
CN107028886A (zh) 2009-11-04 2017-08-11 不列颠哥伦比亚大学 含有核酸的脂质粒子及相关的方法
CA2767028A1 (en) 2009-11-25 2011-06-03 Quantalife, Inc. Methods and compositions for detecting genetic material
JP2013511991A (ja) 2009-11-25 2013-04-11 クアンタライフ， インコーポレイテッド 遺伝子材料を検出する方法および組成物
US9023769B2 (en) 2009-11-30 2015-05-05 Complete Genomics, Inc. cDNA library for nucleic acid sequencing
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
EP2513333B1 (en) 2009-12-17 2013-10-02 Keygene N.V. Restriction enzyme based whole genome sequencing
US10837883B2 (en) 2009-12-23 2020-11-17 Bio-Rad Laboratories, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
JP5901046B2 (ja) 2010-02-19 2016-04-06 国立大学法人 千葉大学 ＯＡＴＰ１Ｂ３ｍＲＮＡの新規な選択的スプライシングバリアント
US20110257889A1 (en) 2010-02-24 2011-10-20 Pacific Biosciences Of California, Inc. Sequence assembly and consensus sequence determination
DK2539450T3 (da) 2010-02-25 2016-05-30 Advanced Liquid Logic Inc Fremgangsmåde til fremstilling af nukleinsyrebiblioteker
US8236574B2 (en) 2010-03-01 2012-08-07 Quanterix Corporation Ultra-sensitive detection of molecules or particles using beads or other capture objects
CA2767182C (en) 2010-03-25 2020-03-24 Bio-Rad Laboratories, Inc. Droplet generation for droplet-based assays
FR2958186A1 (fr) 2010-03-30 2011-10-07 Ecole Polytech Dispositif de formation de gouttes dans un circuit microfluide.
WO2011127099A1 (en) 2010-04-05 2011-10-13 Prognosys Biosciences, Inc. Spatially encoded biological assays
US9255291B2 (en) 2010-05-06 2016-02-09 Bioo Scientific Corporation Oligonucleotide ligation methods for improving data quality and throughput using massively parallel sequencing
US20120000777A1 (en) 2010-06-04 2012-01-05 The Regents Of The University Of California Devices and methods for forming double emulsion droplet compositions and polymer particles
EP2580378A4 (en) 2010-06-08 2014-01-01 Nugen Technologies Inc MULTIPLEX SEQUENCING METHODS AND COMPOSITION
US8703493B2 (en) 2010-06-15 2014-04-22 Src, Inc. Location analysis using fire retardant-protected nucleic acid-labeled tags
US20120003657A1 (en) 2010-07-02 2012-01-05 Samuel Myllykangas Targeted sequencing library preparation by genomic dna circularization
WO2012012037A1 (en) 2010-07-19 2012-01-26 New England Biolabs, Inc. Oligonucleotide adaptors: compositions and methods of use
CN103202812B (zh) 2010-08-09 2015-10-28 南京大学 一种制备用于体内递送药理活性物质的蛋白纳米粒的方法
EP2616103A1 (en) 2010-09-16 2013-07-24 The University of North Carolina At Chapel Hill Asymmetric bifunctional silyl monomers and particles thereof as prodrugs and delivery vehicles for pharmaceutical, chemical and biological agents
ES2523140T3 (es) 2010-09-21 2014-11-21 Population Genetics Technologies Ltd. Aumento de la confianza en las identificaciones de alelos con el recuento molecular
NZ610129A (en) 2010-10-04 2014-08-29 Genapsys Inc Systems and methods for automated reusable parallel biological reactions
US9999886B2 (en) 2010-10-07 2018-06-19 The Regents Of The University Of California Methods and systems for on demand droplet generation and impedance based detection
CA2814047C (en) 2010-10-08 2017-11-14 President And Fellows Of Harvard College High-throughput immune sequencing
GB2497912B (en) 2010-10-08 2014-06-04 Harvard College High-throughput single cell barcoding
EP2633069B1 (en) 2010-10-26 2015-07-01 Illumina, Inc. Sequencing methods
US20130225623A1 (en) 2010-10-27 2013-08-29 Mount Sinai School Of Medicine Methods of Treating Psychiatric or Neurological Disorders with MGLUR Antagonists
EP3574990B1 (en) 2010-11-01 2022-04-06 Bio-Rad Laboratories, Inc. System for forming emulsions
US9074251B2 (en) 2011-02-10 2015-07-07 Illumina, Inc. Linking sequence reads using paired code tags
WO2012061832A1 (en) 2010-11-05 2012-05-10 Illumina, Inc. Linking sequence reads using paired code tags
US8829171B2 (en) 2011-02-10 2014-09-09 Illumina, Inc. Linking sequence reads using paired code tags
WO2012083225A2 (en) 2010-12-16 2012-06-21 Gigagen, Inc. System and methods for massively parallel analysis of nycleic acids in single cells
WO2012088348A2 (en) * 2010-12-23 2012-06-28 Sequenom, Inc. Fetal genetic variation detection
US9163281B2 (en) 2010-12-23 2015-10-20 Good Start Genetics, Inc. Methods for maintaining the integrity and identification of a nucleic acid template in a multiplex sequencing reaction
WO2012100216A2 (en) 2011-01-20 2012-07-26 Knome, Inc. Methods and apparatus for assigning a meaningful numeric value to genomic variants, and searching and assessing same
US8765455B2 (en) 2011-01-27 2014-07-01 Lawrence Livermore National Security, Llc Chip-based droplet sorting
GB201101429D0 (en) 2011-01-27 2011-03-16 Biocompatibles Uk Ltd Drug delivery system
WO2012103545A1 (en) 2011-01-28 2012-08-02 Illumina, Inc. Oligonucleotide replacement for di-tagged and directional libraries
WO2016100976A2 (en) 2014-12-19 2016-06-23 Apprise Bio, Inc. Methods for identifying multiple epitopes in selected sub-populations of cells
WO2012106385A2 (en) 2011-01-31 2012-08-09 Apprise Bio, Inc. Methods of identifying multiple epitopes in cells
CN103443338B (zh) * 2011-02-02 2017-09-22 华盛顿大学商业化中心 大规模平行邻接作图
EP3412778A1 (en) 2011-02-11 2018-12-12 Raindance Technologies, Inc. Methods for forming mixed droplets
EP2673382B1 (en) 2011-02-11 2020-05-06 Bio-Rad Laboratories, Inc. Thermocycling device for nucleic acid amplification and methods of use
WO2012112804A1 (en) * 2011-02-18 2012-08-23 Raindance Technoligies, Inc. Compositions and methods for molecular labeling
CN103492588A (zh) 2011-02-25 2014-01-01 伊路敏纳公司 用于单体型测定的方法和系统
WO2012122546A2 (en) 2011-03-09 2012-09-13 Lawrence Ganeshalingam Biological data networks and methods therefor
WO2012129363A2 (en) 2011-03-24 2012-09-27 President And Fellows Of Harvard College Single cell nucleic acid detection and analysis
GB2489714B (en) 2011-04-05 2013-11-06 Tracesa Ltd Fluid Identification Method
US20140141442A1 (en) 2011-04-05 2014-05-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Linear dna amplification
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
EP2754078A4 (en) 2011-04-14 2015-12-02 Complete Genomics Inc PROCESSING AND ANALYSIS OF COMPLEX NUCLEIC ACID SEQUENCE DATA
EP3395957B1 (en) * 2011-04-25 2020-08-12 Bio-Rad Laboratories, Inc. Methods and compositions for nucleic acid analysis
EP3495497B1 (en) 2011-04-28 2021-03-24 Life Technologies Corporation Methods and compositions for multiplex pcr
CN103732738A (zh) 2011-04-28 2014-04-16 小利兰斯坦福大学托管委员会 与样品相关的多核苷酸的鉴定
US20140227706A1 (en) 2011-05-16 2014-08-14 Dna Chip Research Inc. Method for assessing progression of clinical state of malignant neoplasm by quantitative detection of DNA in blood
BR112013029729A2 (pt) 2011-05-23 2017-01-24 Basf Se controle de emulsões, incluindo emulsões múltiplas
US9005935B2 (en) 2011-05-23 2015-04-14 Agilent Technologies, Inc. Methods and compositions for DNA fragmentation and tagging by transposases
EP2714938B1 (en) 2011-05-27 2017-11-15 President and Fellows of Harvard College Methods of amplifying whole genome of a single cell
EP3216872B1 (en) 2011-06-02 2020-04-01 Bio-Rad Laboratories, Inc. Enzyme quantification
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
US9150916B2 (en) 2011-06-24 2015-10-06 Beat Christen Compositions and methods for identifying the essential genome of an organism
US8927218B2 (en) 2011-06-27 2015-01-06 Flir Systems, Inc. Methods and compositions for segregating target nucleic acid from mixed nucleic acid samples
EP2729501A2 (en) 2011-07-07 2014-05-14 Life Technologies Corporation Polymer particles, nucleic acid polymer particles and methods of making and using the same
US20130017978A1 (en) 2011-07-11 2013-01-17 Finnzymes Oy Methods and transposon nucleic acids for generating a dna library
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
US9605304B2 (en) 2011-07-20 2017-03-28 The Hong Kong Polytechnic University Ultra-stable oligonucleotide-gold and-silver nanoparticle conjugates and method of their preparation
JP6158808B2 (ja) 2011-08-04 2017-07-05 セイジ サイエンス，インコーポレイティド 流体を処理するためのシステム及び方法
WO2013035114A1 (en) 2011-09-08 2013-03-14 Decode Genetics Ehf Tp53 genetic variants predictive of cancer
AU2012304328B2 (en) 2011-09-09 2017-07-20 The Board Of Trustees Of The Leland Stanford Junior University Methods for obtaining a sequence
EP2760578B1 (en) 2011-09-28 2020-08-26 President and Fellows of Harvard College Systems and methods for droplet production and/or fluidic manipulation
US9514272B2 (en) * 2011-10-12 2016-12-06 Complete Genomics, Inc. Identification of DNA fragments and structural variations
US9469874B2 (en) * 2011-10-18 2016-10-18 The Regents Of The University Of California Long-range barcode labeling-sequencing
US20130109576A1 (en) 2011-10-28 2013-05-02 Anthony P. Shuber Methods for detecting mutations
EP2774277A4 (en) 2011-11-04 2015-07-22 Intel Corp SIGNALING FOR THE CONFIGURATION OF COORDINATED DOWNLINK MULTIPORT COMMUNICATIONS
CN103946548B (zh) 2011-11-16 2016-10-05 国际商业机器公司 具有可变形阀的微流体器件
US9938524B2 (en) 2011-11-22 2018-04-10 Active Motif, Inc. Multiplex isolation of protein-associated nucleic acids
US10689643B2 (en) 2011-11-22 2020-06-23 Active Motif, Inc. Targeted transposition for use in epigenetic studies
CN107345204B (zh) 2011-12-03 2021-02-12 Emd密理博公司 用于微流体细胞培养的微型培育系统和方法
EP4249605B1 (en) 2011-12-22 2024-08-28 President And Fellows Of Harvard College Methods for analyte detection
WO2013096643A1 (en) 2011-12-23 2013-06-27 Gigagen Methods and apparatuses for droplet mixing
CN104245745B (zh) 2012-02-09 2017-03-29 生命技术公司 亲水性聚合物颗粒及其制备方法
JP2015507928A (ja) 2012-02-14 2015-03-16 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｍｉｒｎａ解析方法
WO2013123382A1 (en) 2012-02-15 2013-08-22 Wisconsin Alumni Research Foundation Dithioamine reducing agents
US10202628B2 (en) 2012-02-17 2019-02-12 President And Fellows Of Harvard College Assembly of nucleic acid sequences in emulsions
EP3309262B1 (en) 2012-02-24 2019-09-25 Bio-Rad Laboratories, Inc. Labeling and sample preparation for sequencing
EP3305918B1 (en) 2012-03-05 2020-06-03 President and Fellows of Harvard College Methods for epigenetic sequencing
NO2694769T3 (https=) 2012-03-06 2018-03-03
US9552458B2 (en) 2012-03-16 2017-01-24 The Research Institute At Nationwide Children's Hospital Comprehensive analysis pipeline for discovery of human genetic variation
EP2647426A1 (en) 2012-04-03 2013-10-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Replication of distributed nucleic acid molecules with preservation of their relative distribution through hybridization-based binding
US8209130B1 (en) 2012-04-04 2012-06-26 Good Start Genetics, Inc. Sequence assembly
JP2015519886A (ja) 2012-04-16 2015-07-16 バイオロジカル ダイナミクス，インク． 核酸サンプル調製
US20130296173A1 (en) 2012-04-23 2013-11-07 Complete Genomics, Inc. Pre-anchor wash
WO2013177046A1 (en) 2012-05-21 2013-11-28 Solulink, Inc. Methods and/or use of oligonucleotide conjugates for suppressing background due to cross-hybridization
EP4148142B1 (en) * 2012-05-21 2025-08-13 The Scripps Research Institute Methods of sample preparation
EP2861760B1 (en) 2012-06-15 2020-01-01 The Board of Regents of The University of Texas System High throughput sequencing of multiple transcripts of a single cell
EP2877604A1 (en) 2012-07-24 2015-06-03 Sequenta, Inc. Single cell analysis using sequence tags
EP2882868B1 (en) 2012-08-08 2019-07-31 H. Hoffnabb-La Roche Ag Increasing dynamic range for identifying multiple epitopes in cells
AU2013302867A1 (en) 2012-08-13 2015-02-26 The Regents Of The University Of California Methods and systems for detecting biological components
US20140378349A1 (en) 2012-08-14 2014-12-25 10X Technologies, Inc. Compositions and methods for sample processing
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US20140378345A1 (en) 2012-08-14 2014-12-25 10X Technologies, Inc. Compositions and methods for sample processing
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9701998B2 (en) 2012-12-14 2017-07-11 10X Genomics, Inc. Methods and systems for processing polynucleotides
US20150005200A1 (en) 2012-08-14 2015-01-01 10X Technologies, Inc. Compositions and methods for sample processing
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10584381B2 (en) 2012-08-14 2020-03-10 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US20150005199A1 (en) 2012-08-14 2015-01-01 10X Technologies, Inc. Compositions and methods for sample processing
US10221442B2 (en) 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
US20140378322A1 (en) 2012-08-14 2014-12-25 10X Technologies, Inc. Compositions and methods for sample processing
AU2013302756C1 (en) 2012-08-14 2018-05-17 10X Genomics, Inc. Microcapsule compositions and methods
WO2014047561A1 (en) 2012-09-21 2014-03-27 The Broad Institute Inc. Compositions and methods for labeling of agents
US9644199B2 (en) 2012-10-01 2017-05-09 Agilent Technologies, Inc. Immobilized transposase complexes for DNA fragmentation and tagging
GB201217772D0 (en) 2012-10-04 2012-11-14 Base4 Innovation Ltd Sequencing method
FR2996545B1 (fr) 2012-10-08 2016-03-25 Ecole Polytech Procede microfluidique de traitement et d'analyse d'une solution contenant un materiel biologique, et circuit microfluidique correspondant.
FR2996544B1 (fr) 2012-10-08 2015-03-13 Ecole Polytech Circuit microfluidique permettant la mise en contact de gouttes de plusieurs fluides, et procede microfluidique correspondant.
CN104838014B (zh) 2012-10-15 2017-06-30 生命技术公司 用于标靶核酸富集的组合物、方法、系统和试剂盒
EP4592400A3 (en) 2012-10-17 2025-10-29 10x Genomics Sweden AB Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
WO2014071361A1 (en) 2012-11-05 2014-05-08 Rubicon Genomics Barcoding nucleic acids
WO2014072703A1 (en) 2012-11-06 2014-05-15 Oxford Nanopore Technologies Limited Quadruplex method
EP2917368A1 (en) 2012-11-07 2015-09-16 Good Start Genetics, Inc. Methods and systems for identifying contamination in samples
EP2925894A4 (en) 2012-12-03 2016-06-29 Elim Biopharmaceuticals Inc METHODS FOR AMPLIFYING SINGLE-STRANDED POLYNUCLEOTIDES
EP2931899A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
IL239344B2 (en) 2012-12-12 2024-06-01 Broad Inst Inc Systems engineering, methods and optimal guiding components for sequence manipulation
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
CA2894694C (en) 2012-12-14 2023-04-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
EP2749653A1 (en) 2012-12-28 2014-07-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Molecular coding for analysis of composition of macromolecules and molecular complexes
EP2752664A1 (en) 2013-01-07 2014-07-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Label-free method for the detection of analytes
US9683230B2 (en) 2013-01-09 2017-06-20 Illumina Cambridge Limited Sample preparation on a solid support
GB2523495A (en) 2013-01-17 2015-08-26 Edico Genome Corp Bioinformatics systems, apparatuses, and methods executed on an integrated circuit processing platform
KR101984699B1 (ko) 2013-01-24 2019-05-31 삼성전자주식회사 핵산 분석용 미세 유체 시스템
HK1218151A1 (zh) 2013-01-25 2017-02-03 Bio-Rad Laboratories, Inc. 实施液滴膨胀的系统和方法
US10381106B2 (en) 2013-01-28 2019-08-13 Hasso-Plattner-Institut Fuer Softwaresystemtechnik Gmbh Efficient genomic read alignment in an in-memory database
US11110458B2 (en) 2013-02-01 2021-09-07 Bio-Rad Laboratories, Inc. System for detection of spaced droplets
KR20200140929A (ko) 2013-02-08 2020-12-16 10엑스 제노믹스, 인크. 폴리뉴클레오티드 바코드 생성
CN108212237B (zh) 2013-03-06 2020-12-08 哈佛学院院长及董事 形成相对单分散液滴的装置和方法
DK2970951T3 (da) 2013-03-13 2019-05-13 Illumina Inc Fremgangsmåder til nukleinsyresekventering
US9273349B2 (en) 2013-03-14 2016-03-01 Affymetrix, Inc. Detection of nucleic acids
WO2014152155A1 (en) 2013-03-14 2014-09-25 The Broad Institute, Inc. Massively multiplexed rna sequencing
GB2525568B (en) 2013-03-15 2020-10-14 Abvitro Llc Single cell barcoding for antibody discovery
WO2014145078A1 (en) 2013-03-15 2014-09-18 Verinata Health, Inc. Generating cell-free dna libraries directly from blood
US20140272996A1 (en) 2013-03-15 2014-09-18 Bio-Rad Laboratories, Inc. Droplet generator with collection tube
US9328382B2 (en) 2013-03-15 2016-05-03 Complete Genomics, Inc. Multiple tagging of individual long DNA fragments
EP2971080B1 (en) 2013-03-15 2018-01-03 Expedeon, S.L. Methods for amplification and sequencing using thermostable tthprimpol
US20140274729A1 (en) 2013-03-15 2014-09-18 Nugen Technologies, Inc. Methods, compositions and kits for generation of stranded rna or dna libraries
EP3736573A1 (en) 2013-03-15 2020-11-11 Prognosys Biosciences, Inc. Methods for detecting peptide/mhc/tcr binding
WO2014165559A2 (en) 2013-04-02 2014-10-09 Raindance Technologies, Inc. Systems and methods for handling microfluidic droplets
EP2994559B1 (en) 2013-05-09 2020-07-08 Bio-rad Laboratories, Inc. Magnetic immuno digital pcr assay
SG11201508985VA (en) 2013-05-23 2015-12-30 Univ Leland Stanford Junior Transposition into native chromatin for personal epigenomics
ES2754177T3 (es) 2013-06-12 2020-04-16 Massachusetts Gen Hospital Métodos para la detección multiplexada de moléculas diana y sus usos
WO2014201273A1 (en) 2013-06-12 2014-12-18 The Broad Institute, Inc. High-throughput rna-seq
RU2716420C2 (ru) 2013-06-17 2020-03-11 Те Брод Инститьют Инк. Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
US20160208323A1 (en) 2013-06-21 2016-07-21 The Broad Institute, Inc. Methods for Shearing and Tagging DNA for Chromatin Immunoprecipitation and Sequencing
CA2916662C (en) 2013-06-25 2022-03-08 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
AU2014302277A1 (en) 2013-06-27 2015-12-24 10X Genomics, Inc. Compositions and methods for sample processing
EP3019618B1 (en) 2013-07-12 2018-10-31 University of South Alabama Minimal piggybac vectors for genome integration
CN103394410B (zh) 2013-07-25 2016-04-20 博奥生物集团有限公司 一种位置可调节的智能磁力架
GB2516684A (en) 2013-07-30 2015-02-04 Sphere Fluidics Ltd Microfluidic devices and systems
KR102758333B1 (ko) 2013-08-28 2025-01-23 벡톤 디킨슨 앤드 컴퍼니 대량의 동시 단일 세포 분석
US10395758B2 (en) 2013-08-30 2019-08-27 10X Genomics, Inc. Sequencing methods
EP3049067A4 (en) 2013-09-24 2017-05-03 The Regents of the University of California Encapsulated sensors and sensing systems for bioassays and diagnostics and methods for making and using them
GB201317301D0 (en) 2013-09-30 2013-11-13 Linnarsson Sten Method for capturing and encoding nucleic acid from a plurality of single cells
WO2015065924A2 (en) 2013-10-28 2015-05-07 Massachusetts Institute Of Technology Hydrogel microstructures with immiscible fluid isolation for small reaction volumes
US9824068B2 (en) 2013-12-16 2017-11-21 10X Genomics, Inc. Methods and apparatus for sorting data
US20140315755A1 (en) 2013-12-26 2014-10-23 Tao Chen Genome-wide Antisense Oligonucleotide and RNAi
DK3089822T3 (da) 2013-12-30 2022-05-02 Atreca Inc Analyse af nukleinsyrer associeret med enkelte celler under anvendelse af nukleinsyrestregkoder
KR101464100B1 (ko) 2014-01-29 2014-11-21 성균관대학교산학협력단 생체 적용 가능한 리포솜-핵산형광 나노 융합체, 이의 응용, 및 이의 제조방법
EP3102691B1 (en) 2014-02-03 2019-09-11 Thermo Fisher Scientific Baltics UAB Method for controlled dna fragmentation
DK3110975T3 (da) 2014-02-27 2021-10-11 Jumpcode Genomics Inc Fremgangsmåder til analyse af somatiske mobile elementer og anvendelser deraf
BR112016023625A2 (pt) 2014-04-10 2018-06-26 10X Genomics, Inc. dispositivos fluídicos, sistemas e métodos para encapsular e particionar reagentes, e aplicações dos mesmos
WO2015160895A2 (en) 2014-04-15 2015-10-22 Illumina, Inc. Modified transposases for improved insertion sequence bias and increased dna input tolerance
AU2015250034B2 (en) 2014-04-21 2019-06-20 President And Fellows Of Harvard College Systems and methods for barcoding nucleic acids
US20150298091A1 (en) 2014-04-21 2015-10-22 President And Fellows Of Harvard College Systems and methods for barcoding nucleic acids
US10975371B2 (en) 2014-04-29 2021-04-13 Illumina, Inc. Nucleic acid sequence analysis from single cells
US10526601B2 (en) 2014-05-23 2020-01-07 Digenomix Corporation Haploidome determination by digitized transposons
SG10202005892SA (en) 2014-06-06 2020-07-29 Herlev Hospital Determining antigen recognition through barcoding of mhc multimers
US9534215B2 (en) 2014-06-11 2017-01-03 Life Technologies Corporation Systems and methods for substrate enrichment
AU2015273480A1 (en) 2014-06-11 2016-12-08 Samplix S.A.R.L. Nucleotide sequence exclusion enrichment by droplet sorting (needls)
WO2015188839A2 (en) 2014-06-13 2015-12-17 Immudex Aps General detection and isolation of specific cells by binding of labeled molecules
US10480021B2 (en) 2014-06-23 2019-11-19 Yale University Methods for closed chromatin mapping and DNA methylation analysis for single cells
WO2015200541A1 (en) 2014-06-24 2015-12-30 Bio-Rad Laboratories, Inc. Digital pcr barcoding
WO2015200893A2 (en) 2014-06-26 2015-12-30 10X Genomics, Inc. Methods of analyzing nucleic acids from individual cells or cell populations
CA2953469A1 (en) 2014-06-26 2015-12-30 10X Genomics, Inc. Analysis of nucleic acid sequences
US10017759B2 (en) 2014-06-26 2018-07-10 Illumina, Inc. Library preparation of tagged nucleic acid
CA2953473A1 (en) 2014-06-26 2015-12-30 10X Genomics, Inc. Methods and compositions for sample analysis
KR20170023979A (ko) 2014-06-26 2017-03-06 10엑스 제노믹스, 인크. 핵산 서열 조립을 위한 프로세스 및 시스템
EP3169803B1 (en) 2014-07-18 2019-11-20 Illumina, Inc. Non-invasive prenatal diagnosis of fetal genetic condition using cellular dna and cell free dna
US20160024558A1 (en) 2014-07-23 2016-01-28 10X Genomics, Inc. Nucleic acid binding proteins and uses thereof
EP3186418A2 (en) 2014-08-26 2017-07-05 Nugen Technologies, Inc. Compositions and methods for targeted nucleic acid sequence enrichment and high efficiency library generation
CN107873054B (zh) 2014-09-09 2022-07-12 博德研究所 用于复合单细胞核酸分析的基于微滴的方法和设备
EP3950944A1 (en) 2014-09-15 2022-02-09 AbVitro LLC High-throughput nucleotide library sequencing
RU2736728C2 (ru) 2014-10-17 2020-11-19 Иллумина Кембридж Лимитед Транспозиция с сохранением сцепления генов
BR112017008877A2 (pt) 2014-10-29 2018-07-03 10X Genomics Inc métodos e composições para sequenciamento de ácido nucleico-alvo
US9975122B2 (en) 2014-11-05 2018-05-22 10X Genomics, Inc. Instrument systems for integrated sample processing
US10783984B2 (en) 2014-12-18 2020-09-22 Pacific Biosciences Of California, Inc. De novo diploid genome assembly and haplotype sequence reconstruction
JP6769969B2 (ja) 2015-01-12 2020-10-14 １０エックス ジェノミクス， インコーポレイテッド 核酸配列決定ライブラリーを作製するためのプロセス及びシステム、並びにこれらを使用して作製したライブラリー
WO2016115273A1 (en) 2015-01-13 2016-07-21 10X Genomics, Inc. Systems and methods for visualizing structural variation and phasing information
EP3253479B1 (en) 2015-02-04 2022-09-21 The Regents of The University of California Sequencing of nucleic acids via barcoding in discrete entities
WO2016130578A1 (en) 2015-02-09 2016-08-18 10X Genomics, Inc. Systems and methods for determining structural variation and phasing using variant call data
CN107406890B (zh) 2015-02-10 2023-07-18 亿明达股份有限公司 用于分析细胞组分的方法和组合物
EP3262407B1 (en) 2015-02-24 2023-08-30 10X Genomics, Inc. Partition processing methods and systems
MX2017010857A (es) 2015-02-24 2017-12-11 10X Genomics Inc Metodos para la cobertura de secuencia de acidos nucleicos seleccionados como diana.
WO2016138496A1 (en) 2015-02-27 2016-09-01 Cellular Research, Inc. Spatially addressable molecular barcoding
WO2016149661A1 (en) 2015-03-18 2016-09-22 The Broad Institute, Inc. Massively parallel on-chip coalescence of microemulsions
US20180073073A1 (en) 2015-03-18 2018-03-15 Cellular Research, Inc. Methods and compositions for labeling targets and haplotype phasing
US20160289769A1 (en) 2015-03-30 2016-10-06 Verily Life Sciences Llc Methods for Combining Single Cell Profiling with Combinatorial Nanoparticle Conjugate Library Screening and In Vivo Diagnostic System
EP3901282B1 (en) 2015-04-10 2023-06-28 Spatial Transcriptomics AB Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11746367B2 (en) 2015-04-17 2023-09-05 President And Fellows Of Harvard College Barcoding systems and methods for gene sequencing and other applications
CN107250447B (zh) 2015-04-20 2020-05-05 深圳华大生命科学研究院 一种长片段dna文库构建方法
EP3285928B1 (en) 2015-04-22 2020-04-08 Stilla Technologies Contact-less priming method for loading a solution in a microfluidic device and associated system
US20160314242A1 (en) 2015-04-23 2016-10-27 10X Genomics, Inc. Sample indexing methods and compositions for sequencing applications
KR20180008493A (ko) 2015-05-18 2018-01-24 10엑스 제노믹스, 인크. 생화학 반응 및 분석에 사용하기 위한 이동성 고체상 조성물
CN107532218A (zh) 2015-05-18 2018-01-02 10X基因组学有限公司 稳定化还原剂及其使用方法
WO2016187717A1 (en) 2015-05-26 2016-12-01 Exerkine Corporation Exosomes useful for genome editing
WO2016191618A1 (en) 2015-05-27 2016-12-01 Jianbiao Zheng Methods of inserting molecular barcodes
JP2018527016A (ja) 2015-06-24 2018-09-20 オックスフォード バイオダイナミックス リミテッド 染色体相互作用の検出
MX2018000729A (es) 2015-07-17 2018-09-06 Harvard College Métodos para amplificar las secuencias de ácido nucleico.
LT3334841T (lt) 2015-08-12 2020-02-10 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Nukleorūgščių tyrimo būdai
WO2017034970A1 (en) 2015-08-21 2017-03-02 The General Hospital Corporation Combinatorial single molecule analysis of chromatin
MX2018003532A (es) 2015-09-24 2019-04-25 Abvitro Llc Conjugados de afinidad-oligonucleotido y usos de los mismos.
JP2018537414A (ja) 2015-10-13 2018-12-20 プレジデント アンド フェローズ オブ ハーバード カレッジ ゲルマイクロスフェアの作製及び使用のためのシステム及び方法
EP3366818B1 (en) 2015-10-19 2021-04-14 Zhejiang Annoroad Bio-Technology Co., Ltd. Method for constructing high-resolution single cell hi-c library with a lot of information
EP3365454A1 (en) 2015-10-20 2018-08-29 10X Genomics, Inc. Methods and systems for high throughput single cell genetic manipulation
WO2017075294A1 (en) 2015-10-28 2017-05-04 The Board Institute Inc. Assays for massively combinatorial perturbation profiling and cellular circuit reconstruction
US11092607B2 (en) 2015-10-28 2021-08-17 The Board Institute, Inc. Multiplex analysis of single cell constituents
JP7064439B2 (ja) 2015-11-04 2022-05-10 アトレカ インコーポレイテッド 単一細胞に関連する核酸の解析のための、核酸バーコードの組み合わせセット
CN108350499B (zh) 2015-11-19 2022-05-13 10X基因组学有限公司 可转化标记组合物、方法及结合其的过程
JP6954899B2 (ja) 2015-12-04 2021-10-27 １０エックス ゲノミクス，インコーポレイテッド 核酸の解析のための方法及び組成物
CN108779492A (zh) 2015-12-30 2018-11-09 生物辐射实验室股份有限公司 数字蛋白质定量
WO2017138984A1 (en) 2016-02-11 2017-08-17 10X Genomics, Inc. Systems, methods, and media for de novo assembly of whole genome sequence data
US20170260584A1 (en) 2016-02-11 2017-09-14 10X Genomics, Inc. Cell population analysis using single nucleotide polymorphisms from single cell transcriptomes
WO2017151828A1 (en) 2016-03-01 2017-09-08 Universal Sequencing Technology Corporation Methods and kits for tracking nucleic acid target origin for nucleic acid sequencing
WO2017156336A1 (en) 2016-03-10 2017-09-14 The Board Of Trustees Of The Leland Stanford Junior University Transposase-mediated imaging of the accessible genome
JP2019514002A (ja) 2016-04-15 2019-05-30 プレジデント アンド フェローズ オブ ハーバード カレッジ 液滴および／または他の実体の収集のためのシステムおよび方法
US20190127789A1 (en) 2016-04-19 2019-05-02 President And Fellows Of Harvard College Immobilization-based systems and methods for genetic analysis and other applications
WO2017197343A2 (en) 2016-05-12 2017-11-16 10X Genomics, Inc. Microfluidic on-chip filters
WO2017197338A1 (en) 2016-05-13 2017-11-16 10X Genomics, Inc. Microfluidic systems and methods of use
AU2017311306A1 (en) 2016-08-10 2019-03-14 President And Fellows Of Harvard College Methods of de novo assembly of barcoded genomic DNA fragments
US10688494B2 (en) 2016-08-23 2020-06-23 10X Genomics, Inc. Microfluidic surface-mediated emulsion stability control
WO2018044831A1 (en) 2016-08-30 2018-03-08 Integrated Dna Technologies, Inc. Cleavable hairpin primers
RU2736351C2 (ru) 2016-08-31 2020-11-16 Президент Энд Фэллоуз Оф Харвард Коллидж Способы дискретной амплификации полного генома
CN118853848A (zh) 2016-08-31 2024-10-29 哈佛学院董事及会员团体 将生物分子的检测组合到使用荧光原位测序的单个试验的方法
US20180080021A1 (en) 2016-09-17 2018-03-22 The Board Of Trustees Of The Leland Stanford Junior University Simultaneous sequencing of rna and dna from the same sample
CN109791157B (zh) 2016-09-26 2022-06-07 贝克顿迪金森公司 使用具有条形码化的寡核苷酸序列的试剂测量蛋白质表达
DK3529357T3 (da) 2016-10-19 2022-04-25 10X Genomics Inc Fremgangsmåder til stregkodning af nukleinsyremolekyler fra individuelle celler
GB201619458D0 (en) 2016-11-17 2017-01-04 Spatial Transcriptomics Ab Method for spatial tagging and analysing nucleic acids in a biological specimen
ES2922281T3 (es) 2016-12-07 2022-09-12 Mgi Tech Co Ltd Método para construir una biblioteca de secuenciación de una célula individual y uso del mismo
CN110139932B (zh) 2016-12-19 2024-05-17 生物辐射实验室股份有限公司 液滴加标的相邻性保留的标签化dna
CA3047328A1 (en) 2016-12-21 2018-06-28 The Regents Of The University Of California Single cell genomic sequencing using hydrogel based droplets
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US20190177800A1 (en) 2017-12-08 2019-06-13 10X Genomics, Inc. Methods and compositions for labeling cells
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
JP7234114B2 (ja) 2016-12-29 2023-03-07 イルミナ インコーポレイテッド 細胞区画内の生体分子への直交アクセスおよび細胞区画内の生体分子のタグ付けのための分析システム
JP7229923B2 (ja) 2017-01-06 2023-02-28 エディタス・メディシン、インコーポレイテッド ヌクレアーゼ切断を評価する方法
EP3568508A4 (en) 2017-01-12 2020-12-16 Massachusetts Institute Of Technology METHODS FOR T-LYMPHOCYTE RECEPTOR AND B-LYMPHOCYTE RECEPTOR ANALYSIS
EP4029939B1 (en) 2017-01-30 2023-06-28 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
US10995333B2 (en) 2017-02-06 2021-05-04 10X Genomics, Inc. Systems and methods for nucleic acid preparation
US10347365B2 (en) 2017-02-08 2019-07-09 10X Genomics, Inc. Systems and methods for visualizing a pattern in a dataset
GB201704402D0 (en) 2017-03-20 2017-05-03 Blacktrace Holdings Ltd Single cell DNA sequencing
KR20190133711A (ko) 2017-03-24 2019-12-03 싱가포르국립대학교 분자의 다중 검출 방법
WO2018191563A1 (en) 2017-04-12 2018-10-18 Karius, Inc. Sample preparation methods, systems and compositions
US12054764B2 (en) 2017-04-14 2024-08-06 The Broad Institute, Inc. High-throughput screens for exploring biological functions of microscale biological systems
US20180312822A1 (en) 2017-04-26 2018-11-01 10X Genomics, Inc. Mmlv reverse transcriptase variants
EP4435113B1 (en) 2017-05-18 2025-12-10 10X Genomics, Inc. Methods and systems for sorting droplets and beads
US10544413B2 (en) 2017-05-18 2020-01-28 10X Genomics, Inc. Methods and systems for sorting droplets and beads
EP3625715A4 (en) 2017-05-19 2021-03-17 10X Genomics, Inc. DATA SET ANALYSIS SYSTEMS AND METHODS
US10400235B2 (en) 2017-05-26 2019-09-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
WO2018226546A1 (en) 2017-06-05 2018-12-13 10X Genomics, Inc. Gaskets for the distribution of pressures in a microfluidic system
CN110719959B (zh) 2017-06-05 2021-08-06 贝克顿迪金森公司 针对单细胞的样品索引
CN110799679A (zh) 2017-06-20 2020-02-14 10X基因组学有限公司 用于改善液滴稳定的方法和系统
CA3068273A1 (en) 2017-06-21 2018-12-27 Bluedot Llc Systems and methods for identification of nucleic acids in a sample
EP3662084B1 (en) 2017-08-01 2024-10-30 Illumina, Inc. Hydrogel beads for nucleotide sequencing
US9946577B1 (en) 2017-08-14 2018-04-17 10X Genomics, Inc. Systems and methods for distributed resource management
US10610865B2 (en) 2017-08-22 2020-04-07 10X Genomics, Inc. Droplet forming devices and system with differential surface properties
US10837047B2 (en) 2017-10-04 2020-11-17 10X Genomics, Inc. Compositions, methods, and systems for bead formation using improved polymers
US10590244B2 (en) 2017-10-04 2020-03-17 10X Genomics, Inc. Compositions, methods, and systems for bead formation using improved polymers
WO2019084043A1 (en) 2017-10-26 2019-05-02 10X Genomics, Inc. METHODS AND SYSTEMS FOR NUCLEIC ACID PREPARATION AND CHROMATIN ANALYSIS
WO2019084328A1 (en) 2017-10-26 2019-05-02 10X Genomics, Inc. METHODS FOR PREPARING NUCLEIC ACID MOLECULES
WO2019083852A1 (en) 2017-10-26 2019-05-02 10X Genomics, Inc. MICROFLUIDIC CHANNEL NETWORKS FOR PARTITIONING
US20190127731A1 (en) 2017-10-26 2019-05-02 10X Genomics, Inc. Methods for preparing nucleic acid molecules
EP3700672B1 (en) 2017-10-27 2022-12-28 10X Genomics, Inc. Methods for sample preparation and analysis
SG11201913654QA (en) 2017-11-15 2020-01-30 10X Genomics Inc Functionalized gel beads
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
WO2019108851A1 (en) 2017-11-30 2019-06-06 10X Genomics, Inc. Systems and methods for nucleic acid preparation and analysis
WO2019113235A1 (en) 2017-12-06 2019-06-13 10X Genomics, Inc. Methods and systems for processing nucleic acid molecules
EP3724658A1 (en) 2017-12-12 2020-10-21 10X Genomics, Inc. Systems and methods for single cell processing
CN111712579B (zh) 2017-12-22 2024-10-15 10X基因组学有限公司 用于处理来自一个或多个细胞的核酸分子的系统和方法
WO2019148042A1 (en) 2018-01-26 2019-08-01 10X Genomics, Inc. Compositions and methods for sample processing
US12377396B2 (en) 2018-02-05 2025-08-05 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for multiplexed measurements in single and ensemble cells
SG11202007686VA (en) 2018-02-12 2020-09-29 10X Genomics Inc Methods characterizing multiple analytes from individual cells or cell populations
SG11202008080RA (en) 2018-02-22 2020-09-29 10X Genomics Inc Ligation mediated analysis of nucleic acids
WO2019169028A1 (en) 2018-02-28 2019-09-06 10X Genomics, Inc. Transcriptome sequencing through random ligation
WO2019169347A1 (en) 2018-03-02 2019-09-06 10X Genomics, Inc. Systems and apparatus for holding plates
WO2019191321A1 (en) 2018-03-28 2019-10-03 10X Genomics, Inc. Nucleic acid enrichment within partitions
CN112262218B (zh) 2018-04-06 2024-11-08 10X基因组学有限公司 用于单细胞处理中的质量控制的系统和方法
US20190345636A1 (en) 2018-05-10 2019-11-14 10X Genomics, Inc. Methods and systems for molecular library generation
WO2019217758A1 (en) 2018-05-10 2019-11-14 10X Genomics, Inc. Methods and systems for molecular library generation
US20190352717A1 (en) 2018-05-18 2019-11-21 10X Genomics, Inc. Targeted non-invasive prenatal testing
US11932899B2 (en) 2018-06-07 2024-03-19 10X Genomics, Inc. Methods and systems for characterizing nucleic acid molecules
US11703427B2 (en) 2018-06-25 2023-07-18 10X Genomics, Inc. Methods and systems for cell and bead processing
WO2020006183A1 (en) 2018-06-28 2020-01-02 10X Genomics, Inc. Systems and methods for visualization of single-cell resolution characteristics
US20200033366A1 (en) 2018-07-27 2020-01-30 10X Genomics, Inc. Systems and methods for metabolome analysis
US20200032335A1 (en) 2018-07-27 2020-01-30 10X Genomics, Inc. Systems and methods for metabolome analysis
SG11202101164TA (en) 2018-08-03 2021-03-30 10X Genomics Inc Methods and systems to minimize barcode exchange
WO2020041148A1 (en) 2018-08-20 2020-02-27 10X Genomics, Inc. Methods and systems for detection of protein-dna interactions using proximity ligation
US12065688B2 (en) 2018-08-20 2024-08-20 10X Genomics, Inc. Compositions and methods for cellular processing
US20200105373A1 (en) 2018-09-28 2020-04-02 10X Genomics, Inc. Systems and methods for cellular analysis using nucleic acid sequencing
US11459607B1 (en) 2018-12-10 2022-10-04 10X Genomics, Inc. Systems and methods for processing-nucleic acid molecules from a single cell using sequential co-partitioning and composite barcodes
EP3906318A1 (en) 2019-01-06 2021-11-10 10X Genomics, Inc. Methods and systems for enrichment of barcodes
US11467153B2 (en) 2019-02-12 2022-10-11 10X Genomics, Inc. Methods for processing nucleic acid molecules
EP3924505B1 (en) 2019-02-12 2025-12-17 10X Genomics, Inc. Methods for processing nucleic acid molecules
WO2020167862A1 (en) 2019-02-12 2020-08-20 10X Genomics, Inc. Systems and methods for transfer of reagents between droplets
WO2020167866A1 (en) 2019-02-12 2020-08-20 10X Genomics, Inc. Systems and methods for transposon loading
US11655499B1 (en) 2019-02-25 2023-05-23 10X Genomics, Inc. Detection of sequence elements in nucleic acid molecules
SG11202111242PA (en) 2019-03-11 2021-11-29 10X Genomics Inc Systems and methods for processing optically tagged beads
EP3947722A1 (en) 2019-03-27 2022-02-09 10X Genomics, Inc. Systems and methods for processing rna from cells
WO2021046475A1 (en) 2019-09-06 2021-03-11 10X Genomics, Inc. Systems and methods for barcoding cells and cell beads
CN115135984B (zh) 2019-12-23 2025-12-23 10X基因组学有限公司 可逆固定试剂及其使用方法
EP4081656A1 (en) 2019-12-23 2022-11-02 10X Genomics, Inc. Compositions and methods for using fixed biological samples in partition-based assays
CN115461470A (zh) 2020-02-28 2022-12-09 10X基因组学有限公司 用于从组织中分离核和细胞的方法
WO2021207610A1 (en) 2020-04-10 2021-10-14 10X Genomics, Inc. Cold protease treatment method for preparing biological samples
CN115916972A (zh) 2020-04-16 2023-04-04 10X基因组学有限公司 用于被固定样品的组合物和方法
WO2021222301A1 (en) 2020-04-27 2021-11-04 10X Genomics, Inc. Methods and systems for analysis and identification of barcode multiplets
WO2021222302A1 (en) 2020-04-27 2021-11-04 10X Genomics, Inc. Methods and systems for increasing cell recovery efficiency
US20220162671A1 (en) 2020-10-15 2022-05-26 10X Genomics, Inc. Methods and systems for barcoding multiple nucleic acid analytes
WO2022103712A1 (en) 2020-11-13 2022-05-19 10X Genomics, Inc. Nano-partitions (encapsulated nucleic acid processing enzymes) for cell-lysis and multiple reactions in partition-based assays
CN117015617B (zh) 2021-02-23 2025-04-04 10X基因组学有限公司 基于探针的核酸和蛋白质分析
EP4298239B1 (en) 2021-02-23 2025-11-05 10X Genomics, Inc. Drug screening methods
US20220403375A1 (en) 2021-06-09 2022-12-22 10X Genomics, Inc. Methods for enriching nucleic acid libraries for target molecules that do not produce artefactual antisense reads
EP4359755A1 (en) 2021-06-23 2024-05-01 10X Genomics, Inc. Chop-fix method and chopping device for preparing biological samples
US20230167496A1 (en) 2021-10-01 2023-06-01 10X Genomics, Inc. Compositions and methods for isolating nucleic acid molecules
WO2023076528A2 (en) 2021-10-28 2023-05-04 10X Genomics, Inc. Methods for sample preparation
EP4547858A1 (en) 2022-06-29 2025-05-07 10x Genomics, Inc. Probe-based analysis of nucleic acids and proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lo et al. (2013) "On the design of clone-based haplotyping" Genome Biology 14(9):R100 *

Cited By (265)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10741270B2 (en) 2012-03-08 2020-08-11 The Chinese University Of Hong Kong Size-based analysis of cell-free tumor DNA for classifying level of cancer
US11031100B2 (en) 2012-03-08 2021-06-08 The Chinese University Of Hong Kong Size-based sequencing analysis of cell-free tumor DNA for classifying level of cancer
US12037634B2 (en) 2012-08-14 2024-07-16 10X Genomics, Inc. Capsule array devices and methods of use
US11021749B2 (en) 2012-08-14 2021-06-01 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9695468B2 (en) 2012-08-14 2017-07-04 10X Genomics, Inc. Methods for droplet-based sample preparation
US10450607B2 (en) 2012-08-14 2019-10-22 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11359239B2 (en) 2012-08-14 2022-06-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11441179B2 (en) 2012-08-14 2022-09-13 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10400280B2 (en) 2012-08-14 2019-09-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11078522B2 (en) 2012-08-14 2021-08-03 10X Genomics, Inc. Capsule array devices and methods of use
US10584381B2 (en) 2012-08-14 2020-03-10 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10752950B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US11035002B2 (en) 2012-08-14 2021-06-15 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10221442B2 (en) 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10053723B2 (en) 2012-08-14 2018-08-21 10X Genomics, Inc. Capsule array devices and methods of use
US12098423B2 (en) 2012-08-14 2024-09-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10669583B2 (en) 2012-08-14 2020-06-02 10X Genomics, Inc. Method and systems for processing polynucleotides
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10597718B2 (en) 2012-08-14 2020-03-24 10X Genomics, Inc. Methods and systems for sample processing polynucleotides
US9689024B2 (en) 2012-08-14 2017-06-27 10X Genomics, Inc. Methods for droplet-based sample preparation
US10626458B2 (en) 2012-08-14 2020-04-21 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11999949B2 (en) 2012-12-10 2024-06-04 Resolution Bioscience, Inc. Methods for targeted genomic analysis
US11421274B2 (en) 2012-12-14 2022-08-23 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9701998B2 (en) 2012-12-14 2017-07-11 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10253364B2 (en) 2012-12-14 2019-04-09 10X Genomics, Inc. Method and systems for processing polynucleotides
US11473138B2 (en) 2012-12-14 2022-10-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9856530B2 (en) 2012-12-14 2018-01-02 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10676789B2 (en) 2012-12-14 2020-06-09 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10612090B2 (en) 2012-12-14 2020-04-07 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10227648B2 (en) 2012-12-14 2019-03-12 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11193121B2 (en) 2013-02-08 2021-12-07 10X Genomics, Inc. Partitioning and processing of analytes and other species
US10150963B2 (en) 2013-02-08 2018-12-11 10X Genomics, Inc. Partitioning and processing of analytes and other species
US9644204B2 (en) 2013-02-08 2017-05-09 10X Genomics, Inc. Partitioning and processing of analytes and other species
US10150964B2 (en) 2013-02-08 2018-12-11 10X Genomics, Inc. Partitioning and processing of analytes and other species
US12131805B2 (en) 2013-08-30 2024-10-29 10X Genomics, Inc. Sequencing methods
US12249402B2 (en) 2013-08-30 2025-03-11 10X Genomics, Inc. Sequencing methods
US10395758B2 (en) 2013-08-30 2019-08-27 10X Genomics, Inc. Sequencing methods
US11853389B2 (en) 2013-12-16 2023-12-26 10X Genomics, Inc. Methods and apparatus for sorting data
US11030276B2 (en) 2013-12-16 2021-06-08 10X Genomics, Inc. Methods and apparatus for sorting data
US9824068B2 (en) 2013-12-16 2017-11-21 10X Genomics, Inc. Methods and apparatus for sorting data
US12005454B2 (en) 2014-04-10 2024-06-11 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US10150117B2 (en) 2014-04-10 2018-12-11 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US10071377B2 (en) 2014-04-10 2018-09-11 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US9694361B2 (en) 2014-04-10 2017-07-04 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US10343166B2 (en) 2014-04-10 2019-07-09 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US11713457B2 (en) 2014-06-26 2023-08-01 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11629344B2 (en) 2014-06-26 2023-04-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10457986B2 (en) 2014-06-26 2019-10-29 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10839939B2 (en) 2014-06-26 2020-11-17 10X Genomics, Inc. Processes and systems for nucleic acid sequence assembly
US11133084B2 (en) 2014-06-26 2021-09-28 10X Genomics, Inc. Systems and methods for nucleic acid sequence assembly
US12163191B2 (en) 2014-06-26 2024-12-10 10X Genomics, Inc. Analysis of nucleic acid sequences
US12312640B2 (en) 2014-06-26 2025-05-27 10X Genomics, Inc. Analysis of nucleic acid sequences
WO2015200893A2 (en) 2014-06-26 2015-12-30 10X Genomics, Inc. Methods of analyzing nucleic acids from individual cells or cell populations
US10344329B2 (en) 2014-06-26 2019-07-09 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10337061B2 (en) 2014-06-26 2019-07-02 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10480028B2 (en) 2014-06-26 2019-11-19 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10030267B2 (en) 2014-06-26 2018-07-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10208343B2 (en) 2014-06-26 2019-02-19 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10760124B2 (en) 2014-06-26 2020-09-01 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10041116B2 (en) 2014-06-26 2018-08-07 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11062789B2 (en) 2014-07-18 2021-07-13 The Chinese University Of Hong Kong Methylation pattern analysis of tissues in a DNA mixture
US11984195B2 (en) 2014-07-18 2024-05-14 The Chinese University Of Hong Kong Methylation pattern analysis of tissues in a DNA mixture
US20180179578A1 (en) * 2014-08-22 2018-06-28 Resolution Bioscience, Inc. Methods for quantitative genetic analysis of cell free dna
US12203127B2 (en) * 2014-08-22 2025-01-21 Resolution Bioscience, Inc. Methods for quantitative genetic analysis of cell free DNA
US11739368B2 (en) 2014-10-29 2023-08-29 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequencing
US10287623B2 (en) 2014-10-29 2019-05-14 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequencing
US11135584B2 (en) 2014-11-05 2021-10-05 10X Genomics, Inc. Instrument systems for integrated sample processing
US12553074B2 (en) 2015-01-12 2026-02-17 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US11414688B2 (en) 2015-01-12 2022-08-16 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US10221436B2 (en) 2015-01-12 2019-03-05 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US10557158B2 (en) 2015-01-12 2020-02-11 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US10364467B2 (en) 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
US20160203196A1 (en) * 2015-01-13 2016-07-14 10X Genomics, Inc. Systems and methods for visualizing structural variation and phasing information
US10650912B2 (en) * 2015-01-13 2020-05-12 10X Genomics, Inc. Systems and methods for visualizing structural variation and phasing information
US12387821B2 (en) 2015-01-13 2025-08-12 10X Genomics, Inc. Systems and methods for visualizing structural variation and phasing information
US10854315B2 (en) 2015-02-09 2020-12-01 10X Genomics, Inc. Systems and methods for determining structural variation and phasing using variant call data
US11603554B2 (en) 2015-02-24 2023-03-14 10X Genomics, Inc. Partition processing methods and systems
US10697000B2 (en) 2015-02-24 2020-06-30 10X Genomics, Inc. Partition processing methods and systems
US11274343B2 (en) 2015-02-24 2022-03-15 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequence coverage
US11568957B2 (en) 2015-05-18 2023-01-31 Regeneron Pharmaceuticals Inc. Methods and systems for copy number variant detection
US10395759B2 (en) 2015-05-18 2019-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for copy number variant detection
US11339391B2 (en) 2015-11-11 2022-05-24 Resolution Bioscience, Inc. High efficiency construction of DNA libraries
US11371094B2 (en) 2015-11-19 2022-06-28 10X Genomics, Inc. Systems and methods for nucleic acid processing using degenerate nucleotides
US12152278B2 (en) 2015-11-19 2024-11-26 10X Genomics, Inc. Systems and methods for differentially tagging nucleic acid molecules
US11873528B2 (en) 2015-12-04 2024-01-16 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US11473125B2 (en) 2015-12-04 2022-10-18 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US11624085B2 (en) 2015-12-04 2023-04-11 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US12421539B2 (en) 2015-12-04 2025-09-23 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US10774370B2 (en) 2015-12-04 2020-09-15 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
EP3414341A4 (en) * 2016-02-11 2019-10-09 10X Genomics, Inc. SYSTEMS, METHODS AND MEDIA FOR DE-NOVO ARRANGEMENT OF ALL GENERIC SEQUENCE DATA
US11081208B2 (en) 2016-02-11 2021-08-03 10X Genomics, Inc. Systems, methods, and media for de novo assembly of whole genome sequence data
US12071669B2 (en) 2016-02-12 2024-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for detection of abnormal karyotypes
US12104212B2 (en) 2016-03-22 2024-10-01 Myriad Women's Health, Inc. Personalized methods for detecting circulating tumor DNA
US12344901B2 (en) 2016-03-22 2025-07-01 Myriad Women's Health, Inc. Automated methods of detecting cell free DNA
US12215392B2 (en) 2016-03-22 2025-02-04 Myriad Women's Health, Inc. Methods of preparing a DNA fraction enriched with circulating tumor DNA
US11932910B2 (en) 2016-03-22 2024-03-19 Myriad Women's Health, Inc. Combinatorial DNA screening
US12215391B1 (en) 2016-03-22 2025-02-04 Myriad Women's Health, Inc. Automated methods of detecting cell free DNA
WO2017165463A1 (en) 2016-03-22 2017-09-28 Counsyl, Inc. Combinatorial dna screening
US12545963B1 (en) 2016-03-22 2026-02-10 Myriad Women's Health, Inc. Personalized methods of detecting circulating tumor DNA
EP4071250A1 (en) 2016-03-22 2022-10-12 Myriad Women's Health, Inc. Combinatorial dna screening
EP4574992A2 (en) 2016-03-22 2025-06-25 Myriad Women's Health, Inc. Combinatorial dna screening
US12270082B2 (en) 2016-03-22 2025-04-08 Myriad Women's Health, Inc. Methods of detecting DNA in a sample
US12024749B2 (en) 2016-03-22 2024-07-02 Myriad Women's Health, Inc. Combinatorial DNA screening
US12351880B2 (en) 2016-03-22 2025-07-08 Myriad Women's Health, Inc. Methods of detecting and enriching circulating tumor DNA
US12351879B2 (en) 2016-03-22 2025-07-08 Myriad Women's Health, Inc. Enrichment of circulating tumor DNA
US12019078B2 (en) 2016-05-02 2024-06-25 Encodia, Inc. Macromolecule analysis employing nucleic acid encoding
US12019077B2 (en) 2016-05-02 2024-06-25 Encodia, Inc. Macromolecule analysis employing nucleic acid encoding
JP2022065157A (ja) * 2016-05-02 2022-04-26 エンコディア， インコーポレイテッド 核酸エンコーディングを使用した巨大分子解析
US12517133B2 (en) 2016-05-02 2026-01-06 Encodia, Inc. Macromolecule analysis employing nucleic acid encoding
JP7333975B2 (ja) 2016-05-02 2023-08-28 エンコディア， インコーポレイテッド 核酸エンコーディングを使用した巨大分子解析
US12123878B2 (en) * 2016-05-02 2024-10-22 Encodia, Inc. Macromolecule analysis employing nucleic acid encoding
US12235276B2 (en) 2016-05-02 2025-02-25 Encodia, Inc. Macromolecule analysis employing nucleic acid encoding
US11959922B2 (en) 2016-05-02 2024-04-16 Encodia, Inc. Macromolecule analysis employing nucleic acid encoding
US12320813B2 (en) 2016-05-02 2025-06-03 Encodia, Inc. Macromolecule analysis employing nucleic acid encoding
US12416047B2 (en) * 2016-05-06 2025-09-16 Myriad Women's Health, Inc. Noninvasive prenatal diagnostic methods
US20170321270A1 (en) * 2016-05-06 2017-11-09 Counsyl, Inc. Noninvasive prenatal diagnostic methods
US12427518B2 (en) 2016-05-12 2025-09-30 10X Genomics, Inc. Microfluidic on-chip filters
US12138628B2 (en) 2016-05-13 2024-11-12 10X Genomics, Inc. Microfluidic systems and methods of use
US11084036B2 (en) 2016-05-13 2021-08-10 10X Genomics, Inc. Microfluidic systems and methods of use
US11319594B2 (en) 2016-08-25 2022-05-03 Resolution Bioscience, Inc. Methods for the detection of genomic copy changes in DNA samples
US12559799B2 (en) 2016-08-25 2026-02-24 Resolution Bioscience, Inc. Methods for the detection of genomic copy changes in DNA samples
US11435339B2 (en) 2016-11-30 2022-09-06 The Chinese University Of Hong Kong Analysis of cell-free DNA in urine
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US12534760B2 (en) 2016-12-22 2026-01-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10858702B2 (en) 2016-12-22 2020-12-08 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10793905B2 (en) 2016-12-22 2020-10-06 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11732302B2 (en) 2016-12-22 2023-08-22 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10954562B2 (en) 2016-12-22 2021-03-23 10X Genomics, Inc. Methods and systems for processing polynucleotides
US12084716B2 (en) 2016-12-22 2024-09-10 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11180805B2 (en) 2016-12-22 2021-11-23 10X Genomics, Inc Methods and systems for processing polynucleotides
US10480029B2 (en) 2016-12-22 2019-11-19 10X Genomics, Inc. Methods and systems for processing polynucleotides
US12110549B2 (en) 2016-12-22 2024-10-08 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11248267B2 (en) 2016-12-22 2022-02-15 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10323278B2 (en) 2016-12-22 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10428326B2 (en) 2017-01-30 2019-10-01 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
US12600961B2 (en) 2017-01-30 2026-04-14 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
US12264316B2 (en) 2017-01-30 2025-04-01 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
US11193122B2 (en) 2017-01-30 2021-12-07 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
US12264411B2 (en) 2017-01-30 2025-04-01 10X Genomics, Inc. Methods and systems for analysis
US10995333B2 (en) 2017-02-06 2021-05-04 10X Genomics, Inc. Systems and methods for nucleic acid preparation
US12365893B2 (en) 2017-02-06 2025-07-22 10X Genomics, Inc. Systems and methods for nucleic acid preparation
EP4375376A2 (en) 2017-04-26 2024-05-29 10X Genomics, Inc. Mmlv reverse transcriptase variants
WO2018200867A1 (en) 2017-04-26 2018-11-01 10X Genomics, Inc. Mmlv reverse transcriptase variants
US12577545B2 (en) 2017-04-26 2026-03-17 10X Genomics, Inc. MMLV reverse transcriptase variants
US10544413B2 (en) 2017-05-18 2020-01-28 10X Genomics, Inc. Methods and systems for sorting droplets and beads
US11660601B2 (en) 2017-05-18 2023-05-30 10X Genomics, Inc. Methods for sorting particles
US12325023B2 (en) 2017-05-18 2025-06-10 10X Genomics, Inc. Methods for sorting particles
US11898206B2 (en) 2017-05-19 2024-02-13 10X Genomics, Inc. Systems and methods for clonotype screening
US11155810B2 (en) 2017-05-26 2021-10-26 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US20180340169A1 (en) * 2017-05-26 2018-11-29 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10400235B2 (en) 2017-05-26 2019-09-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10844372B2 (en) 2017-05-26 2020-11-24 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10927370B2 (en) 2017-05-26 2021-02-23 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US11198866B2 (en) 2017-05-26 2021-12-14 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US11773389B2 (en) 2017-05-26 2023-10-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US11565263B2 (en) 2017-08-22 2023-01-31 10X Genomics, Inc. Droplet forming devices and system with differential surface properties
US10549279B2 (en) 2017-08-22 2020-02-04 10X Genomics, Inc. Devices having a plurality of droplet formation regions
US10610865B2 (en) 2017-08-22 2020-04-07 10X Genomics, Inc. Droplet forming devices and system with differential surface properties
US12201983B2 (en) 2017-08-22 2025-01-21 10X Genomics, Inc. Droplet forming devices and system with differential surface properties
US10766032B2 (en) 2017-08-22 2020-09-08 10X Genomics, Inc. Devices having a plurality of droplet formation regions
US10357771B2 (en) 2017-08-22 2019-07-23 10X Genomics, Inc. Method of producing emulsions
US10898900B2 (en) 2017-08-22 2021-01-26 10X Genomics, Inc. Method of producing emulsions
US10583440B2 (en) 2017-08-22 2020-03-10 10X Genomics, Inc. Method of producing emulsions
US10821442B2 (en) 2017-08-22 2020-11-03 10X Genomics, Inc. Devices, systems, and kits for forming droplets
US10837047B2 (en) 2017-10-04 2020-11-17 10X Genomics, Inc. Compositions, methods, and systems for bead formation using improved polymers
US11884964B2 (en) 2017-10-04 2024-01-30 10X Genomics, Inc. Compositions, methods, and systems for bead formation using improved polymers
US10590244B2 (en) 2017-10-04 2020-03-17 10X Genomics, Inc. Compositions, methods, and systems for bead formation using improved polymers
US11441172B2 (en) 2017-10-04 2022-09-13 10X Genomics, Inc. Compositions, methods, and systems for bead formation using improved polymers
US11833515B2 (en) 2017-10-26 2023-12-05 10X Genomics, Inc. Microfluidic channel networks for partitioning
US12252732B2 (en) 2017-10-26 2025-03-18 10X Genomics, Inc. Methods and systems for nucleic acid preparation and chromatin analysis
US11725231B2 (en) 2017-10-26 2023-08-15 10X Genomics, Inc. Methods and systems for nucleic acid preparation and chromatin analysis
US12473585B2 (en) 2017-10-27 2025-11-18 10X Genomics, Inc. Methods and systems for sample preparation and analysis
US11584954B2 (en) 2017-10-27 2023-02-21 10X Genomics, Inc. Methods and systems for sample preparation and analysis
US10386338B2 (en) * 2017-10-30 2019-08-20 Cynthia Rena Wright DNA/RNA PEMS microcantilever probe for detection of viral infection and detection of genetic variants
US12130291B2 (en) 2017-10-31 2024-10-29 Encodia, Inc. Kits for analysis using nucleic acid encoding and/or label
US11782062B2 (en) 2017-10-31 2023-10-10 Encodia, Inc. Kits for analysis using nucleic acid encoding and/or label
US12292446B2 (en) 2017-10-31 2025-05-06 Encodia, Inc. Kits for analysis using nucleic acid encoding and/or label
US11884962B2 (en) 2017-11-15 2024-01-30 10X Genomics, Inc. Functionalized gel beads
US10745742B2 (en) 2017-11-15 2020-08-18 10X Genomics, Inc. Functionalized gel beads
US10876147B2 (en) 2017-11-15 2020-12-29 10X Genomics, Inc. Functionalized gel beads
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
US11365438B2 (en) 2017-11-30 2022-06-21 10X Genomics, Inc. Systems and methods for nucleic acid preparation and analysis
EP4589059A3 (en) * 2017-12-01 2025-12-10 Personal Genome Diagnostics, Inc. Process for microsatellite instability detection
WO2019108807A1 (en) 2017-12-01 2019-06-06 Personal Genome Diagnositics Inc. Process for microsatellite instability detection
EP3717520B1 (en) * 2017-12-01 2025-04-16 Personal Genome Diagnostics Inc. Process for microsatellite instability detection
US12411132B2 (en) 2017-12-12 2025-09-09 10X Genomics, Inc. Systems and methods for single cell processing
US12104200B2 (en) 2017-12-22 2024-10-01 10X Genomics, Inc Systems and methods for processing nucleic acid molecules from one or more cells
US11002731B2 (en) 2018-02-12 2021-05-11 10X Genomics, Inc. Methods and systems for antigen screening
US10816543B2 (en) 2018-02-12 2020-10-27 10X Genomics, Inc. Methods and systems for analysis of major histocompatability complex
US10928386B2 (en) 2018-02-12 2021-02-23 10X Genomics, Inc. Methods and systems for characterizing multiple analytes from individual cells or cell populations
WO2019157529A1 (en) 2018-02-12 2019-08-15 10X Genomics, Inc. Methods characterizing multiple analytes from individual cells or cell populations
US11739440B2 (en) 2018-02-12 2023-08-29 10X Genomics, Inc. Methods and systems for analysis of chromatin
US11255847B2 (en) 2018-02-12 2022-02-22 10X Genomics, Inc. Methods and systems for analysis of cell lineage
US10725027B2 (en) 2018-02-12 2020-07-28 10X Genomics, Inc. Methods and systems for analysis of chromatin
US11131664B2 (en) 2018-02-12 2021-09-28 10X Genomics, Inc. Methods and systems for macromolecule labeling
US12049712B2 (en) 2018-02-12 2024-07-30 10X Genomics, Inc. Methods and systems for analysis of chromatin
US12092635B2 (en) 2018-02-22 2024-09-17 10X Genomics, Inc. Methods and systems for characterizing analytes from individual cells or cell populations
US11852628B2 (en) 2018-02-22 2023-12-26 10X Genomics, Inc. Methods and systems for characterizing analytes from individual cells or cell populations
US11639928B2 (en) 2018-02-22 2023-05-02 10X Genomics, Inc. Methods and systems for characterizing analytes from individual cells or cell populations
US12054773B2 (en) 2018-02-28 2024-08-06 10X Genomics, Inc. Transcriptome sequencing through random ligation
WO2019169028A1 (en) 2018-02-28 2019-09-06 10X Genomics, Inc. Transcriptome sequencing through random ligation
US11155881B2 (en) 2018-04-06 2021-10-26 10X Genomics, Inc. Systems and methods for quality control in single cell processing
US12049621B2 (en) 2018-05-10 2024-07-30 10X Genomics, Inc. Methods and systems for molecular composition generation
US11932899B2 (en) 2018-06-07 2024-03-19 10X Genomics, Inc. Methods and systems for characterizing nucleic acid molecules
US11703427B2 (en) 2018-06-25 2023-07-18 10X Genomics, Inc. Methods and systems for cell and bead processing
US12117378B2 (en) 2018-06-25 2024-10-15 10X Genomics, Inc. Methods and systems for cell and bead processing
US12188014B1 (en) 2018-07-25 2025-01-07 10X Genomics, Inc. Compositions and methods for nucleic acid processing using blocking agents
US11873530B1 (en) 2018-07-27 2024-01-16 10X Genomics, Inc. Systems and methods for metabolome analysis
US12163179B2 (en) 2018-08-03 2024-12-10 10X Gemomics, Inc. Methods and systems to minimize barcode exchange
US12065688B2 (en) 2018-08-20 2024-08-20 10X Genomics, Inc. Compositions and methods for cellular processing
US12209271B2 (en) 2018-08-20 2025-01-28 10X Genomics, Inc. Methods and systems for detection of protein-DNA interactions using proximity ligation
US12139756B2 (en) 2018-12-10 2024-11-12 10X Genomics, Inc. Systems and methods for processing-nucleic acid molecules from a single cell using sequential co-partitioning and composite barcodes
US11459607B1 (en) 2018-12-10 2022-10-04 10X Genomics, Inc. Systems and methods for processing-nucleic acid molecules from a single cell using sequential co-partitioning and composite barcodes
US12169198B2 (en) 2019-01-08 2024-12-17 10X Genomics, Inc. Systems and methods for sample analysis
US11845983B1 (en) 2019-01-09 2023-12-19 10X Genomics, Inc. Methods and systems for multiplexing of droplet based assays
US12275993B2 (en) 2019-02-12 2025-04-15 10X Genomics, Inc. Analysis of nucleic acid sequences
US12391975B2 (en) 2019-02-12 2025-08-19 10X Genomics, Inc. Systems and methods for transposon loading
US11851683B1 (en) 2019-02-12 2023-12-26 10X Genomics, Inc. Methods and systems for selective analysis of cellular samples
US11467153B2 (en) 2019-02-12 2022-10-11 10X Genomics, Inc. Methods for processing nucleic acid molecules
US12416102B2 (en) 2019-02-12 2025-09-16 10X Genomics, Inc. Systems and methods for transfer of reagents between droplets
US12305239B2 (en) 2019-02-12 2025-05-20 10X Genomics, Inc. Analysis of nucleic acid sequences
US12612714B2 (en) 2019-02-12 2026-04-28 10X Genomics, Inc. Systems and methods for transfer of reagents between droplets
US11584953B2 (en) 2019-02-12 2023-02-21 10X Genomics, Inc. Methods for processing nucleic acid molecules
US11655499B1 (en) 2019-02-25 2023-05-23 10X Genomics, Inc. Detection of sequence elements in nucleic acid molecules
US11920183B2 (en) 2019-03-11 2024-03-05 10X Genomics, Inc. Systems and methods for processing optically tagged beads
US12606860B2 (en) 2019-03-27 2026-04-21 10X Genomics, Inc. Systems and methods for processing RNA from cells
US11634709B2 (en) 2019-04-30 2023-04-25 Encodia, Inc. Methods for preparing analytes and related kits
US11535891B2 (en) 2019-05-03 2022-12-27 The Regents Of The University Of California Barcoded solid supports and methods of making and using same
US12235262B1 (en) 2019-09-09 2025-02-25 10X Genomics, Inc. Methods and systems for single cell protein analysis
GB2627085A (en) * 2019-11-06 2024-08-14 Univ Leland Stanford Junior Methods and systems for analysing nucleic acid molecules
GB2627085B (en) * 2019-11-06 2024-11-13 Univ Leland Stanford Junior Methods and systems for analysing nucleic acid molecules
US11447833B2 (en) 2019-11-06 2022-09-20 The Board Of Trustees Of The Leland Stanford Junior University Methods for preparing nucleic acid libraries for sequencing
GB2623904B (en) * 2019-11-06 2024-07-24 Univ Leland Stanford Junior Methods and systems for analyzing nucleic acid molecules
CN118834950A (zh) * 2019-11-06 2024-10-25 斯坦福大学托管董事会 用于分析核酸分子的方法和系统
US12492434B2 (en) 2019-11-06 2025-12-09 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules
US11634779B2 (en) 2019-11-06 2023-04-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules
US11851716B2 (en) 2019-11-06 2023-12-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules
US11965215B2 (en) 2019-11-06 2024-04-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules
GB2623904A (en) * 2019-11-06 2024-05-01 Univ Leland Stanford Junior Methods and systems for analyzing nucleic acid molecules
US11613787B2 (en) 2019-11-06 2023-03-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules
US11932882B2 (en) 2019-12-11 2024-03-19 10X Genomics, Inc. Reverse transcriptase variants
US12297463B2 (en) 2019-12-11 2025-05-13 10X Genomics, Inc. Engineered reverse transcriptase enzymes with enhanced enzymatic activity in nanoliter reaction
US12112833B2 (en) 2020-02-04 2024-10-08 10X Genomics, Inc. Systems and methods for index hopping filtering
US12421558B2 (en) 2020-02-13 2025-09-23 10X Genomics, Inc. Systems and methods for joint interactive visualization of gene expression and DNA chromatin accessibility
US12391976B2 (en) 2020-05-13 2025-08-19 10X Genomics, Inc. Methods, kits, and compositions for processing extracellular molecules
US11851700B1 (en) 2020-05-13 2023-12-26 10X Genomics, Inc. Methods, kits, and compositions for processing extracellular molecules
US12168801B1 (en) 2020-07-02 2024-12-17 10X Genomics, Inc. Hybrid/capture probe designs for full-length cDNA
US12580044B1 (en) 2020-09-02 2026-03-17 10X Genomics, Inc. Systems and methods for identifying cells that are antigen-specific for an immunogenic feature
US12084715B1 (en) 2020-11-05 2024-09-10 10X Genomics, Inc. Methods and systems for reducing artifactual antisense products
US12480158B1 (en) 2020-11-05 2025-11-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US12398262B1 (en) 2021-01-22 2025-08-26 10X Genomics, Inc. Triblock copolymer-based cell stabilization and fixation system and methods of use thereof
US11952626B2 (en) 2021-02-23 2024-04-09 10X Genomics, Inc. Probe-based analysis of nucleic acids and proteins
US12467088B2 (en) 2021-02-23 2025-11-11 10X Genomics, Inc. Probe-based analysis of nucleic acids and proteins
GB2621782B (en) * 2021-05-05 2024-08-14 Univ Leland Stanford Junior Methods and systems for analyzing nucleic acid molecules
GB2621782A (en) * 2021-05-05 2024-02-21 Univ Leland Stanford Junior Methods and systems for analyzing nucleic acid molecules
CN117580963A (zh) * 2021-05-05 2024-02-20 斯坦福大学托管董事会 用于分析核酸分子的方法和系统
WO2022236221A1 (en) * 2021-05-05 2022-11-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules
US11783912B2 (en) 2021-05-05 2023-10-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for analyzing nucleic acid molecules

Also Published As

Publication number Publication date
US20250059606A1 (en) 2025-02-20
AU2015279617A1 (en) 2017-01-12
EP3161162A1 (en) 2017-05-03
MX2016016904A (es) 2017-03-27
EP3161162A4 (en) 2018-01-10
US20180265928A1 (en) 2018-09-20
US12163191B2 (en) 2024-12-10
CA2953469A1 (en) 2015-12-30
IL249619A0 (en) 2017-02-28
JP2017522866A (ja) 2017-08-17
KR20170026383A (ko) 2017-03-08
CN106536756A (zh) 2017-03-22
US20210123103A1 (en) 2021-04-29
WO2015200869A1 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
US20250059606A1 (en) Analysis of nucleic acid sequences
JP7713054B2 (ja) 循環細胞の分析方法
US11530454B2 (en) Detecting mutations and ploidy in chromosomal segments
US20220356530A1 (en) Methods for determining velocity of tumor growth
EP3322816B1 (en) System and methodology for the analysis of genomic data obtained from a subject
US20240336973A1 (en) Methods for detecting neoplasm in pregnant women
US20260085347A1 (en) Detecting mutations and ploidy in chromosomal segments

Legal Events

Date Code Title Description
AS Assignment

Owner name: 10X GENOMICS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHNALL0LEVIN, MICHAEL;SAXONOV, SERGE;JAROSZ, MIRNA;AND OTHERS;SIGNING DATES FROM 20150725 TO 20150819;REEL/FRAME:036406/0930

AS Assignment

Owner name: 10X GENOMICS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHNALL-LEVIN, MICHAEL;JAROSZ, MIRNA;HINDSON, CHRISTOPHER;AND OTHERS;SIGNING DATES FROM 20150727 TO 20150819;REEL/FRAME:036539/0087

AS Assignment

Owner name: 10X GENOMICS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ZHENG, XINYING;REEL/FRAME:046698/0539

Effective date: 20180710

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION